Compositions and methods for targeting BCL11A
Patent Information
- Application Number
- JP2023533861
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-03
- Filing Date
- 2021-12-02
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-12-02
AI Technical Summary
Current treatments for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, are limited by the need for ex vivo cell editing followed by transplantation, and there is a lack of effective methods to modulate BCL11A in vivo to increase fetal hemoglobin production.
The use of modified Class 2, Type V CRISPR proteins and guide nucleic acids to target and modify the BCL11A gene, allowing for in vivo knockdown or knockout of the BCL11A gene to increase fetal hemoglobin production.
This approach effectively increases fetal hemoglobin levels in vivo, reducing the clinical severity of hemoglobinopathies by targeting and modifying the BCL11A gene using CRISPR technology, providing a therapeutic strategy for conditions like sickle cell anemia and beta-thalassemia.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 1200233,885, filed December 3, 2020, the contents of which are incorporated herein by reference in their entirety.
[0002] INCORPORATION-BY-REFERENCE TO SEQUENCE LISTING This application contains an ASCII Sequence Listing that was submitted via EFS-Web and is incorporated herein by reference in its entirety. The ASCII copy was created on December 1, 2021, is named SCRB_030_01WO_SeqList_ST25.txt, and has a file size of 8.78 MB. [Background technology]
[0003] Fetal hemoglobin (also hemoglobin F, HbF, or α2γ2) is the major oxygen carrier protein in the human fetus. HbF has a different composition than the adult form of hemoglobin, allowing it to bind oxygen more tightly than the adult form, enabling the developing fetus to retrieve oxygen from the maternal bloodstream. HbF is a tetramer of two adult α-globin polypeptides and two fetal β-like γ-globin polypeptides. During pregnancy, the duplicated γ-globin gene constitutes the predominant gene transcribed in the β-globin cluster. After birth, γ-globin is replaced by adult β-globin in a process called the “fetal switch” that involves the expression of BCL11A, a regulator of HbF silencing (Sankaran, V.G., et al. Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A. Science 322(5909):1839-1842(2008); Liu, N., et al. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell 173(2):430(2018)). In healthy adults, the composition of hemoglobin is hemoglobin A (approximately 97%), hemoglobin A2 (2.2-3.5%), and hemoglobin F (<1%) (Thomas, C and Lumb, AB Physiology of hemoglobin. Continuing Education in Anaesthesia Critical Care & Pain. 12(5):251-256 (2012)).
[0004] Hemoglobinopathies are most often inherited single-gene disorders inherited as autosomal codominant traits. Common hemoglobinopathies include sickle cell disease and alpha- and beta-thalassemia. Hemoglobinopathies are most common in people from Africa, the Mediterranean, and Southeast Asia. Most hemoglobinopathies, including sickle cell anemia, are simply structural abnormalities of the globin protein itself. Sickle cell anemia results from a point mutation in the beta-globin structural gene, HBB, resulting in the production of abnormal hemoglobin (HbS) and reduced blood oxygen-carrying capacity. Thalassemia, in contrast, usually results in insufficient production of normal globin protein and, often through mutations in regulatory genes, in the absence or deficiency of adult hemoglobin (HbA). In beta-thalassemia, beta-globin is deficient, and increased expression of gamma-globin reduces the imbalance between alpha- and beta-globin chains, which underlies the pathophysiology of anemia in this condition (Liu, N., et al. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell 173(2):430(2018)). Both sickle cell disease and thalassemia can cause anemia.
[0005] B-cell lymphoma / leukemia 11A (BCL11A) is a protein encoded by the BCL11A gene in humans. During hematopoietic cell differentiation, this gene is downregulated and has been found to play a role in suppressing fetal hemoglobin production. BCL11A is a major repressor protein of hemoglobin F production by binding to the promoter region of the gene encoding the gamma subunit (Sankaran VG, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322:1839 (2008)). Because increased γ-globin reduces the clinical severity of β-hemoglobinopathies, sickle cell disease, and β-thalassemia, which are caused by mutations or reduced expression of β-globin, gene editing of BCL11A to increase γ-globin expression beyond the remaining approximately 1% of fetal hemoglobin has been proposed as an attractive therapeutic strategy in adults with hemoglobinopathies (Smith, EC, et al. Strict in vivo specificity of the Bcl11a erythroid enhancer. Blood 128(19):2338(2016)).
[0006] The emergence of CRISPR / Cas systems and the programmable nature of these minimal systems have facilitated their use as a versatile technology for genome manipulation and engineering. To date, the use of CRISPR / Cas systems for the treatment of hemoglobinopathies has been limited to ex vivo cell editing followed by transplantation into subjects suffering from the underlying hemoglobinopathies. Therefore, there is a need for compositions and methods for regulating BCL11A to reduce direct in vivo repression of the γ-globin gene promoter in subjects with these diseases. To address this need, compositions and methods for targeting the BCL11A gene are provided herein. Summary of the Invention
[0007] The present disclosure relates to compositions of modified Class 2, V-type CRISPR proteins and guide nucleic acids used to modify target nucleic acids, including the BCL11A gene, in cells. The Class 2, V-type CRISPR proteins and guide nucleic acids are modified to passively enter target cells. The Class 2, V-type CRISPR proteins and guide nucleic acids are useful in various methods for modifying target nucleic acids for BCL11A-associated diseases, and methods are also provided.
[0008] In one aspect, the present disclosure relates to a CasX:guide nucleic acid system (CasX:gRNA system) and methods used to knockdown or knockout the BCL11A gene to reduce or eliminate expression of the BCL11A gene product in subjects with a beta hemoglobinopathy-associated disease.
[0009] In some embodiments, the gRNA of the CasX:gRNA system is a gRNA or a chimera of RNA and DNA, and can be a single-molecule gRNA or a two-molecule gRNA. In other embodiments, the gRNA of the CasX:gRNA system has a targeting sequence complementary to a target nucleic acid sequence comprising a region within the BCL11A gene. In some embodiments, the targeting sequence of the gRNA is selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% identity thereto. The gRNA can comprise a targeting sequence comprising 15-20 contiguous nucleotides. In other embodiments, the targeting sequence of the gRNA consists of 20 nucleotides. In other embodiments, the targeting sequence consists of 19 nucleotides. In other embodiments, the targeting sequence consists of 18 nucleotides. In other embodiments, the targeting sequence consists of 17 nucleotides. In another embodiment, the targeting sequence consists of 16 nucleotides. In another embodiment, the targeting sequence consists of 15 nucleotides. In another embodiment, the targeting sequence of the gRNA has a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789. In another embodiment, the targeting sequence of the gRNA has a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789, with a single nucleotide removed from the 3' end of the sequence. In another embodiment, the targeting sequence consists of 18 nucleotides and has a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789, with two nucleotides removed from the 3' end of the sequence. In another embodiment, the targeting sequence consists of 17 nucleotides and has a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789, with three nucleotides removed from the 3' end of the sequence. In another embodiment, the targeting sequence consists of 16 nucleotides and has a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789, with 4 nucleotides removed from the 3' end of the sequence.In another embodiment, the targeting sequence consists of 15 nucleotides and has a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789, with 5 nucleotides removed from the 3' end of the sequence.
[0010] In some embodiments, the gRNA has a scaffold comprising a sequence selected from the group consisting of SEQ ID NOs: 2238-2285, 26794-26839, and 27219-27265, or a sequence set forth in Table 3, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the gRNA has a scaffold comprising a sequence selected from the group consisting of SEQ ID NOs: 2238-2285, 26794-26839, and 27219-27265. In some embodiments, the gRNA has a scaffold comprising a sequence selected from the group consisting of SEQ ID NOs: 2101-2285, 26794-26839, and 27219-27265.
[0011] In some embodiments, the CasX:gRNA system comprises a CasX variant sequence having a sequence selected from the group consisting of SEQ ID NOs: 36-99, 101-148, 26908-27154, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the CasX:gRNA system comprises a CasX variant sequence having a sequence selected from the group consisting of SEQ ID NOs: 36-99, 101-148, 26908-27154. In some embodiments, the CasX:gRNA system comprises a CasX variant sequence having a sequence selected from the group consisting of SEQ ID NOs:59, 72-99, 101-148, and 26908-27154, or a sequence set forth in Table 4, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the CasX:gRNA system comprises a CasX variant sequence having a sequence selected from the group consisting of SEQ ID NOs:59, 72-99, 101-148, and 26908-27154. In some embodiments, the CasX:gRNA system comprises a CasX variant sequence having a sequence selected from the group consisting of SEQ ID NOs:132-148 and 26908-27154, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the CasX:gRNA system comprises a CasX variant sequence having a sequence selected from the group consisting of SEQ ID NOs:132-148 and 26908-27154.In these embodiments, the CasX variant exhibits one or more improved characteristics compared to any one of the reference CasX proteins of SEQ ID NOs: 1-3. In some embodiments, the CasX variant protein has binding affinity for a protospacer adjacent motif (PAM) sequence selected from the group consisting of TTC, ATC, GTC, and CTC. In some embodiments, the CasX variant protein has binding affinity for a PAM sequence selected from the group consisting of TTC, ATC, GTC, and CTC that is at least 1.5-fold greater than the binding affinity of any one of the reference CasX proteins of SEQ ID NOs: 1-3 for a PAM sequence selected from the group consisting of TTC, ATC, GTC, and CTC.
[0012] In other embodiments of the CasX:gRNA system, the CasX and gRNA molecules associate together in a ribonucleoprotein complex (RNP). In certain embodiments, an RNP comprising a CasX variant and a gRNA variant exhibits higher editing efficiency and / or binding of a target sequence in a target DNA compared to the editing efficiency and / or binding of an RNP comprising a reference CasX protein and a reference gRNA in a comparable assay system when any one of the PAM sequences TTC, ATC, GTC, or CTC is located one nucleotide 5' to a non-target strand sequence that shares identity with the targeting sequence of the gRNA in the cellular assay system.
[0013] In some embodiments, the CasX:gRNA system further includes a donor template comprising a nucleic acid comprising at least a portion of the BCL11A gene and having at least one to about five mutations compared to the wild-type sequence, wherein the BCL11A gene portion is selected from the group consisting of a BCL11A exon, a BCL11A intron, a BCL11A intron-exon junction, a BCL11A regulatory element, or a combination thereof, and the donor template is used to knock down or knock out the BCL11A gene. In some cases, the donor sequence is a single-stranded DNA template or a single-stranded RNA template. In other cases, the donor template is a double-stranded DNA template.
[0014] In other embodiments, the present disclosure relates to nucleic acids encoding the CasX:gRNA system of any of the embodiments described herein, as well as vectors comprising the nucleic acids. In some embodiments, the vector is selected from the group consisting of a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes simplex virus (HSV) vector, a plasmid, a minicircle, a nanoplasmid, and an RNA vector. In other embodiments, the vector is a CasX delivery particle (XDP) comprising the RNP of CasX and gRNA of any of the embodiments described herein, and optionally a donor template nucleic acid and a targeting moiety (e.g., a viral-derived glycoprotein).
[0015] In other embodiments, the present disclosure provides methods for modifying a BCL11A target nucleic acid sequence in a cell population, the method comprising introducing into the cells: a) a CasX:gRNA system according to any of the embodiments disclosed herein; b) a nucleic acid according to any of the embodiments disclosed herein; c) a vector according to any of the embodiments disclosed herein; d) an XDP according to any of the embodiments disclosed herein; or e) a combination of the foregoing. In some embodiments of the method, modifying comprises introducing an insertion, deletion, substitution, duplication, or inversion of one or more nucleotides in the target nucleic acid sequence compared to the wild-type sequence. The target BCL11A gene comprises a GATA1 erythroid-specific enhancer-binding site (GATA1) as a regulatory element. In some embodiments, the modifying method comprises modifying the GATA1 sequence, such that the BCL11A gene is knocked down or knocked out by the modification. Optionally, the method further comprises contacting the target nucleic acid with a donor template nucleic acid according to any of the embodiments disclosed herein. In some embodiments of the method, the donor template comprises a nucleic acid comprising at least a portion of the BCL11A gene but with one or more mutations to knock out or knock down the BCL11A gene. Optionally, modification of the target nucleic acid sequence occurs in vitro or ex vivo. Optionally, modification of the target nucleic acid sequence occurs in vivo. In some embodiments, the cell is a eukaryotic cell selected from the group consisting of a rodent cell, a mouse cell, a rat cell, a primate cell, and a non-human primate cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is selected from the group consisting of a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), a CD34+ stem cell, a mesenchymal stem cell (MSC), an induced pluripotent stem cell (iPSC), a common myeloid progenitor cell, a proerythroblast cell, and an erythroblast cell. In some embodiments, the cells are autologous cells derived from a subject with a beta hemoglobinopathy-associated disease.In other embodiments, the cells are allogeneic, that is, of the same species as the subject being treated.
[0016] In other embodiments, the present disclosure provides a method for modifying a target nucleic acid sequence in the BCL11A gene, wherein a target cell population is contacted using a vector encoding a CasX protein and one or more gRNAs comprising a targeting sequence complementary to the BCL11A gene, and optionally further comprising a donor template. In some cases, the vector is an adeno-associated virus (AAV) vector selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-Rh74, or AAVRh10. In other cases, the vector is a lentiviral vector. In other embodiments, the present disclosure provides a method for contacting target cells using a vector, wherein the vector is a CasX delivery particle (XDP) comprising the RNP of CasX and gRNA of any of the embodiments described herein, and optionally a donor template nucleic acid. In some embodiments of the method, the vector is administered to the subject at a therapeutically effective dose. The subject may be a mouse, rat, pig, non-human primate, or human. The dose may be administered by a route of administration selected from implantation, local injection, systemic infusion, or a combination thereof.
[0017] In other embodiments, the present disclosure provides a method of treating a beta hemoglobinopathy-associated disease in a subject in need thereof, comprising modifying a gene encoding the BCL11A gene in the subject's cells, wherein the modifying comprises contacting the cells with: a) a CasX:gRNA system according to any of the embodiments disclosed herein; b) a nucleic acid according to any of the embodiments disclosed herein; c) a vector according to any of the embodiments disclosed herein; d) an XDP according to any of the embodiments disclosed herein; or e) a combination of the foregoing. In some embodiments, the beta hemoglobinopathy-associated disease is sickle cell anemia or beta thalassemia. In some cases, the method of treating a subject with a beta hemoglobinopathy-associated disease results in improvement of at least one clinically relevant parameter. In other cases, the method of treating a subject with a beta hemoglobinopathy-associated disease results in improvement of at least two clinically relevant parameters.
[0018] In other embodiments, the present disclosure provides use of a CasX:gRNA system, nucleic acid, vector, or XDP described herein to treat a beta hemoglobinopathy-associated disease in a subject in need thereof. In some embodiments, the use comprises modifying a gene encoding the BCL11A gene in a cell of the subject, wherein modifying comprises contacting the cell with: a) a CasX:gRNA system of any of the embodiments disclosed herein, b) a nucleic acid of any of the embodiments disclosed herein, c) a vector of any of the embodiments disclosed herein, d) an XDP of any of the embodiments disclosed herein, or e) a combination of the foregoing.
[0019] Incorporation by Reference All publications, patents, and patent applications mentioned herein are incorporated by reference as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. The contents of U.S. Provisional Application Nos. 63 / 121,196, filed December 3, 2020, 63 / 162,346, filed March 17, 2021, and 63 / 208,855, filed June 9, 2021, which disclose CasX and gRNA variants, are incorporated by reference in their entireties. The contents of International Application Publication Nos. 2020 / 247882, published on December 10, 2020, 2020 / 247883, published on December 10, 2020, and 2021 / 113772, published on June 10, 2021, are incorporated by reference in their entirety into this specification. [Brief explanation of the drawings]
[0020] The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings, in which: [Figure 1]
[0023] Figure 1 is a graph of the results of an assay to quantify the active fraction of RNPs formed by sgRNA174 (SEQ ID NO:2238) and CasX variants 119 (SEQ ID NO:59), 457 (SEQ ID NO:101), 488 (SEQ ID NO:123), and 491 (SEQ ID NO:126), as described in Example 8. Equimolar amounts of RNP and target were co-incubated, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Biphasic matches of combined replicates are shown. "2" refers to the reference CasX protein of SEQ ID NO:2. [Figure 2]Figure 1 shows quantification of the active fraction of RNPs formed by CasX2 (reference CasX protein of SEQ ID NO: 2) and modified sgRNAs, as described in Example 8. Equimolar amounts of RNP and target were co-incubated, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Biphasic matches of combined replicates are shown. [Figure 3] Figure 1 shows quantification of the active fraction of RNPs formed by CasX 491 and modified sgRNA under guide-restricted conditions, as described in Example 8. Equimolar amounts of RNP and target were co-incubated, and the amount of cleaved target was determined at the indicated time points. A two-phase fit of the data is shown. [Figure 4] Figure 1 shows quantification of the cleavage rates of RNPs formed by sgRNA174 and CasX variants, as described in Example 8. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point, except for 488 and 491, where a single replicate is shown. Monophasic matches of combined replicates are shown. [Figure 5]
[0023] Figure 1 shows quantification of the cleavage rates of RNPs formed by CasX2 and the indicated sgRNA variants, as described in Example 8. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Monophasic matching of combined replicates is shown. [Figure 6] Quantification of the initial rates of RNPs formed by CasX2 and sgRNA variants is shown, as described in Example 8. The first two time points from previous cleavage experiments were fitted to a linear model to determine the initial cleavage rates. [Figure 7] Figure 1 shows quantification of the cleavage rates of RNPs formed by CasX491 and sgRNA variants as described in Example 8. Target DNA was incubated with a 20-fold excess of the indicated RNPs at 10°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of the time points are shown. [Figure 8] Figure 1 shows quantification of the competent fraction of RNPs of CasX variants 515 (SEQ ID NO: 133) and 526 (SEQ ID NO: 143) complexed with gRNA variant 174 compared to the RNP of reference CasX 2 complexed with gRNA 2, using equimolar amounts of the indicated RNP and complementary target, as described in Example 8. Biphasic fits are shown for each time course or combined replicate set. [Figure 9] Quantification of the cleavage rates of RNPs of CasX variants 515 and 526 complexed with gRNA variant 174 compared to the RNP of reference CasX 2 complexed with gRNA 2, using a 20-fold excess of the indicated RNPs, as described in Example 8. [Figure 10A] Figure 1 shows quantification of cleavage rates of CasX variants against a TTC PAM, as described in Example 5. Target DNA substrates with identical spacers and the indicated PAM sequences were incubated with a 20-fold excess of the indicated RNPs at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 10B] Figure 1 shows quantification of cleavage rates of CasX variants against CTC PAM, as described in Example 5. Target DNA substrates with identical spacers and the indicated PAM sequences were incubated with a 20-fold excess of the indicated RNPs at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 10C] Figure 1 shows quantification of cleavage rates of CasX variants against a GTC PAM, as described in Example 5. Target DNA substrates with the same spacer and the indicated PAM sequence were incubated with a 20-fold excess of the indicated RNP at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 10D]Figure 1 shows quantification of cleavage rates of CasX variants against the ATC PAM, as described in Example 5. Target DNA substrates with the same spacer and the indicated PAM sequence were incubated with a 20-fold excess of the indicated RNP at 37°C, and the amount of cleaved target was determined at the indicated time points. Monophasic matches of a single repeat are shown. [Figure 11A] Figure 1 shows quantification of RNP cleavage rates of CasX variant 491 and guide 174 against the NTC PAM, as described in Example 5. Time points were taken over a 10 minute period and the cleaved fraction was graphed for each target and time point, although for clarity only the first 2 minutes of the time course is shown. [Figure 11B] Figure 1 shows quantification of RNP cleavage rates of CasX variant 491 and guide 174 against the NTT PAM, as described in Example 5. Time points were taken over a 10 minute period and the fraction cleaved was graphed for each target and time point. [Figure 12A] Figure 1 shows quantification of cleavage by RNPs formed by sgRNA174 and CasX variant 515 using spacers of 18, 19, or 20 nucleotides in length, as described in Example 9. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Monophasic matches of combined replicates are shown. [Figure 12B] Figure 1 shows quantification of cleavage by RNPs formed by sgRNA174 and CasX variant 526 using spacers of 18, 19, or 20 nucleotides in length, as described in Example 9. Target DNA was incubated with a 20-fold excess of the indicated RNPs, and the amount of cleaved target was determined at the indicated time points. The mean and standard deviation of three independent replicates are shown for each time point. Monophasic matches of combined replicates are shown. [Figure 13]
[0023] Figure 1 is a schematic diagram showing an example of a CasX protein and scaffold DNA sequence for packaging in adeno-associated virus (AAV). The DNA segment between the AAV inverted terminal repeats (ITRs), consisting of the DNA encoding CasX and its promoter, and the DNA encoding the scaffold and its promoter, is packaged into the AAV capsid during AAV production. [Figure 14] Figure 1 shows the results of an editing assay comparing gRNA scaffolds 229-237 (see Table 3 for corresponding sequences and SEQ ID NO: 27197) with scaffold 174 in mouse neural progenitor cells (mNPCs) isolated from Ai9-tdtomato transgenic mice. Cells were nucleofected with the indicated doses of p59 plasmids encoding CasX 491, the scaffolds, and spacer 11.30 (5'AAGGGGCUCCGCACCACGCC3', SEQ ID NO: 27197) targeting mRHO. Editing at the mRHO locus was assessed by next-generation sequencing (NGS) 5 days after transfection. Figure 1 shows that editing with constructs carrying scaffolds 230, 231, 234, and 235 demonstrated greater editing compared to constructs carrying scaffold 174 at both doses. [Figure 15] Figure 1 shows the results of an editing assay comparing gRNA scaffolds 229-237 and scaffold 174 in mNPC cells. Cells were nucleofected with the indicated doses of p59 plasmids encoding CasX 491, scaffold, and spacer 12.7 (5'CUGCAUUCUAGUUGUGGUUU 3', SEQ ID NO: 27198), which targets a repeat element that prevents expression of the tdTomato fluorescent protein. Five days after transfection, editing was assessed by FACS to quantify the percentage of tdTomato-positive cells. Cells nucleofected with scaffolds 231-235 showed approximately 35% greater editing at the high dose and approximately 25% greater editing at the low dose compared to the construct with scaffold 174. [Figure 16]Figure 1 shows the results of an editing assay comparing CasX nucleases 2, 119, 491, 515, 527, 528, 529, 530, and 531 (see Table 4 for corresponding sequences and SEQ ID NOs) in the custom HEK293 cell line PASS_V1.01. Cells were lipofected with 2 μg of p67 plasmid encoding the indicated CasX proteins. Five days later, cellular genomic DNA was extracted. PCR amplification and next-generation sequencing were performed to isolate and quantify the fraction of cells edited at the custom-designed, on-target editing sites. For each sample, editing was assessed at target sites (individual points) consisting of the following PAM sequences: 48 TTC, 14 ATC, 22 CTC, and 11 GTC individual sites, and the percentage of editing was normalized to the vehicle control. Cells lipofected with any nuclease showed higher average editing at TTC PAM target sites (horizontal bars) than that of the wild-type nuclease CasX 2, except for CasX 528. The relative preference of any given nuclease for four different PAM sequences is also shown in a violin plot. Notably, CasX nucleases 527, 528, and 529 show PAM preferences that are substantially different from that of the wild-type nuclease CasX 2. [Figure 17]This figure shows the results of an editing assay comparing the improved CasX nuclease 491 with the improved nucleases 532 and 533 in the custom HEK293 cell line PASS_V1.01. Cells were lipofected in duplicate with 2 μg of p67 plasmid encoding the indicated CasX protein and a puromycin resistance gene and grown under puromycin selection. After 3 days, cellular genomic DNA was extracted. PCR amplification and next-generation sequencing were performed to isolate and quantify the fraction of cells edited at the custom-designed on-target editing sites. For each sample, editing was assessed at target sites consisting of the following PAM sequences: 48 TTC, 14 ATC, 22 CTC, and 11 GTC individual sites, and the percentage of editing was normalized to the vehicle control. Cells lipofected with CasX 532 or 533 showed higher average editing than Cas 491 at each of the PAM sequences, except for CasX 533 at the TTC PAM target site. Error bars represent the standard error of the mean for n=2 biological samples. [Figure 18] 1 shows the results of editing the BCL11A erythroid enhancer locus in HEK293T cells with CasX protein variant 438 with scaffold 174 compared to the Cas9 system, as described in Example 13. [Figure 19] 1 shows the results of editing at the GATA1 binding region of the BCL11A erythroid enhancer locus in K562 cells by CasX protein variant 491 with scaffold 174 compared to CasX protein variant 119 with scaffold 174, as described in Example 14. [Figure 20] 1 shows the results of editing at the GATA1 binding region of the BCL11A erythroid enhancer locus in K562 cells by CasX protein variant 491 with scaffold 174 delivered by various doses of XDP, as described in Example 14. [Figure 21]1 shows the results of editing at the GATA1 binding region of the BCL11A erythroid enhancer locus in HSC cells by CasX protein variant 491 with scaffold 174 compared to CasX protein variant 119 with scaffold 174, as described in Example 15. [Figure 22] 1 shows the results of editing at the GATA1 binding region of the BCL11A erythroid enhancer locus in HSC cells by CasX protein variant 491 with scaffold 174 delivered by various doses of XDP, as described in Example 15. [Figure 23] Schematic diagram showing the placement of spacer 21.1 (SEQ ID NO: 22) relative to the GATA1 binding site sequence in the target nucleic acid. Top strand: SEQ ID NO: 26790, bottom strand: SEQ ID NO: 26791. DETAILED DESCRIPTION OF THE INVENTION
[0021] While exemplary embodiments have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention as claimed herein. It is understood that various alternatives to the embodiments described herein may be employed in practicing embodiments of the present disclosure. It is intended that the following claims define the scope of the invention, and that methods and structures within the scope of these claims and their equivalents be covered thereby.
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present embodiments, suitable methods and materials are described below. In case of conflict, the present patent specification, including definitions, will control. Additionally, the materials, methods, and examples are illustrative only and are not intended to be limiting. Numerous variations, changes, and substitutions will occur to those skilled in the art without departing from the invention.
[0023] definition The terms "polynucleotide" and "nucleic acid" are used interchangeably herein and refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, the terms "polynucleotide" and "nucleic acid" encompass single-stranded DNA, double-stranded DNA, multi-stranded DNA, single-stranded RNA, double-stranded RNA, multi-stranded RNA, genomic DNA, cDNA, DNA-RNA hybrids, and polymers that contain purine and pyrimidine bases or other naturally occurring, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.
[0024] "Hybridizable" or "complementary" are used interchangeably and mean comprising a sequence of nucleotides that allows a nucleic acid (e.g., RNA, DNA) to non-covalently bind (i.e., form Watson-Crick base pairs and / or G / U base pairs), "anneal," or "hybridize" (i.e., a nucleic acid specifically binds to a complementary nucleic acid) to another nucleic acid in a sequence-specific antiparallel manner under appropriate in vitro and / or in vivo conditions of temperature and solution ionic strength. It is understood that the sequence of a polynucleotide need not be 100% complementary to the sequence of its target nucleic acid to be specifically hybridizable. It can have at least about 70%, at least about 80%, or at least about 90%, or at least about 95% sequence identity and still be able to hybridize to a target nucleic acid. Furthermore, a polynucleotide can hybridize over one or more segments without intervening or adjacent segments participating in the hybridization event (e.g., a loop or hairpin structure, a "bulge," a "bubble," etc.).
[0025] For purposes of this disclosure, a "gene" includes a DNA region that encodes a gene product (e.g., protein, RNA), as well as all DNA regions that regulate the production of a gene product (whether or not such regulatory element sequences are adjacent to the coding and / or transcribed sequence). Thus, a gene can include regulatory sequences, including, but not necessarily limited to, promoter sequences, terminators, translational control sequences (e.g., ribosome binding sites and internal ribosome entry sites), enhancers, silencers, insulators, boundary elements, origins of replication, matrix attachment sites, and locus control regions. A coding sequence encodes a gene product upon transcription or transcription and translation. A coding sequence of the present disclosure can include a fragment of an open reading frame and need not include the entire length. A gene can include both the transcribed strand (e.g., the strand containing the coding sequence) and the complementary strand.
[0026] The term "downstream" refers to a nucleotide sequence located 3' of a reference nucleotide sequence. In certain embodiments, the downstream nucleotide sequence relates to the sequence following the start of transcription. For example, the translation start codon of a gene is located downstream of the transcription start site.
[0027] The term "upstream" refers to a nucleotide sequence located 5' to a reference nucleotide sequence. In certain embodiments, an upstream nucleotide sequence relates to a coding region or a sequence located 5' to the transcription start site. For example, most promoters are located upstream of the transcription start site.
[0028] The term "adjacent to," with respect to a polynucleotide or amino acid sequence, refers to sequences that are next to or adjacent to each other in a polynucleotide or polypeptide. One of skill in the art will understand that two sequences can be considered adjacent to each other and still encompass a limited amount of intervening sequence, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or amino acids.
[0029] The term "regulatory element" is used interchangeably herein with the term "regulatory sequence" and is intended to include promoters, enhancers, and other expression control elements (e.g., transcription termination signals such as polyadenylation signals and polyU sequences). Exemplary regulatory elements include, but are not limited to, transcription promoters (e.g., CMV, CMV + intron A, SV40, RSV, HIV-Ltr, elongation factor 1 alpha (EF1α), MMLV-Ltr), internal ribosome entry sites (IRES) or P2A peptides (which allow translation of multiple genes from a single transcript), metallothionein, transcription enhancer elements, transcription termination signals, polyadenylation sequences, sequences for optimizing translation initiation, and translation termination sequences. It will be understood that the selection of appropriate regulatory elements will depend on the encoded component (e.g., protein or RNA) to be expressed, or whether the nucleic acid contains multiple components requiring different polymerases or is not intended to be expressed as a fusion protein.
[0030] The term "promoter" refers to a DNA sequence that contains an RNA polymerase binding site, a transcription initiation site, a TATA box, and / or a B recognition element, and that assists or facilitates the transcription and expression of an associated transcribable polynucleotide sequence and / or gene (or transgene). A promoter can be produced synthetically or derived from a known or naturally occurring promoter sequence or another promoter sequence. A promoter can be proximal or distal to the gene to be transcribed. A promoter can also include chimeric promoters, which contain a combination of two or more heterologous sequences to confer particular properties. Promoters of the present disclosure can include variants of promoter sequences that are similar in composition but not identical to other promoter sequences known or provided herein. Promoters can be classified according to criteria related to the expression pattern of the associated coding or transcribable sequence or gene operably linked to the promoter (e.g., constitutive, developmental, tissue-specific, inducible, etc.).
[0031] The term "enhancer" refers to a regulatory element DNA sequence that, when bound by specific proteins called transcription factors, regulates the expression of an associated gene. Enhancers can be located in the introns of a gene or 5' or 3' of the coding sequence of a gene. Enhancers can be proximal to the gene (i.e., within tens or hundreds of base pairs (bp) of the promoter) or distal to the gene (i.e., thousands, hundreds of thousands, or even millions of bp away from the promoter). A single gene may be regulated by more than one enhancer, all of which are contemplated within the scope of this disclosure.
[0032] As used herein, a "post-transcriptional regulatory element (PRE)" (e.g., a hepatitis PRE) refers to a DNA sequence that, when transcribed, generates a tertiary structure that can exhibit post-transcriptional activity that enhances or promotes expression of an associated gene operably linked to it.
[0033] The term "GATA binding site" refers to the DNA binding site of the GATA family of transcription factors. GATA transcription factors typically recognize target sites that conform to the consensus sequence WGATAR (where W=A or T, and R=A or G).
[0034] As used herein, "recombinant" means that a particular nucleic acid (DNA or RNA) is the product of various combinations of cloning, restriction, and / or ligation steps, resulting in a construct having structural coding or non-coding sequences distinguishable from the endogenous nucleic acid found in natural systems. Generally, DNA sequences encoding structural coding sequences can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of synthetic oligonucleotides, to provide a synthetic nucleic acid that can be expressed from a recombinant transcription unit contained in a cell or a cell-free transcription and translation system. Such sequences can be provided in the form of an open reading frame uninterrupted by internal untranslated sequences, or introns, typically present in eukaryotic genes. Genomic DNA containing the relevant sequence can also be used in forming recombinant genes or transcription units. Sequences of untranslated DNA can be present 5' or 3' from the open reading frame, where such sequences do not interfere with the manipulation or expression of the coding region and may, in fact, act to regulate production of the desired product by various mechanisms (see "enhancer" and "promoter" above).
[0035] The term "recombinant polynucleotide" or "recombinant nucleic acid" refers to something that does not occur in nature, e.g., something that is created through human intervention, by the artificial combination of two otherwise isolated segments of sequence. This artificial combination is often accomplished either by chemical synthesis means or by the artificial manipulation of isolated segments of nucleic acid (e.g., genetic engineering techniques). This can typically be done to replace codons with redundant codons that encode the same or a conservative amino acid, while introducing or removing sequence recognition sites. Alternatively, it can be done by ligating nucleic acid segments of desired functions together to produce a desired combination of functions. This artificial combination is often accomplished either by chemical synthesis means or by the artificial manipulation of isolated segments of nucleic acid (e.g., genetic engineering techniques).
[0036] Similarly, the term "recombinant polypeptide" or "recombinant protein" refers to a polypeptide or protein that does not occur in nature, e.g., one that is created through human intervention by the artificial combination of two otherwise separate segments of amino acid sequence. Thus, for example, a protein that includes a heterologous amino acid sequence is recombinant.
[0037] As used herein, the term "contacting" refers to establishing a physical connection between two or more entities. For example, contacting a target nucleic acid sequence with a guide nucleic acid means that the target nucleic acid sequence and the guide nucleic acid are made to share a physical connection (e.g., can hybridize if the sequences share sequence similarity).
[0038] "Dissociation constant" or "K d " are used interchangeably and refer to the affinity between a ligand "L" and a protein "P" (i.e., how strongly a ligand binds to a particular protein). It is expressed by the formula K d= [L][P] / [LP], where [P], [L], and [LP] represent the molar concentrations of the protein, ligand, and complex, respectively.
[0039] The present disclosure provides compositions and methods useful for editing a target nucleic acid sequence. As used herein, "editing" is used interchangeably with "modification" and includes, but is not limited to, truncation, nicking, deletion, knock-in, knock-out, etc.
[0040] The term "knockout" refers to the elimination of a gene or the expression of a gene. For example, a gene can be knocked out by either deleting or adding a nucleotide sequence that results in a disruption of the reading frame. As another example, a gene can be knocked out by replacing a portion of the gene with an unrelated sequence. The term "knockdown," as used herein, refers to the reduction of the expression of a gene or its gene product. As a result of gene knockdown, protein activity or function can be attenuated, or protein levels can be reduced or eliminated.
[0041] As used herein, "homology-directed repair" (HDR) refers to a form of DNA repair that occurs during repair of double-strand breaks in cells. This process requires nucleotide sequence homology and uses a donor template to repair or knock out target DNA, resulting in the transfer of genetic information from the donor (e.g., donor template) to the target. Homology-directed repair can result in sequence alterations of the target nucleic acid sequence by insertion, deletion, or mutation if the donor template differs from the target DNA sequence and some or all of the donor template sequence is integrated into the target DNA at the correct genomic locus.
[0042] As used herein, "non-homologous end joining" (NHEJ) refers to the repair of double-strand breaks in DNA by direct ligation of the broken ends to each other without the need for a homologous template (as opposed to homology-mediated repair, which requires homologous sequences to guide the repair). NHEJ often results in indels (losses (deletions) or insertions of nucleotide sequences near the double-strand break site).
[0043] As used herein, "microhomology-mediated end joining" (MMEJ) refers to a mutagenic double-strand break (DSB) repair mechanism that does not require a homologous template (as opposed to homology-mediated repair, which requires homologous sequences to guide the repair) and is always associated with a deletion adjacent to the break site. MMEJ often results in the loss (deletion) of nucleotide sequences near the double-strand break site.
[0044] A polynucleotide or polypeptide (or protein) has a certain percent "sequence similarity" or "sequence identity" with another polynucleotide or polypeptide, which means the percentage of identical bases or amino acids that are in the same relative positions when two sequences are compared (aligned). Sequence similarity (also referred to as percent similarity, percent identity, or homology) can be determined in several different ways. To determine sequence similarity, sequences can be aligned using methods and computer programs known in the art, including BLAST, available on the World Wide Web at ncbi.nlm.nih.gov / BLAST. The percent complementarity between particular stretches of nucleic acid sequence within a nucleic acid can be determined using any convenient method. Exemplary methods include the BLAST program (Basic Local Alignment Search Tool) and PowerBLAST program (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656) (or by using the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), e.g., using default settings using the Smith and Waterman algorithm (Adv. Appl. Math., 1981, 2, 482-489)).
[0045] The terms "polypeptide" and "protein" are used interchangeably herein to refer to polymeric forms of amino acids of any length, which may include coded and non-coded amino acids, amino acids that have been chemically or biochemically modified or derivatized, and polypeptides with modified peptide backbones. This term encompasses fusion proteins, including, but not limited to, fusion proteins with heterologous amino acid sequences.
[0046] A "vector" or "expression vector" is a replicon, such as a plasmid, phage, virus, virus-like particle, or cosmid, to which another DNA segment (i.e., the "insert") can be attached, so as to bring about the replication or expression of the attached segment in a cell.
[0047] As used herein, the terms "naturally occurring" or "unmodified" or "wild-type" when applied to a nucleic acid, polypeptide, cell, or organism, refer to a nucleic acid, polypeptide, cell, or organism that is found in nature.
[0048] As used herein, a "mutation" refers to an insertion, deletion, substitution, duplication, or inversion of one or more amino acids or nucleotides compared to a wild-type or reference amino acid sequence, or compared to a wild-type or reference nucleotide sequence.
[0049] As used herein, the term "isolated" is meant to refer to a polynucleotide, polypeptide, or cell that is in an environment that is different from the environment that the polynucleotide, polypeptide, or cell naturally occurs in. An isolated genetically modified host cell may be present in a mixed population of genetically modified host cells.
[0050] As used herein, "host cell" means a eukaryotic cell, a prokaryotic cell, or a cell derived from a multicellular organism cultured as a unicellular entity (e.g., a cell line), and includes the progeny of the original cell that has been used as a recipient of a nucleic acid (e.g., an expression vector) and that has been genetically modified by the nucleic acid. It is understood that the progeny of a single cell may not necessarily be completely identical in morphology or in genomic or total DNA complement to the original parent due to natural, accidental, or deliberate mutation. A "recombinant host cell" (also called a "genetically modified host cell") is a host cell into which a heterologous nucleic acid (e.g., an expression vector) has been introduced.
[0051] The term "conservative amino acid substitution" refers to the interchangeability of amino acid residues in proteins that have similar side chains. For example, the group of amino acids with aliphatic side chains consists of glycine, alanine, valine, leucine, and isoleucine; the group of amino acids with aliphatic hydroxyl side chains consists of serine and threonine; the group of amino acids with amide-containing side chains consists of asparagine and glutamine; the group of amino acids with aromatic side chains consists of phenylalanine, tyrosine, and tryptophan; the group of amino acids with basic side chains consists of lysine, arginine, and histidine; and the group of amino acids with sulfur-containing side chains consists of cysteine and methionine. Exemplary conservative amino acid substitution groups are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
[0052] As used herein, "treatment" or "treating" are used interchangeably herein and refer to an approach for obtaining a beneficial or desired result, including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. Therapeutic benefit refers to the eradication or amelioration of the underlying disorder or disease being treated. Therapeutic benefit can also be achieved by the eradication or amelioration of one or more symptoms associated with the underlying disease, or the improvement of one or more clinical parameters, such that an improvement is observed in a subject, even though the subject may still be afflicted with the underlying disease.
[0053] The terms "therapeutically effective amount" and "therapeutically effective dose," as used herein, refer to an amount of a drug or biologic, alone or as part of a composition, that, when administered to a subject (e.g., a human or experimental animal) in single or repeated doses, can have any detectable beneficial effect on any symptom, aspect, measured parameter, or characteristic of a disease state or condition. Such effect need not be absolute to be beneficial.
[0054] As used herein, "administering" refers to a method of giving a dosage of a composition of the present disclosure to a subject.
[0055] As used herein, a "subject" is a mammal, including, but not limited to, domestic animals, primates, non-human primates, humans, dogs, porcine (pigs), rabbits, mice, rats, and other rodents.
[0056] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0057] I. General Methods The practice of the present invention will employ, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA, which are described in such standard textbooks as Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al., Harbor Laboratory Press 2001), Short Protocols in Molecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999), Protein Methods (Bollag et al., John Wiley & Sons 1996), Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999), Viral Vectors (Kaplift & Loewy eds., Academic Press 1995), Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997), and Cell and Tissue Culture: Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998), the disclosures of which are incorporated herein by reference.
[0058] When a range of values is provided, it is understood that the endpoints are included, and that each intervening value between the upper and lower limit of that range, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, includes any other stated or intervening value in that stated range. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also included subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included.
[0059] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials for which the publications are cited.
[0060] Please note that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include their plural referents unless the context clearly dictates otherwise.
[0061] It will be understood that certain features of the present disclosure that are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. In other cases, for brevity, various features of the present disclosure that are described in the context of a single embodiment may also be provided separately or in any suitable subcombination. All combinations of the embodiments related to the present disclosure are specifically embraced by the present disclosure and are intended to be disclosed herein as if each and every combination were individually and explicitly disclosed herein. In addition, all subcombinations of the various embodiments and elements thereof are also specifically embraced by the present disclosure and are intended to be disclosed herein as if each and every such subcombination were individually and explicitly disclosed herein.
[0062] II. System for gene editing of the BCL11A gene In a first aspect, the present disclosure provides a system comprising a Class 2, Type V CRISPR nuclease protein and one or more guide nucleic acids (gRNAs) for use in modifying or editing the BCL11A gene to reduce or eliminate expression of the BCL11A gene product. Exemplary Class 2, Type V CRISPR nuclease protein and guide nucleic acid systems include the CasX:gRNA system. The CasX:gRNA system is specifically designed to modify the BCL11A gene in eukaryotic cells. In some cases, the CasX:gRNA system is designed to knock down or knock out the BCL11A gene. Generally, any portion of the BCL11A gene can be targeted using the programmable compositions and methods provided herein. In some embodiments, the modified BCL11A gene is the wild-type sequence and the modified portion is selected from the group consisting of a BCL11A intron, a BCL11A exon, a BCL11A intron-exon junction, a BCL11A regulatory element, and an intergenic region, or the modification is a deletion or mutation of one or more exons.
[0063] As used herein, a "system," such as a system comprising a CRISPR nuclease protein of the present disclosure and one or more gRNAs, a nucleic acid encoding a CRISPR nuclease protein and gRNA of the present disclosure, and a vector comprising a nucleic acid or CRISPR nuclease protein and one or more gRNAs of the present disclosure, is used interchangeably with the term "composition."
[0064] The human BCL11A gene (HGNC:13221) encodes a protein (Q9H165) with the following sequence: (SEQ ID NO: 100). The BCL11A gene is defined as the sequence spanning chr2 60450520-60554467 of the human genome on chromosome 2 (GRCh38 / hg38 Ensembl 100).
[0065] In some embodiments, the present disclosure provides a system specifically designed to modify the BCL11A gene in eukaryotic cells, either in vitro, ex vivo, or in vivo in a subject. Generally, any portion of the BCL11A target nucleic acid can be targeted using the programmable compositions and methods provided herein. In some embodiments, the CRISPR nuclease is a class 2, type V nuclease. While there are differences among members of class 2 type V CRISPR-Cas systems, they share several common features that distinguish them from the Cas9 system. First, type V nucleases have an RNA-guided single effector containing a RuvC domain but no HNH domain, and recognize a T-rich PAM 5' upstream of the target region on the non-target strand. This differs from the Cas9 system, which relies on a G-rich PAM 3' to the target sequence. Unlike Cas9, which generates a blunt end proximal to the PAM, type V nucleases generate a double-strand break distal to the PAM sequence. Additionally, type V nucleases degrade ssDNA in trans when activated by target dsDNA or ssDNA binding in cis. In some embodiments, the present disclosure provides a class 2, type V nuclease selected from the group consisting of Cas12a, Cas12b, Cas12c, Cas12d (CasY), Cas12j, Cas12k, CasZ, and CasX. In some embodiments, the present disclosure provides a CasX:gRNA system comprising one or more CasX proteins and one or more guide nucleic acids (gRNAs). In other embodiments, the CasX:gRNA system of the present disclosure comprises one or more CasX proteins, one or more guide nucleic acids (gRNAs), and one or more donor template nucleic acids comprising a nucleic acid encoding a portion of the BCL11A gene, wherein the donor template nucleic acid comprises one or more nucleotide deletions, insertions, or mutations compared to the genomic nucleic acid sequence encoding the BCL11A protein. Each of these components and their use in editing the BCL11A gene are described herein below.
[0066] In some embodiments, the present disclosure provides gene editing pairs of CasX and gRNA of any of the embodiments described herein, which can be combined together prior to their use for gene editing, and are thus "pre-complexed" as a ribonucleoprotein complex (RNP). The use of a pre-complexed RNP confers advantages in the delivery of system components to cells or target nucleic acid sequences for editing of the target nucleic acid sequence.
[0067] In some embodiments, functional RNPs can be delivered to cells ex vivo by electrophoresis or chemical means. In other embodiments, functional RNPs can be delivered in their functional form by vectors either ex vivo or in vivo. In some embodiments, RNPs can be delivered to a subject in vivo using CasX delivery particles (XDPs). The gRNA can provide target specificity to the complex by including a targeting sequence (or "spacer") having a nucleotide sequence complementary to that of the target nucleic acid sequence. Meanwhile, the CasX variant protein of the pre-complexed CasX:gRNA is directed to (e.g., stabilized at) the target site within the target nucleic acid sequence by its association with the gRNA, providing site-specific activity, such as cleavage or nicking of the target sequence.
[0068] The system is useful in treating subjects with hemoglobinopathy diseases (e.g., sickle cell anemia or beta-thalassemia). Each of the components of the CasX:gRNA system, their functions, and their use in editing target nucleic acids in cells is described in further detail below.
[0069] III. Nucleic Acid Guide Systems for Gene Editing In another aspect, the present disclosure relates to specially designed guide ribonucleic acids (gRNAs) that contain a targeting sequence that is complementary to (and therefore capable of hybridizing with) a target nucleic acid sequence in the BCL11A gene, which, when complexed with a CRISPR nuclease, is useful for genome editing of a BCL11A target nucleic acid in a cell. In some embodiments, it is contemplated that multiple gRNAs are delivered in the system for modification of the target nucleic acid. For example, a pair of gRNAs with targeting sequences to different or overlapping regions of a target nucleic acid sequence can be used, each complexed with a CRISPR nuclease to bind and cleave at two different or overlapping sites within a gene, and the gene is then edited by non-homologous end joining (NHEJ), homology-directed repair (HDR), homology-independent targeted integration (HITI), micro-homology mediated end joining (MMEJ), single strand annealing (SSA), or base excision repair (BER).
[0070] In some embodiments, the present disclosure provides gRNAs utilized in a CasX:gRNA system, which is useful for genome editing of the BCL11A gene in eukaryotic cells. In certain embodiments, the gRNA of the system can form a complex with CasX nuclease. The present disclosure provides specially designed gRNAs, whose targeting sequence (or spacer, described in more detail below) is complementary to (and therefore capable of hybridizing with) the target nucleic acid sequence when used as a component of a gene editing CasX:gRNA system. Table 1 provides the sequence numbers of representative, but non-limiting, examples of targeting sequences for BCL11A target nucleic acids that can be utilized with the gRNAs of the present embodiments, which are described in more detail below.
[0071] a. Reference gRNA and gRNA variants As used herein, a "reference gRNA" refers to a CRISPR guide nucleic acid comprising the wild-type sequence of a naturally occurring gRNA. In some embodiments, a reference gRNA of the present disclosure may be subjected to one or more mutagenesis methods (e.g., mutagenesis methods described herein, which may include deep mutational evolution (DME), deep mutational scanning (DMS), error-prone PCR, cassette mutagenesis, random mutagenesis, staggered extension PCR, gene shuffling, or domain swapping) to generate one or more gRNA variants with enhanced or different properties compared to the reference gRNA. gRNA variants also include variants that contain one or more exogenous sequences, for example, fused to either the 5' or 3' end or inserted internally. The activity of a reference gRNA may be used as a benchmark against which the activity of a gRNA variant is compared, thereby measuring improvement in function or other characteristics of the gRNA variant. In other embodiments, a reference gRNA may be subjected to one or more deliberate, specifically targeted mutations to produce gRNA variants (e.g., rationally designed variants).
[0072] The gRNA of the present disclosure comprises two segments: a targeting sequence and a protein-binding segment. The targeting segment of a gRNA comprises a nucleotide sequence (interchangeably referred to as a guide sequence, spacer, targeter, or targeting sequence) that is complementary to (and therefore hybridizes with) a specific sequence (target site) within a target nucleic acid sequence (e.g., a target ssRNA, a target ssDNA, a strand of a double-stranded target DNA, etc.), as described in more detail below. The targeting sequence of a gRNA can bind to a target nucleic acid sequence (including a coding sequence, a complement of a coding sequence, or a non-coding sequence) and a regulatory element. The protein-binding segment (or "activator" or "protein-binding sequence") interacts with (e.g., binds to) the CasX protein as a complex forming an RNP (described in more detail below). Alternatively, the protein-binding segment is referred to herein as a "scaffold," which is composed of several regions (described in more detail below).
[0073] In the case of a dual guide RNA (dgRNA), the targeter and activator portions each have a duplex-forming segment, and the targeter duplex-forming segment and the activator duplex-forming segment are complementary to each other and hybridize to each other to form a double-stranded duplex (a dsRNA duplex for a gRNA). When the gRNA is a gRNA, the term "targeter" or "targeter RNA" is used herein to refer to the crRNA-like molecule (crRNA: "CRISPR RNA") of a CasX dual guide RNA (and thus of a CasX single guide RNA when the "activator" and "targeter" are linked together, e.g., by an intervening nucleotide). The crRNA has a 5' region that anneals to the tracrRNA, followed by nucleotides of the targeting sequence. Thus, for example, a guide RNA (dgRNA or sgRNA) comprises a guide sequence and a duplex-forming segment of the crRNA (which may also be referred to as a crRNA repeat). The corresponding tracrRNA-like molecule (activator) also contains a duplex-forming stretch of nucleotides that forms the other half of the dsRNA duplex of the protein-binding segment of the guide RNA. Thus, the targeter and activator hybridize as a matched pair to form a dual-guide NA (referred to herein as a "dual-guide NA," "binary gRNA," "dgRNA," "binary guide NA," or "binary guide NA"). Site-specific binding and / or cleavage of a target nucleic acid sequence (e.g., genomic DNA) by the CasX protein can occur at one or more positions (e.g., the sequence of the target nucleic acid) determined by base-pairing complementarity between the targeting sequence of the gRNA and the target nucleic acid sequence. Thus, for example, a gRNA of the present disclosure has a sequence complementary to a target nucleic acid adjacent to a sequence complementary to a TC PAM motif (or a PAM sequence such as ATC, CTC, GTC, or TTC) and is therefore capable of hybridizing to the target nucleic acid. Because the targeting sequence of the guide sequence hybridizes with the sequence of the target nucleic acid sequence, the targeter can be modified by the user to hybridize with a specific target nucleic acid sequence, as long as the position of the PAM sequence is taken into consideration.Thus, in some cases, the targeter sequence may be a non-naturally occurring sequence. In other cases, the targeter sequence may be a naturally occurring sequence derived from the gene to be edited. In other embodiments, the activator and targeter of a gRNA are covalently linked to each other (rather than hybridized to each other) and comprise a single molecule (referred to herein as a "single-molecule gRNA," "one-molecule guide NA," "single-guide NA," "single guide RNA," "single-molecule guide RNA," "one-molecule guide RNA," or "sgRNA"). In some embodiments, the sgRNA comprises an "activator" or a "targeter," and thus may be an "activator RNA" and a "targeter RNA," respectively. In some embodiments, the gRNA is a ribonucleic acid molecule ("gRNA"); in other embodiments, the gRNA is chimeric and comprises both DNA and RNA. As used herein, the term gRNA encompasses naturally occurring molecules as well as sequence variants.
[0074] In summary, the constructed gRNAs of the present disclosure comprise four distinct regions or domains: an RNA triplex, a scaffold stem, an extension stem, and a targeting sequence (which in embodiments of the present disclosure is specific to the target nucleic acid and located at the 3' end of the gRNA). The RNA triplex, scaffold stem, and extension stem together are referred to as the "scaffold" of the gRNA.
[0075] b.RNA triplex In some embodiments of the guide NAs (including reference sgRNAs) provided herein, there is an RNA triplex that includes a UUU-nX(about 4-15)-UUU (SEQ ID NO: 226) stem-loop sequence that terminates in AAAG after two intervening stem-loops (a scaffold stem-loop and an extended stem-loop), forming a pseudoknot that may extend across the triplex into a double-stranded pseudoknot. The UU-UUU-AAA sequence of the triplex forms a nexus between the targeting sequence, the scaffold stem, and the extended stem. In an exemplary CasX sgRNA, the UUU-loop-UUU region is encoded first, followed by the scaffold stem-loop, followed by the extended stem-loop connected by a tetraloop, followed by AAAG to close the triplex before the targeting sequence.
[0076] c. Scaffold stem loop In some embodiments of sgRNAs of the present disclosure, the triplex region is followed by a scaffold stem-loop. The scaffold stem-loop is the region of the gRNA to which a CasX protein (e.g., a reference or CasX variant protein) binds. In some embodiments, the scaffold stem-loop is a fairly short and stable stem-loop. In some cases, the scaffold stem-loop does not tolerate much variation and requires some form of RNA bubble. In some embodiments, the scaffold stem is required for the function of the CasX sgRNA. While this is similar to the nexus stem of Cas9, which is likely a critical stem-loop, the scaffold stem of the CasX sgRNA in some embodiments possesses a necessary bulge (RNA bubble), which differs from many other stem-loops found in CRISPR / Cas systems. In some embodiments, the presence of this bulge is conserved across sgRNAs that interact with different CasX proteins. An exemplary sequence for a gRNA scaffold stem-loop sequence comprises the sequence CCAGCGACUAUGUCGUAUGG (SEQ ID NO: 20).
[0077] d. extended stem loop In some embodiments of the CasX sgRNA of the present disclosure, the scaffold stem-loop is followed by an extended stem-loop. In some embodiments, the extended stem primarily comprises a synthetic tracrRNA and crRNA fusion without the CasX protein bound. In some embodiments, the extended stem-loop can be highly malleable. In some embodiments, the single-guide gRNA is generated using a GAAA tetraloop or GAGAAA linker between the tracrRNA and crRNA in the extended stem-loop. In some cases, the targeter and activator of the CasX sgRNA are linked to each other by an intervening nucleotide, and the linker can have a length of 3 to 20 nucleotides. In some embodiments of the CasX sgRNA of the present disclosure, the extended stem is a large 32-bp loop located outside the CasX protein in the ribonucleoprotein complex. An exemplary sequence of the extended stem-loop sequence of the sgRNA includes the sequence GCGCUUAUUUAUCGGAGAGAAAUCCGAUAAAUAAGAAGC (SEQ ID NO: 21). In some embodiments, the extended stem-loop comprises a GAGAAA spacer sequence.
[0078] e. targeting sequence In some embodiments of gRNAs of the present disclosure, the extended stem-loop is followed by a region that forms part of a triplex, followed by a targeting sequence (or "spacer") at the 3' end of the gRNA. The targeting sequence targets the CasX ribonucleoprotein holocomplex to a specific region of the target nucleic acid sequence of the gene to be modified. Thus, for example, a gRNA targeting sequence of the present disclosure has a sequence that is complementary to (and therefore capable of hybridizing to) a portion of the BCL11A gene in a eukaryotic nucleic acid (e.g., a eukaryotic chromosome, chromosomal sequence, eukaryotic RNA, etc.) as a component of an RNP when the TC PAM motif or any one of the PAM sequences TTC, ATC, GTC, or CTC is located one nucleotide 5' to the non-target strand sequence that is complementary to the target sequence. The targeting sequence of a gRNA can be modified to enable the gRNA to target a desired sequence of any desired target nucleic acid sequence, as long as the position of the PAM sequence is taken into consideration. In some embodiments, the gRNA scaffold is located at the 5' end of the target sequence, and the targeting sequence is located at the 3' end of the gRNA. In some embodiments, the PAM motif sequence recognized by the nuclease of RNP is TC. In other embodiments, the PAM sequence recognized by the nuclease of RNP is NTC.
[0079] In some embodiments, the gRNA targeting sequence is specific to a portion of the gene encoding the BCL11A protein. In some embodiments, the gRNA targeting sequence is specific to an exon of BCL11A. In some embodiments, the gRNA targeting sequence is specific to an intron of BCL11A. In some embodiments, the gRNA targeting sequence is specific to an intron-exon junction of BCL11A. In some embodiments, the gRNA targeting sequence has a sequence that hybridizes to a BCL11A regulatory element, a coding region of BCL11A, a non-coding region of BCL11A, or a combination thereof (e.g., the intersection of two regions). In some embodiments, the regulatory element comprises a GATA-binding sequence. In some embodiments, the gRNA targeting sequence is complementary to a sequence comprising one or more single nucleotide polymorphisms (SNPs) in the BCL11A gene or its complement. SNPs within the coding sequence of BCL11A or within the non-coding sequence of BCL11A are both within the scope of the present disclosure. In other embodiments, the targeting sequence of the gRNA is complementary to a sequence in an intergenic region of the BCL11A gene or is a sequence complementary to an intergenic region of the BCL11A gene.
[0080] In some embodiments, the targeting sequence of the gRNA is designed to be specific for regulatory elements that regulate the expression of the BCL11A gene product. Such regulatory elements include, but are not limited to, promoter regions, enhancer regions, intergenic regions, 5' untranslated regions (5'UTRs), 3' untranslated regions (3'UTRs), conserved elements, and regions containing cis-regulatory elements. The promoter region is intended to encompass nucleotides within 5 kb of the start of the coding sequence, or, in the case of gene enhancer elements or conserved elements, may be thousands, hundreds of thousands, or millions of base pairs (bp) away from the coding sequence of the gene of the target nucleic acid. In certain embodiments, the targeting sequence of the gRNA hybridizes to a sequence complementary to a regulatory element of BCL11A. In one embodiment, the targeting sequence of the gRNA is UGGAGCCUGUGAUAAAAGCA (SEQ ID NO: 22), which hybridizes to or has at least 90% or at least 95% sequence identity with the BCL11A GATA1 erythroid-specific enhancer binding site sequence (see Figure 23). In another embodiment, the targeting sequence of the gRNA is UGCUUUUAUCACAGGCUCCA (SEQ ID NO: 23), or has at least 90% or at least 95% sequence identity thereto. In another embodiment, the targeting sequence of the gRNA is UGCUUUUAUCACAGGCUCCA (SEQ ID NO: 23), or has at least 90% or at least 95% sequence identity thereto. In other embodiments, the targeting sequence of the gRNA is selected from the group consisting of CAGGCUCCAGGAAGGGUUUG (SEQ ID NO: 2949), GAGGCCAAACCCUUCCUGGA (SEQ ID NO: 2948), AGUGCAAGCUAACAGUUGCU (SEQ ID NO: 15747), and AUACAACUUUGAAGCUAGUC (SEQ ID NO: 15748).
[0081] In postnatally maturing subjects, GATA1 binding enhances BCL11A expression, which in turn suppresses hemoglobin F (HbF) expression in favor of hemoglobin gamma. However, suppressing BCL11A expression in subjects with certain hemoglobinopathies has been demonstrated to restore HbF expression, allowing the subject to compensate for otherwise defective hemoglobin.
[0082] In some embodiments, the targeting sequence of the gRNA has 14 to 35 contiguous nucleotides. In some embodiments, the targeting sequence has 14, 15, 16, 18, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 contiguous nucleotides. In some embodiments, the targeting sequence consists of 20 contiguous nucleotides. In some embodiments, the targeting sequence consists of 19 contiguous nucleotides. In some embodiments, the targeting sequence consists of 18 contiguous nucleotides. In some embodiments, the targeting sequence consists of 17 contiguous nucleotides. In some embodiments, the targeting sequence consists of 16 contiguous nucleotides. In some embodiments, the targeting sequence consists of 15 contiguous nucleotides. In some embodiments, the targeting sequence has 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 contiguous nucleotides, and the targeting sequence can contain 0 to 5, 0 to 4, 0 to 3, or 0 to 2 mismatches to the target nucleic acid sequence and retain sufficient binding specificity such that an RNP containing a gRNA that includes the targeting sequence can form a complementary bond to the target nucleic acid.
[0083] Representative, but non-limiting, examples of targeting sequences for target nucleic acid sequences contemplated for use in gRNAs of the present disclosure are provided as SEQ ID NOs: 272-2100 and 2286-26789 (see Table 1). In some embodiments, the present disclosure provides targeting sequences for ATC PAMs comprising sequences that are at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the sequences of SEQ ID NOs: 272-2100 or 2286-5625. In some embodiments, the present disclosure provides targeting sequences for ATC PAMs comprising the sequences of SEQ ID NOs: 272-2100 or 2286-5625. In some embodiments, the present disclosure provides targeting sequences for CTC PAMs comprising a sequence that is at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the sequence of SEQ ID NOs: 5626-13616. In some embodiments, the present disclosure provides targeting sequences for GTC PAMs comprising a sequence that is at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the sequence of SEQ ID NOs: 13617-17903. In some embodiments, the present disclosure provides a targeting sequence for a GTC PAM comprising the sequence of SEQ ID NOs: 13617-17903.In some embodiments, the present disclosure provides a targeting sequence for a TTC PAM comprising a sequence that is at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, or 100% identical to the sequence of SEQ ID NOs: 17904-26789. In some embodiments, the present disclosure provides a targeting sequence for a TTC PAM comprising the sequence of SEQ ID NOs: 17904-26789. In some embodiments, a targeting sequence contemplated for use in a gRNA of the present disclosure comprises the sequence of SEQ ID NOs: 272-2100 or 2286-26789 with a single nucleotide removed from the 3' end of the sequence. In other embodiments, the targeting sequence of a gRNA comprises the sequence of SEQ ID NOs: 272-2100 or 2286-26789 with two nucleotides removed from the 3' end of the sequence. In other embodiments, the gRNA targeting sequence comprises the sequence of SEQ ID NOs: 272-2100 or 2286-26789 with three nucleotides removed from the 3' end of the sequence. In other embodiments, the gRNA targeting sequence comprises the sequence of SEQ ID NOs: 272-2100 or 2286-26789 with four nucleotides removed from the 3' end of the sequence. In other embodiments, the gRNA targeting sequence comprises the sequence of SEQ ID NOs: 272-2100 or 2286-26789 with five nucleotides removed from the 3' end of the sequence. In the preceding embodiments of the paragraph, thymine (T) nucleotides can replace one or more or all of the uracil (U) nucleotides in any of the targeting sequences, such that the gRNA targeting sequence can be a gDNA or gRNA, or a chimera of RNA and DNA, or when the coding sequence of the spacer is incorporated into an expression vector. In some embodiments, the targeting sequence of SEQ ID NOs: 272-2100 or 2286-26789 has at least 1, 2, 3, 4, 5, or 6 or more thymine nucleotides substituted with uracil nucleotides.
[0084] [Table 1]
[0085] In some embodiments, the CasX:gRNA system includes a first gRNA and further includes a second (and optionally, a third, fourth, fifth, or more) gRNA, where the second or additional gRNA has a targeting sequence complementary to a different or overlapping portion of the target nucleic acid sequence compared to the targeting sequence of the first gRNA, thereby targeting multiple points in the target nucleic acid, e.g., introducing multiple cleavages in the target nucleic acid by CasX. In such cases, it will be understood that the second or additional gRNA is complexed with additional copies of the CasX protein. Depending on the selection of the gRNA targeting sequence, defined regions of the target nucleic acid sequence surrounding specific positions within the target nucleic acid can be modified or edited using the CasX:gRNA system described herein, including facilitating insertion of a donor template containing a mutation in the BCL11A gene. In certain embodiments, the second gRNA can include a targeting sequence complementary to a sequence adjacent to the GATA1 binding site on the 5' or 3' side, such that the GATA1 binding site is disrupted.
[0086] f. gRNA scaffold Except for the targeting sequence domain, the remaining components of the gRNA are referred to herein as the scaffold. In some embodiments, the gRNA scaffold is derived from a naturally occurring sequence, described below as a reference gRNA. In other embodiments, the gRNA scaffold is a variant of the reference gRNA, in which mutations, insertions, deletions, or domain substitutions have been introduced to confer desirable or improved properties to the gRNA.
[0087] The term "adjacent to," with respect to a polynucleotide or amino acid sequence, refers to sequences that are next to or adjacent to each other in a polynucleotide or polypeptide. One of skill in the art will understand that two sequences can be considered adjacent to each other and still encompass a limited amount of intervening sequence, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or amino acids.
[0088] Table 2 provides the sequence of a reference gRNA tracr and scaffold sequence. In some embodiments, the present disclosure provides gRNA sequences, wherein the gRNA has a scaffold comprising a sequence having at least one nucleotide alteration compared to a reference gRNA sequence having the sequence of SEQ ID NOs: 4-16 shown in Table 2, or the sequence of any one of SEQ ID NOs: 4-16 in Table 2. In embodiments where the vector comprises DNA encoding the sequence of the gRNA or the gRNA is a chimera of RNA and DNA, it will be understood that thymine (T) bases can be substituted for uracil (U) bases in any of the gRNA sequence embodiments described herein.
[0089] [Table 2]
[0090] g.gRNA variants In another aspect, the present disclosure relates to guide nucleic acid variants (alternatively referred to herein as "gRNA variants" or "gRNA variants") that contain one or more modifications compared to a reference gRNA scaffold. As used herein, "scaffold" refers to all portions of a gRNA that are necessary for the function of the gRNA, excluding the targeting sequence.
[0091] In some embodiments, gRNA variants contain one or more nucleotide substitutions, insertions, deletions, or swapped or substituted regions compared to a reference gRNA sequence of the present disclosure. In some embodiments, mutations can occur in any region of the reference gRNA scaffold to generate a gRNA variant. In some embodiments, the scaffold of the gRNA variant sequence has at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%, at least 80%, at least 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the sequence of SEQ ID NO:4 or SEQ ID NO:5.
[0092] In some embodiments, the gRNA variant comprises one or more nucleotide changes in one or more regions of the reference gRNA that improve characteristics compared to the reference gRNA. Exemplary regions include RNA triplexes, pseudoknots, scaffold stem-loops, and extended stem-loops. In some cases, the variant scaffold stem further comprises a bubble. In other cases, the variant scaffold further comprises a triplex loop region. In still other cases, the variant scaffold further comprises a 5' unstructured region. In one embodiment, the gRNA variant scaffold comprises a scaffold stem-loop having at least 60% sequence identity to SEQ ID NO: 14. In another embodiment, the gRNA variant comprises a scaffold stem-loop having the sequence CCAGCGACUAUGUCGUAGUGG (SEQ ID NO: 25). In another embodiment, the present disclosure provides a C18G substitution, a G55 insertion, a U1 deletion, and an altered extended stem-loop (the original 6 nt loop and 13 most-loop-proximal base pairs (32 nucleotides total) are replaced by a Uvsx hairpin (4 nt loop and 5 most-loop-proximal base pairs; 14 nucleotides total), and the loop-distal base of the extended stem is converted to a perfectly base-paired stem adjacent to the new Uvsx hairpin by an A99 deletion and a G64U substitution) relative to SEQ ID NO: 5. In the foregoing embodiment, the gRNA scaffold comprises the sequence ACUGGCGCUUUUAUCUGAUUACUUUGAGAGCCAUCACCAGCGACUAUGUCGUAGUGGGUAAAGCUCCCUCUUCGGAGGGAGCAUCAAAG (SEQ ID NO: 2238).
[0093] All gRNA variants that have one or more improved functions or characteristics, or that add one or more new functions when the variant gRNA is compared to a reference gRNA described herein, are contemplated within the scope of this disclosure. A representative example of such a gRNA variant is Guide 174 (SEQ ID NO: 2238), the design of which (and the rationale for its design) is described in the Examples. In some embodiments, the gRNA variant adds a new function to the RNP that contains the gRNA variant. In some embodiments, the gRNA variant has an improved characteristic selected from the following: improved stability, improved solubility, improved gRNA transcription, improved resistance to nuclease activity, increased gRNA folding rate, reduced by-product formation during folding, increased productive folding, improved binding affinity for the CasX protein, improved binding affinity for the target DNA when complexed with the CasX protein, improved gene editing when complexed with the CasX protein, improved editing specificity when complexed with the CasX protein, and improved ability to utilize one or more broader PAM sequences including ATC, CTC, GTC, or TTC in editing the target DNA when complexed with the CasX protein, or any combination thereof. In some cases, one or more of the improved characteristics of the gRNA variant is improved by at least about 1.1 to about 100,000-fold compared to the reference gRNA of SEQ ID NO:4 or SEQ ID NO:5. In other cases, one or more improved characteristics of the gRNA variant are improved by at least about 1.1-fold, at least about 10-fold, at least about 100-fold, at least about 1000-fold, at least about 10,000-fold, at least about 100,000-fold, or more compared to the reference gRNA of SEQ ID NO:4 or SEQ ID NO:5.In other cases, one or more of the improved characteristics of the gRNA variant may be about 1.1 to 100,00 fold, about 1.1 to 10,00 fold, about 1.1 to 1,000 fold, about 1.1 to 500 fold, about 1.1 to 100 fold, about 1.1 to 50 fold, about 1.1 to 20 fold, about 10 to 100,00 fold, about 10 to 10,000 fold, about 10 to 500 fold, about 10 to 100 fold, about 10 to 50 fold, about 10 to 20 fold, about 2 to 70 fold, about 2 to 50 fold, about 2 to 30 fold, about 2 to 20 fold, about 2 to 10 fold, about 5 to 50 fold, or , about 5 to 30 times, about 5 to 10 times, about 100 to 100,00 times, about 100 to 10,00 times, about 100 to 1,000 times, about 100 to 500 times, about 500 to 100,00 times, about 500 to 10,000 times, about 500 to 1,000 times, about 500 to 750 times, about 1,000 to 100,00 times, about 10,000 to 100,00 times, about 20 to 500 times, about 20 to 250 times, about 20 to 200 times, about 20 to 100 times, about 20 to 50 times, about 50 to 10,000 times, about 50 to 1,000 times, about 50 to 500 times, about 50 to 200 times, or about 50 to 100 times. In other cases, one or more improved characteristics of the gRNA variant may be about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 25-fold, 30-fold, 40-fold, 45-fold, 50-fold, 55-fold, 60-fold, or greater than ... , 70x, 80x, 90x, 100x, 110x, 120x, 130x, 140x, 150x, 160x, 170x, 180x, 190x, 200x, 210x, 220x, 230x, 240x, 250x, 260x, 270x, 280x, 290x, 300x, 310x, 320x, 330x, 340x, 350x, 360x, 370x, 380x, 390x, 400x, 425x, 450x, 475x, or 500x improvement.
[0094] In some embodiments, gRNA variants can be created by subjecting a reference gRNA to one or more mutagenesis methods, such as those described herein below, which may include comprehensive mutational evolution (DME), comprehensive mutational scanning (DMS), error-prone PCR, cassette mutagenesis, random mutagenesis, tethered extension PCR, gene shuffling, or domain swapping, to generate gRNA variants of the present disclosure. The activity of the reference gRNA may be used as a benchmark against which the activity of a gRNA variant is compared, thereby measuring the improvement in function of the gRNA variant compared to the reference gRNA. In other embodiments, the reference gRNA can be subjected to one or more deliberately targeted mutations, substitutions, or domain swaps to produce gRNA variants (e.g., rationally designed variants). Exemplary gRNA variants produced by such methods are described in the Examples, and representative sequences of gRNA scaffolds are provided in Table 3.
[0095] In some embodiments, the gRNA variant comprises one or more modifications compared to the reference guide nucleic acid scaffold sequence, the one or more modifications being selected from the following: at least one nucleotide substitution in a region of the gRNA variant, at least one nucleotide deletion in a region of the gRNA variant, at least one nucleotide insertion in a region of the gRNA variant, a substitution of all or a portion of a region of the gRNA variant, a deletion of all or a portion of a region of the gRNA variant, or any combination of the above. In some cases, the modification is a substitution of 1 to 15 contiguous or non-contiguous nucleotides in one or more regions of the gRNA variant. In other cases, the modification is a deletion of 1 to 10 contiguous or non-contiguous nucleotides in one or more regions of the gRNA variant. In other cases, the modification is an insertion of 1 to 10 contiguous or non-contiguous nucleotides in one or more regions of the gRNA variant. In other cases, the modification is a replacement of the scaffold stem-loop or extended stem-loop with an RNA stem-loop sequence from a heterologous RNA source having proximal 5' and 3' ends. In some cases, the gRNA variants of the present disclosure contain two or more modifications in one region. In other cases, the gRNA variants of the present disclosure contain modifications in two or more regions. In other cases, the gRNA variants contain any combination of the modifications described in this paragraph.
[0096] In some embodiments, a 5' G is added to the gRNA variant sequence for in vivo expression because transcription from the U6 promoter is more efficient and more consistent with respect to the start site when the +1 nucleotide is G. In other embodiments, two 5' Gs are added to the gRNA variant sequence to increase production efficiency during in vitro transcription because T7 polymerase strongly prefers a G at the +1 position and a purine at the +2 position. In some cases, a 5' G base is added to the reference scaffold in Table 2. In other cases, a 5' G base is added to the variant scaffolds of SEQ ID NOs: 2238-2285, 26794-26839, and 27219-2726 in Table 3.
[0097] Table 3 provides exemplary gRNA variant scaffold sequences of the present disclosure. In some embodiments, the gRNA variant scaffold comprises any one of the sequences listed in SEQ ID NOs: 2238-2285, 26794-26839, and 27219-27265 in Table 3, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the gRNA variant scaffold comprises any one of SEQ ID NOs: 2238-2285, 26794-26839, and 27219-27265. In some embodiments, the gRNA variant scaffold comprises any one of SEQ ID NOs: 2281-2285, 26794-26839, and 27219-27265, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto. In some embodiments, the gRNA variant scaffold comprises any one of SEQ ID NOs: 2281-2285, 26794-26839, and 27219-27265. In embodiments in which the vector comprises DNA encoding the sequence of the gRNA or the gRNA is a chimera of RNA and DNA, it will be understood that thymine (T) bases can be substituted for uracil (U) bases in any of the gRNA sequence embodiments described herein.
[0098] [Table 3-1]
[0099] [Table 3-2]
[0100] [Table 3-3]
[0101] Table 3-4
[0102] Table 3-5
[0103] Table 3-6
[0104] Table 3-7
[0105] Table 3-8
[0106] Table 3-9
[0107] Table 3-10
[0108] Table 3-11
[0109] In some embodiments, the sgRNA variant comprises one or more additional changes to the sequence of SEQ ID NO:2238, SEQ ID NO:2239, SEQ ID NO:2240, SEQ ID NO:2241, SEQ ID NO:2243, SEQ ID NO:2256, SEQ ID NO:2274, SEQ ID NO:2275, SEQ ID NO:2279, SEQ ID NO:2281, SEQ ID NO:2285, SEQ ID NO:26797, or SEQ ID NO:26800 in Table 3.
[0110] In some embodiments of gRNA variants of the present disclosure, the gRNA variant comprises at least one modification, wherein the at least one modification compared to the reference guide scaffold of SEQ ID NO: 5 is selected from one or more of the following: (a) a C18G substitution in the triple-stranded loop, (b) a G55 insertion in the stem bubble, (c) a U1 deletion, (d) (i) a modification of the extended stem-loop in which the 6-nt loop and 13 base pairs proximal to the loop are replaced by a Uvsx hairpin, and (ii) the base distal to the loop is perfectly base-paired due to the deletion of A99 and substitution of G65U. In the above exemplary embodiment, the gRNA variant comprises the sequence of any one of SEQ ID NOs: 2238, 2241, 2244, 2248, 2249, 2256, 2259-2285, 26797, or 26800.
[0111] In some embodiments, the gRNA variant comprises an exogenous stem-loop with a long non-coding RNA (lncRNA). As used herein, lncRNA refers to a non-coding RNA that is greater than about 200 bp in length. In some embodiments, the 5' and 3' ends of the exogenous stem-loop are base-paired (i.e., interact to form a region of double-stranded RNA). In some embodiments, the 5' and 3' ends of the exogenous stem-loop are base-paired, and one or more regions between the 5' and 3' ends of the exogenous stem-loop are not base-paired.
[0112] In some embodiments, the present disclosure provides gRNA variants having nucleotide modifications compared to a reference gRNA, including (a) a substitution of 1 to 15 consecutive or non-consecutive nucleotides in one or more regions of the gRNA variant, (b) a deletion of 1 to 10 consecutive or non-consecutive nucleotides in one or more regions of the gRNA variant, (c) an insertion of 1 to 10 consecutive or non-consecutive nucleotides in one or more regions of the gRNA variant, (d) a replacement of the scaffold stem-loop or extended stem-loop with an RNA stem-loop sequence from a heterologous RNA source having proximal 5' and 3' ends, or any combination of (a)-(d). Any of the substitutions, insertions, and deletions described herein can be combined to generate gRNA variants of the present disclosure. For example, a gNA variant can include at least one substitution and at least one deletion compared to a reference gRNA, at least one substitution and at least one insertion compared to a reference gRNA, at least one insertion and at least one deletion compared to a reference gRNA, or at least one substitution, one insertion, and one deletion compared to a reference gRNA.
[0113] In some embodiments, sgRNA variants of the present disclosure contain one or more additional changes relative to a previously generated variant, which itself serves as the sequence to be modified. In some embodiments, the sgRNA variants contain one or more additional changes relative to the sequence of SEQ ID NO:2238, SEQ ID NO:2239, SEQ ID NO:2240, SEQ ID NO:2241, SEQ ID NO:2241, SEQ ID NO:2274, SEQ ID NO:2275, SEQ ID NO:2279, or SEQ ID NO:2285, SEQ ID NO:26797, or SEQ ID NO:26800.
[0114] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 174 (SEQ ID NO: 2238), and the resulting gRNA variants exhibit functional improvements compared to parent 174 when evaluated in in vitro or in vivo assays under comparable conditions.
[0115] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 175 (SEQ ID NO: 2239), and the resulting gRNA variants exhibit functional improvements compared to the parent 174 when evaluated in in vitro or in vivo assays under comparable conditions.
[0116] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 215 (SEQ ID NO: 2275), and the resulting gRNA variants exhibit functional improvements compared to parent 215 when evaluated in in vitro or in vivo assays under comparable conditions.
[0117] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 221 (SEQ ID NO: 2281), and the resulting gRNA variants exhibit functional improvements compared to parent 221 when evaluated in in vitro or in vivo assays under comparable conditions.
[0118] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 225 (SEQ ID NO: 2285), and the resulting gRNA variants exhibit functional improvements compared to parent 225 when evaluated in in vitro or in vivo assays under comparable conditions.
[0119] In exemplary embodiments, the gRNA variants comprise one or more modifications to gRNA scaffold variant 235 (SEQ ID NO: 26800), and the resulting gRNA variants exhibit functional improvements compared to the parent 225 when evaluated in in vitro or in vivo assays under comparable conditions.
[0120] In some embodiments, the gRNA variant comprises an exogenous extended stem-loop, and such differences from the reference gRNA are as follows: In some embodiments, the exogenous extended stem-loop has little or no identity to the reference stem-loop region disclosed herein (e.g., SEQ ID NO: 15). In some embodiments, the exogenous stem loop is at least 10 bp, at least 20 bp, at least 30 bp, at least 40 bp, at least 50 bp, at least 60 bp, at least 70 bp, at least 80 bp, at least 90 bp, at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp, at least 700 bp, at least 800 bp, at least 900 bp, at least 1,000 bp, at least 2,000 bp, at least 3,000 bp, at least 4,000 bp, at least 5,000 bp, at least 6,000 bp, at least 7,000 bp, at least 8,000 bp, at least 9,000 bp, at least 10,000 bp, at least 12,000 bp, at least 15,000 bp, or at least 20,000 bp. In some embodiments, the gRNA variant comprises an extended stem-loop region comprising at least 10, at least 100, at least 500, at least 1000, or at least 10,000 nucleotides. In some embodiments, the heterologous stem-loop increases the stability of the gRNA. In some embodiments, the heterologous RNA stem-loop is capable of binding to proteins, RNA structures, DNA sequences, or small molecules. In some embodiments, the exogenous stem-loop region replacing the stem-loop comprises an RNA stem-loop or hairpin, and the resulting gRNA has increased stability and can interact with specific cellular proteins or RNAs, depending on the loop selection.Such exogenous extended stem loops include, for example, those derived from thermostable RNAs, such as MS2 hairpin (ACAUGAGGAUCACCCAUGU (SEQ ID NO: 27)), Qβ hairpin (UGCAUGUCUAAGACAGCA (SEQ ID NO: 28)), U1 hairpin II (AAUCCAUUGCACUCCGGAUU (SEQ ID NO: 29)), Uvsx (CCUCUUCGGAGG (SEQ ID NO: 30)), PP7 hairpin (AGGAGUUUCUAUGGAAACCCU (SEQ ID NO: 31)), phage replication loop (AGGUGGGACGACCUCUCGGUCGUCCUAUCU (SEQ ID NO: 32)), kissing loop_a (UGCUCGCUCCGUUCGAGCA (SEQ ID NO: 33)), kissing loop_b (UGCUCGCUCCGUUCGAGCA (SEQ ID NO: 34)), and the like. The gRNA may comprise a stem-loop 1 (UGCUCGACGCGUCCUCGAGCA (SEQ ID NO: 34)), kissing loop_b2 (UGCUCGUUUGCGGCUACGAGCA (SEQ ID NO: 35)), G-triplet M3q (AGGGAGGGAGGGAGAGG (SEQ ID NO: 149)), G-quadruplex telomere basket (GGUUAGGGUUAGGGUUAGG (SEQ ID NO: 150)), sarcin-ricin loop (CUGCUCAGUACGAGAGGAACCGCAG (SEQ ID NO: 151)), or pseudoknot (UACACUGGGAUCGCUGAAUUAGAGAUCGGCGUCCUUUCAUUCUAUAUACUUUGGAGUUUUAAAAUGUCUCUAAGUACA (SEQ ID NO: 152)). In some embodiments, one of the foregoing hairpin sequences is incorporated into the stem-loop to aid in directing incorporation of the gRNA (and associated CasX in the RNP complex) into the budding XDP (described in more detail below).
[0121] In embodiments of gRNA variants, the gRNA variants further comprise a spacer (or targeting sequence) (described in more detail above) located at the 3' end of the gRNA and capable of hybridizing to a target nucleic acid specific for the DMPK sequence, wherein the spacer comprises at least 14 to about 35 nucleotides and is designed with a sequence complementary to the target DNA. In some embodiments, the encoded gRNA variant comprises a targeting sequence of at least 10 to 20 nucleotides complementary to the target DNA. In some embodiments, the targeting sequence has 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nucleotides. In some embodiments, the encoded gRNA variant comprises a targeting sequence having 20 nucleotides. In some embodiments, the targeting sequence has 25 nucleotides. In some embodiments, the targeting sequence has 24 nucleotides. In some embodiments, the targeting sequence has 23 nucleotides. In some embodiments, the targeting sequence has 22 nucleotides. In some embodiments, the targeting sequence has 21 nucleotides. In some embodiments, the targeting sequence has 20 nucleotides. In some embodiments, the targeting sequence has 19 nucleotides. In some embodiments, the targeting sequence has 18 nucleotides. In some embodiments, the targeting sequence has 17 nucleotides. In some embodiments, the targeting sequence has 16 nucleotides. In some embodiments, the targeting sequence has 15 nucleotides. In some embodiments, the targeting sequence has 14 nucleotides.
[0122] h. Complex formation with CasX protein In some embodiments, the gRNA variant, upon expression, is complexed as an RNP with a CasX variant protein comprising any one of the sequences in Table 4 (SEQ ID NOS: 36-99, 101-148, and 26908-27154), or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity thereto. In some embodiments, upon expression, the gRNA variant is complexed as an RNP with a CasX variant protein comprising any one of SEQ ID NOs: 59, 72-99, 101-148, or 26908-27154, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity thereto. In some embodiments, upon expression, the gRNA variant is complexed as an RNP with a CasX variant protein comprising any one of SEQ ID NOs: 132-148 or 26908-27154, or a sequence having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity thereto.
[0123] In some embodiments, the gRNA variant has an improved ability to form a complex with a CasX protein (e.g., a reference CasX or CasX variant protein) compared to a reference gRNA. In some embodiments, the gRNA variant has an improved affinity for a CasX protein (e.g., a reference or variant protein) compared to a reference gRNA, thereby improving its ability to form a ribonucleoprotein (RNP) complex with the CasX protein, as described in the Examples. Improving the formation of a ribonucleoprotein complex can, in some embodiments, improve the efficiency with which functional RNPs are assembled. In some embodiments, more than 90%, more than 93%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99% of RNPs comprising the gRNA variant and its targeting sequence are competent for gene editing of the target nucleic acid.
[0124] An exemplary nucleotide change that can improve the ability of a gRNA variant to form a complex with a CasX protein may, in some embodiments, include replacing the scaffold stem with a thermostable stem-loop. Without wishing to be bound by any theory, replacing the scaffold stem with a thermostable stem-loop can increase the overall binding stability of the gRNA variant with the CasX protein. Alternatively, or additionally, removing a large portion of the stem-loop can alter the folding kinetics of the gRNA variant, e.g., by reducing the extent to which the gRNA variant can "tangle" with itself, which may result in the formation of a functionally folded gRNA more easily and rapidly. In some embodiments, the selection of the scaffold stem-loop sequence can vary depending on the different targeting sequences utilized for the gRNA. In some embodiments, the scaffold sequence can be tailored to the targeting sequence, and thus the target sequence. Biochemical assays, including those in the Examples, can be used to assess the binding affinity of the CasX protein to the gRNA variant to form RNPs. For example, one skilled in the art can measure changes in the amount of fluorescently tagged gRNA bound to immobilized CasX protein in response to increasing concentrations of an additional unlabeled "cold competitor" gRNA. Alternatively, or additionally, one can monitor or observe how the fluorescent signal changes as different amounts of fluorescently labeled gRNA are flowed over the immobilized CasX protein. Alternatively, the ability to form RNPs can be assessed using an in vitro cleavage assay against a defined target nucleic acid sequence.
[0125] IV. Proteins for modifying target nucleic acids The present disclosure provides a system comprising a CRISPR nuclease useful for genome editing in eukaryotic cells. In some embodiments, the CRISPR nuclease used in the genome editing system is a class 2, type V nuclease. Although there are differences between members of class 2, type V CRISPR-Cas systems, they share several common features that distinguish them from the Cas9 system. First, class 2, type V nucleases have a single RNA-guided RuvC domain-containing effector but no HNH domain, and recognize a T-rich PAM 5' upstream of the target region on the non-target strand, which differs from the Cas9 system, which relies on a G-rich PAM 3' to the target sequence. Unlike Cas9, which generates blunt ends at proximal sites close to the PAM, type V nucleases generate double-strand breaks distal to the PAM sequence. Additionally, when activated by target dsDNA or ssDNA binding in cis, type V nucleases degrade ssDNA in trans. In some embodiments, the type V nuclease of the present embodiments recognizes a 5'-TC PAM motif and generates sticky ends that are cleaved only by the RuvC domain. In some embodiments, the type V nuclease is selected from the group consisting of Cas12a, Cas12b, Cas12c, Cas12d (CasY), Cas12j, Cas12k, CasZ, and CasX. In some embodiments, the present disclosure provides a system comprising a CasX protein and one or more gRNA acids (CasX:gRNA system), where the gRNA acids are specifically designed to modify a target nucleic acid sequence in a eukaryotic cell.
[0126] As used herein, the term "CasX protein" refers to a family of proteins and includes all naturally occurring CasX proteins, proteins that share at least 50% identity with a naturally occurring CasX protein, as well as CasX variants that have one or more improved characteristics compared to a naturally occurring reference CasX protein.
[0127] The CasX proteins of the present disclosure comprise at least one of the following domains: a non-target strand binding (NTSB) domain, a target strand loading (TSL) domain, a helix I domain, a helix II domain, an oligonucleotide binding domain (OBD), and a RuvC DNA cleavage domain.
[0128] In some embodiments, a CasX protein can bind to and / or modify (e.g., nick, catalyze double-stranded cleavage, methylate, demethylate, etc.) a target nucleic acid at a specific sequence targeted by an associated gRNA that hybridizes to a sequence within the target nucleic acid sequence.
[0129] a. Reference CasX protein The present disclosure provides naturally occurring CasX proteins (referred to herein as "reference CasX proteins") that have subsequently been modified to generate the CasX variants of the present disclosure. For example, a reference CasX protein can be isolated from a naturally occurring prokaryote, such as a Deltaproteobacteria, Planctomycetes, or Candidatus Sungbacteria species. The reference CasX protein (interchangeably referred to herein as a reference CasX polypeptide) is a type II CRISPR / Cas endonuclease that belongs to the CasX (interchangeably referred to herein as Cas12e) family of proteins that interact with guide RNAs to form ribonucleoprotein (RNP) complexes.
[0130] In some cases, the reference CasX protein is isolated or derived from Deltaproteobacter and has the following sequence:
[0131] [Table 4]
[0132] In some cases, the reference CasX protein is isolated or derived from a Planctomycetes and has the following sequence:
[0133] [Table 5]
[0134] In some cases, the reference CasX protein is isolated or derived from Candidatus Sungbacteria and has the following sequence:
[0135] [Table 6]
[0136] b. CasX variant protein The present disclosure provides variants of a reference CasX protein (interchangeably referred to herein as "CasX variants" or "CasX variant proteins"), where the CasX variants comprise at least one modification in at least one domain compared to the reference CasX protein, including, but not limited to, the sequences of SEQ ID NOs: 1-3.
[0137] The CasX variants of the present disclosure have one or more improved characteristics compared to a reference CasX protein. Exemplary improved characteristics of CasX variant embodiments include, but are not limited to, improved folding of the variant, improved binding affinity for a gRNA, improved binding affinity for a target nucleic acid, improved ability to utilize a wider range of PAM sequences in editing and / or binding to target DNA, improved unwinding of target DNA, increased editing activity, improved editing efficiency, improved editing specificity, an increased percentage of eukaryotic genomes that can be efficiently edited, increased nuclease activity, increased target strand loading for double-stranded cleavage, decreased target strand loading for single-stranded nicking, decreased off-target cleavage, improved binding of non-target strands of DNA, improved protein stability, improved stability of the protein:gRNA (RNP) complex, improved protein solubility, improved solubility of the protein:gRNA (RNP) complex, improved protein yield, improved protein expression, and improved fusion characteristics (described in more detail below). Exemplary improved characteristics are described in WO 2020 / 247882(A1) and WO 2020 / 247883 (incorporated herein by reference). In the foregoing embodiments, one or more of the improved characteristics of the CasX variant is improved by at least about 1.1 to about 100,000-fold compared to a reference CasX protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 when assayed in a comparable manner. In other embodiments, the improvement is at least about 1.1-fold, at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold, at least about 500-fold, at least about 1000-fold, at least about 5000-fold, at least about 10,000-fold, or at least about 100,000-fold compared to a reference CasX protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 when assayed in a comparable manner.In other cases, one or more improved characteristics of the RNP of the CasX variant and gRNA variant are improved by at least about 1.1, at least about 10, at least about 100, at least about 1000, at least about 10,000, at least about 100,000, or more times compared to the RNP of a reference CasX protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 and a gRNA of Table 2. In other cases, one or more of the improved characteristics of the RNP of the CasX variant and gRNA variant, when assayed in a comparable manner, are about 1.1-100,00 fold, about 1.1-10,00 fold, about 1.1-1,000 fold, about 1.1-500 fold, about 1.1-100 fold, about 1.1-50 fold, about 1.1-20 fold, about 10-100,00 fold, about 10-10,00 fold, about 10-1,000 fold, about 10-500 fold, about 10-100 fold, about 10-50 fold, about 10-20 fold, about 2-70 fold, about 2-5 ... 2 to 30 times, 2 to 20 times, 2 to 10 times, 5 to 50 times, 5 to 30 times, 5 to 10 times, 100 to 100,00 times, 100 to 10,00 times , about 100 to 1,000 times, about 100 to 500 times, about 500 to 100,00 times, about 500 to 10,00 times, about 500 to 1,000 times, about 500 to 750 fold, about 1,000 to 100,00 fold, about 10,000 to 100,00 fold, about 20 to 500 fold, about 20 to 250 fold, about 20 to 200 fold, about 20 to 100 fold, about 20 to 50 fold, about 50 to 10,000 fold, about 50 to 1,000 fold, about 50 to 500 fold, about 50 to 200 fold, or about 50 to 100 fold improvement.In other cases, the one or more improved characteristics of the RNP of the CasX variant and gRNA variant may be about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, 22-fold, 23-fold, 24-fold, 25-fold, 26-fold, 27-fold, 28-fold, 29-fold, 30-fold, 31-fold, 32-fold, 33-fold, 34-fold, 35-fold, 36-fold, 37-fold, 38-fold, 39-fold, 40-fold, 41-fold, 42-fold, 43-fold, 44-fold, 45-fold, 46-fold, 47-fold, 48-fold, 49-fold, 50-fold, 51-fold, 52-fold, 53-fold, 54-fold, 55-fold, 56-fold, 57-fold, 58-fold, 59-fold, 60-fold, 61-fold, 62-fold, 63-fold, 64-fold, 65-fold, 66-fold, 67-fold, 68-fold, 69-fold, 70-fold, 71-fold, 72-fold, 73- fold, 25x, 30x, 40x, 45x, 50x, 55x, 60x, 70x, 80x, 90x, 100x, 110x, 120x, 130x, 140x, 150x, 160x, 170x, 180x, 190x, 200x, 210x, 220x, 230x, 240x, 250x, 260x, 270x, 280x, 290x, 300x, 310x, 320x, 330x, 340x, 350x, 360x, 370x, 380x, 390x, 400x, 425x, 450x, 475x, or 500x improvement.
[0138] The term CasX variant includes variants that are fusion proteins, i.e., CasX is "fused" to a heterologous sequence. This includes CasX variants that comprise CasX variant sequences, as well as N-terminal, C-terminal, or internal fusions of CasX to a heterologous protein or domain thereof.
[0139] In some embodiments, the CasX variant comprises at least one modification in the NTSB domain. In some embodiments, the CasX variant comprises at least one modification in the TSL domain. In some embodiments, the CasX variant comprises at least one modification in the helix I domain. In some embodiments, the CasX variant comprises at least one modification in the helix II domain. In some embodiments, the CasX variant comprises at least one modification in the OBD domain. In some embodiments, the CasX variant comprises at least one modification in the RuvC DNA cleavage domain. In some embodiments, at least one modification in the RuvC DNA cleavage domain comprises an amino acid substitution of one or more of amino acids K682, G695, A708, V711, D732, A739, D733, L742, V747, F755, M771, M779, W782, A788, G791, L792, P793, Y797, M799, Q804, S819, or Y857 of SEQ ID NO: 2, or a deletion of amino acid P793.
[0140] In some embodiments, the CasX variant protein comprises at least one modification in at least one domain, in each of at least two domains, in each of at least three domains, in each of at least four domains, or in each of at least five domains of a reference CasX protein comprising a sequence of SEQ ID NOs: 1-3. In some embodiments, the CasX variant protein comprises two or more modifications in at least one domain of a reference CasX protein. In some embodiments, the CasX variant protein comprises at least two modifications in at least one domain of a reference CasX protein, at least three modifications in at least one domain of a reference CasX protein, or at least four modifications in at least one domain of a reference CasX protein. In some embodiments, the CasX variant comprises two or more modifications compared to the reference CasX, each modification independently occurring in a domain selected from the group consisting of the NTSBD, TSLD, helix I domain, helix II domain, OBD, and RuvC DNA cleavage domain. In some embodiments, at least one modification of the CasX variant protein comprises a deletion of at least a portion of one domain of a reference CasX protein of SEQ ID NOs: 1-3. In some embodiments, the deletion is in the NTSBD, TSLD, helix I domain, helix II domain, OBD, or RuvC DNA cleavage domain. In other embodiments, the disclosure provides CasX variants comprising at least one modification compared to another CasX variant. For example, CasX variant 515 is a variant of CasX variant 491. All variants that improve one or more functions or characteristics of the CasX variant protein when compared to the reference CasX proteins described herein (or the variants from which they are derived) are contemplated within the scope of the disclosure.
[0141] In some embodiments, the modification of the CasX variant is a mutation in one or more amino acids of the reference CasX. In other embodiments, the modification is a replacement of one or more domains of the reference CasX with one or more domains from a different CasX. In some embodiments, the insertion comprises the insertion of part or all of a domain from a different CasX protein. The mutation can occur in any one or more domains of the reference CasX protein, including, for example, the deletion of part or all of one or more domains, or the substitution, deletion, or insertion of one or more amino acids in any domain of the reference CasX protein. Domains of the CasX protein include the non-target strand binding (NTSB) domain, the target strand loading (TSL) domain, the helix I domain, the helix II domain, the oligonucleotide binding domain (OBD), and the RuvC DNA cleavage domain. Any change in the amino acid sequence of the reference CasX protein that results in improved characteristics of the CasX protein is considered a CasX variant protein of the present disclosure. For example, a CasX variant can include one or more amino acid substitutions, insertions, deletions, or swapped domains, or any combination thereof, compared to a reference CasX protein sequence.
[0142] Suitable mutagenesis methods for generating the CasX variant proteins of the present disclosure can include, for example, comprehensive mutational evolution (DME), comprehensive mutation scanning (DMS), error-prone PCR, cassette mutagenesis, random mutagenesis, staggered extension PCR, gene shuffling, or domain swapping. In some embodiments, CasX variants are designed, for example, by selecting one or more desired mutations in a reference CasX. In certain embodiments, the activity of the reference CasX protein is used as a benchmark against which the activity of one or more CasX variants is compared, thereby measuring the improvement in the function of the CasX variant.
[0143] In some embodiments of the CasX variants described herein, at least one modification comprises: (a) a substitution of 1 to 100 contiguous or non-contiguous amino acids in the CasX variant compared to a reference CasX of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, CasX variant 491, or CasX variant 515; (b) a deletion of 1 to 100 contiguous or non-contiguous amino acids in the CasX variant compared to the reference CasX or the variant from which it is derived; (c) an insertion of 1 to 100 contiguous or non-contiguous amino acids in the CasX compared to the reference CasX or the variant from which it is derived; or (d) any combination of (a)-(c). In some embodiments, at least one modification comprises: (a) a substitution of 5 to 10 consecutive or non-consecutive amino acids in the CasX variant compared to a reference CasX of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, CasX 491, or CasX 515; (b) a deletion of 1 to 5 consecutive or non-consecutive amino acids in the CasX variant compared to the reference CasX or its derived variant; (c) an insertion of 1 to 5 consecutive or non-consecutive amino acids in the CasX compared to the reference CasX or its derived variant; or (d) any combination of (a)-(c).
[0144] In some embodiments, the CasX variant protein comprises or consists of a sequence having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 modifications compared to the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, CasX 491 (see Table 4), or CasX 515 (see Table 4). These modifications can be amino acid insertions, deletions, substitutions, or any combination thereof. The modifications can be in one domain of the CasX variant, or in either domain, or in any combination of domains. In the substitutions described herein, any amino acid can be substituted for any other amino acid. The substitution can be a conservative substitution (e.g., a basic amino acid is substituted for another basic amino acid). The substitution can also be a non-conservative substitution (e.g., a basic amino acid is substituted for an acidic amino acid, or vice versa). For example, a proline in a reference CasX protein can be substituted with any of arginine, histidine, lysine, aspartic acid, glutamic acid, serine, threonine, asparagine, glutamine, cysteine, glycine, alanine, isoleucine, leucine, methionine, phenylalanine, tryptophan, tyrosine, or valine to generate a CasX variant protein of the present disclosure.
[0145] Any permutation of the substitutions, insertions, and deletions of the embodiments described herein can be combined to generate a CasX variant protein of the present disclosure. For example, a CasX variant protein can include at least one substitution and at least one deletion compared to a reference CasX protein sequence, at least one substitution and at least one insertion compared to a reference CasX protein sequence, at least one insertion and at least one deletion compared to a reference CasX protein sequence, or at least one substitution, one insertion, and one deletion compared to a reference CasX protein sequence.
[0146] In some embodiments, the CasX variant comprises at least one modification selected from one or more of the following compared to the reference CasX sequence of SEQ ID NO: 2: (a) an amino acid substitution of L379R, (b) an amino acid substitution of A708K, (c) an amino acid substitution of T620P, (d) an amino acid substitution of E385P, (e) an amino acid substitution of Y857R, (f) an amino acid substitution of I658V, (g) an amino acid substitution of F399L, (h) an amino acid substitution of Q252K, (i) an amino acid substitution of L404K, and (j) an amino acid deletion of P793.
[0147] In some embodiments, the CasX variant protein comprises 400 to 2000 amino acids, 500 to 1500 amino acids, 700 to 1200 amino acids, 800 to 1100 amino acids, or 900 to 1000 amino acids.
[0148] In some embodiments, the CasX variant protein comprises the sequence of SEQ ID NOs: 59, 72-99, 101-148, and 26908-27154 shown in Table 4. In some embodiments, the CasX variant protein consists of the sequence of SEQ ID NOs: 59, 72-99, 101-148, and 26908-27154 shown in Table 4. In other embodiments, the CasX variant protein comprises a sequence that is at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to the sequence of SEQ ID NOs: 59, 72-99, 101-148, or 26908-27154 shown in Table 4. In some embodiments, the CasX variant protein comprises or consists of the sequence of SEQ ID NOs: 536-99, 101-148, or 26908-27154. In other embodiments, the CasX variant protein comprises a sequence that is at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to the sequence of SEQ ID NOs: 36-99, 101-148, or 26908-27154.In some embodiments, the CasX variant protein comprises or consists of the sequence of SEQ ID NO: 132-148 or 26908-27154. In other embodiments, the CasX variant protein comprises a sequence that is at least 60% identical, at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical to the sequence of SEQ ID NO: 132-148 or 26908-27154.
[0149] [Table 7-1]
[0150] [Table 7-2]
[0151] [Table 7-3]
[0152] [Table 7-4]
[0153] [Table 7-5]
[0154] [Table 7-6]
[0155] [Table 7-7]
[0156] c. CasX variant proteins with domains derived from multiple protein sources In certain embodiments, the present disclosure provides chimeric CasX proteins comprising protein domains from two or more different CasX proteins (e.g., two or more naturally occurring CasX proteins or two or more CasX variant protein sequences described herein). As used herein, "chimeric CasX protein" refers to a CasX comprising at least two domains isolated or derived from different sources (e.g., two naturally occurring proteins), which in some embodiments may be isolated from different species. For example, in some embodiments, a chimeric CasX protein comprises a first domain from a first CasX protein and a second domain from a second, different CasX protein. In some embodiments, the first domain may be selected from the group consisting of NTSB, TSL, helix I, helix II, OBD, and RuvC domains. In some embodiments, the second domain is selected from the group consisting of NTSB, TSL, helix I, helix II, OBD, and RuvC domains, and the second domain is different from said first domain. In the case of split or non-contiguous domains, such as helix I, RuvC, and OBD, portions of the non-contiguous domains can be replaced with corresponding portions from any other source. For example, the helix II domain (sometimes referred to as helix Ia) in SEQ ID NO:2 can be replaced with the corresponding helix II sequence from SEQ ID NO:1, etc. Table 5 lists domain sequences and their coordinates from reference CasX proteins. Representative examples of chimeric CasX proteins include variants of CasX 472-483, 485-491, and 515, the sequences of which are listed in Table 4.
[0157] [Table 8] * OBDa and b, helices Ia and b, and RuvCa and b are also referred to herein as OBDI and II, helices II and I-II, and RuvCI and II.
[0158] d. Protein affinity for gRNA In some embodiments, the CasX variant protein has improved affinity for gRNA compared to a reference CasX protein, resulting in the formation of a ribonucleoprotein complex (RNP). The increased affinity of the CasX variant protein for gRNA can result in, for example, a lower K for the formation of the RNP complex. d This may result in the formation of a more stable ribonucleoprotein complex, in some cases. In some embodiments, increased affinity of the CasX variant protein for gRNA results in increased stability of the ribonucleoprotein complex when delivered to human cells. This increased stability may affect the function and utility of the complex in the subject's cells and may result in improved pharmacokinetic properties in the blood when delivered to a subject. In some embodiments, increased affinity of the CasX variant protein and the resulting increased stability of the ribonucleoprotein complex allow for lower doses of the CasX variant protein to be delivered to a subject or cell while still having the desired activity, e.g., gene editing in vivo or in vitro. In some embodiments, higher affinity (stronger binding) of the CasX variant protein for gRNA allows for more editing events when both the CasX variant protein and gRNA remain in the RNP complex. The increase in editing events can be assessed using an editing assay, such as the tdTom editing assay described herein. In some embodiments, the K of the CasX variant protein for gRNA is measured. dis increased by at least about 1.1, at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100-fold compared to a reference CasX protein. In some embodiments, the CasX variant has an increased binding affinity for the gRNA by about 1.1 to about 10-fold compared to a reference CasX protein of SEQ ID NO:2.
[0159] In some embodiments, increased affinity of the CasX variant protein for the gRNA results in increased stability of the ribonucleoprotein complex when delivered to mammalian cells (including in vivo delivery to a subject). This increased stability can affect the function and utility of the complex in the subject's cells and can result in improved pharmacokinetic properties in the blood when delivered to a subject. In some embodiments, increased affinity of the CasX variant protein and the resulting increased stability of the ribonucleoprotein complex allow lower doses of the CasX variant protein to be delivered to a subject or cell while still having the desired activity (e.g., in vivo or in vitro gene editing). The increased ability to form RNPs and maintain them in a stable form can be assessed using assays (e.g., the in vitro cleavage assay described in the Examples herein). In some embodiments, RNPs containing the disclosed CasX variants, when complexed as RNPs, have at least 2-fold, at least 5-fold, or at least 10-fold higher kappa activity than RNPs containing the reference CasXs of SEQ ID NOS: 1-3. 切断 Speed can be achieved.
[0160] In some embodiments, the higher affinity (tighter binding) of the CasX variant protein for the gRNA allows for more editing events when both the CasX variant protein and the gRNA remain in the RNP complex, which can be assessed using an editing assay such as those described herein.
[0161] Without wishing to be bound by theory, in some embodiments, amino acid changes in the helix I domain can increase the binding affinity of the CasX variant protein to the gRNA targeting sequence, changes in the helix II domain can increase the binding affinity of the CasX variant protein to the gRNA scaffold stem-loop, and changes in the oligonucleotide binding domain (OBD) increase the binding affinity of the CasX variant protein to the gRNA triplex.
[0162] Methods for measuring the binding affinity of a CasX protein to a gRNA include in vitro methods using purified CasX protein and gRNA. Binding affinity to the reference CasX and variant proteins can be measured by fluorescence polarization if the gRNA or CasX protein is tagged with a fluorophore. Alternatively, or additionally, binding affinity can be measured by biolayer interferometry, electrophoretic mobility shift assay (EMSA), or membrane binding. Further standard techniques for quantifying the absolute affinity of an RNA-binding protein, such as a reference CasX and variant proteins of the present disclosure, to a particular gRNA, such as a reference gRNA and its variants, include, but are not limited to, isothermal calorimetry (ITC) and surface plasmon resonance (SPR), as well as methods in the Examples.
[0163] e. affinity for target nucleic acid In some embodiments, the CasX variant protein has improved binding affinity for a target nucleic acid sequence compared to the affinity of a reference CasX protein for the target nucleic acid sequence. In some embodiments, the affinity of a CasX variant protein of the present disclosure for a target nucleic acid molecule is increased by at least about 1.1, at least about 1.2, at least about 1.3, at least about 1.4, at least about 1.5, at least about 1.6, at least about 1.7, at least about 1.8, at least about 1.9, at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100-fold compared to the reference CasX protein.
[0164] CasX variants with higher affinity for their target nucleic acids can, in some embodiments, cleave target nucleic acid sequences more rapidly than reference CasX proteins that do not have increased affinity for target nucleic acids. In some embodiments, improved affinity for target nucleic acid sequences includes improved affinity for the target nucleic acid sequence, improved binding affinity for a wider range of PAM sequences, improved ability to search DNA for target nucleic acid sequences, or any combination thereof, resulting in an increased ability to modify the target nucleic acid. In some embodiments, CasX variant proteins with improved target nucleic acid affinity have increased affinity for specific PAM sequences other than the canonical TTC PAM recognized by the reference CasX protein of SEQ ID NO: 2, including binding affinity for PAM sequences selected from the group consisting of TTC, ATC, GTC, and CTC. Higher overall affinity for DNA can also, in some embodiments, increase the frequency with which the CasX protein can effectively initiate and complete binding and unwinding steps, thereby facilitating target strand invasion and R-loop formation and ultimately cleavage of the target nucleic acid sequence.
[0165] In some embodiments, the CasX variant protein has improved binding affinity for the non-target strand of the target nucleic acid. As used herein, the term "non-target strand" refers to the strand of the DNA target nucleic acid sequence that does not form Watson-Crick base pairs with the targeting sequence in the gRNA and is complementary to the target DNA strand. In some embodiments, the CasX variant protein has an increased binding affinity for the non-target strand of the target nucleic acid of about 1.1 to about 100-fold compared to the reference protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
[0166] Methods for measuring the affinity of CasX variant proteins for target nucleic acid molecules can include electrophoretic mobility shift assays (EMSA), membrane binding, isothermal calorimetry (ITC), and surface plasmon resonance (SPR), fluorescence polarization, and biolayer interferometry (BLI). Additional methods for measuring the affinity of CasX proteins for targets include in vitro biochemical assays that measure DNA cleavage events over time (e.g., as described in the Examples). 切断 speed determination).
[0167] f. Improved specificity for the target site In some embodiments, the CasX variant protein has improved specificity for a target nucleic acid sequence compared to a reference CasX protein. As used herein, "specificity" (interchangeably referred to as "target specificity") refers to the degree to which a CRISPR / Cas system ribonucleoprotein complex cleaves off-target sequences that are similar, but not identical, to the target nucleic acid sequence. For example, a CasX variant RNP with a higher degree of specificity exhibits reduced off-target cleavage of sequences compared to a reference CasX protein. The specificity of a CRISPR / Cas system protein and the reduction of potentially harmful off-target effects can be crucial for achieving an acceptable therapeutic index for use in mammalian subjects.
[0168] In some embodiments, the CasX variant protein has improved specificity for a target site within a target sequence complementary to a gRNA targeting sequence, compared to a reference CasX protein of SEQ ID NOs: 1-3. Without wishing to be bound by theory, amino acid changes in the helix I and II domains that increase the specificity of the CasX variant protein for a target nucleic acid strand may also increase the specificity of the CasX variant protein for the target nucleic acid overall. In some embodiments, amino acid changes that increase the specificity of the CasX variant protein for a target nucleic acid may also result in a decreased affinity of the CasX variant protein for DNA.
[0169] Methods for testing the target specificity of a CasX protein (e.g., variant or reference) can include Circularization for In Vitro Reporting of Cleavage Effects by Sequencing (CIRCLE-seq) or similar methods. Briefly, in CIRCLE-seq technology, genomic DNA is sheared and circularized by ligation of stem-loop adapters, nicking the stem-loop region and exposing a 4-nucleotide palindromic overhang. This is followed by intramolecular ligation and degradation of the remaining linear DNA. The circular DNA molecule containing the CasX cleavage site is then linearized with CasX, and adapter-adapters are ligated to the exposed ends, followed by high-throughput sequencing to generate paired-end reads containing information about off-target sites. Additional assays that can be used to detect off-target events (and thus the specificity of the CasX protein) include assays used to detect and quantify indels (insertions and deletions) formed at these selected off-target sites (e.g., mismatch-detection nuclease assays and next-generation sequencing (NGS)). Exemplary mismatch-detection assays include nuclease assays, in which genomic DNA from cells treated with CasX and sgRNA is PCR-amplified, denatured, and rehybridized to form heteroduplex DNA containing one wild-type strand and one strand with an indel. Mismatches are recognized and cleaved by a mismatch-detection nuclease (e.g., Surveyor nuclease or T7 endonuclease I).
[0170] g. Protospacer and PAM sequences As used herein, a protospacer is defined as a DNA sequence complementary to the targeting sequence of a guide RNA and a DNA sequence complementary to that sequence, referred to as the target strand and non-target strand, respectively. As used herein, a PAM is a nucleotide sequence located one nucleotide 5' of a sequence in the non-target strand that is complementary to a target nucleic acid sequence in the target strand of a target nucleic acid, which, in conjunction with the targeting sequence of a gRNA, helps orient and position CasX for potential cleavage of the protospacer strand. PAM sequences may be degenerate, and particular RNP constructs may have different preferred and accepted PAM sequences that support different cleavage efficiencies. By convention, unless otherwise noted, this disclosure refers to both the PAM and protospacer sequences and their orientation relative to the orientation of the non-target strand. This does not imply that the PAM sequence of the non-target strand, rather than the target strand, is determinative of cleavage or is mechanistically involved in target recognition. For example, when referring to a TTC PAM, it may actually be the complementary GAA sequence required for target cleavage, or some combination of nucleotides from both strands. In the CasX proteins disclosed herein, the PAM is located 5' to the protospacer, with a single nucleotide separating the PAM from the first nucleotide of the protospacer. Thus, for the reference CasX, a TTC PAM should be understood to mean a sequence according to the formula 5'-...NNTTCN(protospacer)NNNNNN...3', where "N" is any DNA nucleotide and "(protospacer)" is a DNA sequence having identity to the targeting sequence of the guide RNA. For CasX variants with extended PAM recognition, a TTC, CTC, GTC, or ATC PAM should be understood to mean a sequence according to the following formula: 5'-...NNTTCN(protospacer)NNNNNN...3'. 5'-...NNCTCN(protospacer)NNNNNN...3', 5'-...NNGTCN(protospacer)NNNNNN...3', or 5'-...NNATCN(protospacer)NNNNNN...3'.
[0171] Alternatively, TC PAM should be understood to mean a sequence according to the formula: 5'-...NNNTCN(protospacer)NNNNNN...3'. Additionally, the CasX variant proteins of the present disclosure have an enhanced ability to efficiently edit and / or bind to target DNA when complexed with a gRNA as an RNP, utilizing a PAM TC motif comprising a PAM sequence selected from TTC, ATC, GTC, or CTC (in the 5' to 3' orientation), compared to an RNP of a reference CasX protein and a reference gRNA. In the foregoing, the PAM sequence is located at least one nucleotide 5' to the non-target strand of a protospacer having identity to the targeting sequence of a gRNA in an assay system, compared to the editing efficiency and / or binding of an RNP comprising a reference CasX protein and a reference gRNA in a comparable assay system. In one embodiment, RNPs of the CasX variant and gRNA variant exhibit higher editing efficiency and / or binding of the target sequence in the target DNA compared to RNPs comprising a reference CasX protein and a reference gRNA in a comparable assay system, where the PAM sequence of the target DNA is TTC. In another embodiment, RNPs of the CasX variant and gRNA variant exhibit higher editing efficiency and / or binding of the target sequence in the target DNA compared to RNPs comprising a reference CasX protein and a reference gRNA in a comparable assay system, where the PAM sequence of the target DNA is ATC. In another embodiment, RNPs of the CasX variant and gRNA variant exhibit higher editing efficiency and / or binding of the target sequence in the target DNA compared to RNPs comprising a reference CasX protein and a reference gRNA in a comparable assay system, where the PAM sequence of the target DNA is CTC. In another embodiment, the RNP of the CasX variant and gRNA variant exhibits higher editing efficiency and / or binding of the target sequence in the target DNA compared to an RNP comprising a reference CasX protein and a reference gRNA in a comparable assay system, wherein the PAM sequence of the target DNA is GTC.In the foregoing embodiments, the increased editing efficiency and / or binding affinity for one or more PAM sequences is at least 1.5-fold greater than the editing efficiency and / or binding affinity for the PAM sequence of the CasX protein of any one of SEQ ID NOS: 1-3 and the RNP of the gRNA in Table 2. Exemplary assays demonstrating improved editing are described in the Examples herein.
[0172] h. DNA unwinding In some embodiments, the CasX variant proteins have improved DNA unwinding ability compared to a reference CasX protein. Insufficient dsDNA unwinding has previously been shown to impair or prevent the ability of the CRISPR / Cas system proteins AnaCas9 or Cas14 to cleave DNA. Thus, without wishing to be bound by any theory, the increased DNA cleavage activity of some of the CasX variant proteins disclosed herein is likely due, at least in part, to their increased ability to find and unwind dsDNA at target sites.
[0173] Without wishing to be bound by theory, it is believed that amino acid changes in the NTSB domain can produce CasX variant proteins with increased DNA unwinding characteristics. Alternatively, or in addition, amino acid changes in the helical domain regions that interact with the OBD or PAM can also produce CasX variant proteins with increased DNA unwinding characteristics.
[0174] Methods for measuring the ability of a CasX protein (e.g., variant or reference) to unwind DNA include, but are not limited to, in vitro assays that observe the increase in on-rate of a dsDNA target in fluorescence polarization or biolayer interferometry.
[0175] i.Catalytic activity The ribonucleoprotein complex of the CasX:RNA system disclosed herein comprises a CasX variant that binds to and cleaves a target nucleic acid sequence. In some embodiments, the CasX variant protein has improved catalytic activity compared to a reference CasX protein. Without wishing to be bound by theory, it is believed that in some cases, cleavage of the target strand may be the limiting factor for Cas12-like molecules in generating dsDNA breaks. In some embodiments, the CasX variant protein improves bending of the target strand of DNA and cleavage of this strand, resulting in improved overall efficiency of dsDNA cleavage by the CasX ribonucleoprotein complex.
[0176] In some embodiments, the CasX variant protein has increased nuclease activity compared to a reference CasX protein. Variants with increased nuclease activity can be generated, for example, through amino acid changes in the RuvC nuclease domain. In some embodiments, the CasX variant comprises a RuvC nuclease domain with nickase activity. In the foregoing, the CasX nickase in the CasX:gRNA system generates a single-strand break within 10-18 nucleotides 3' of the PAM site on the non-target strand. In other embodiments, the CasX variant comprises a RuvC nuclease domain with double-strand break activity. In the foregoing, the CasX in the CasX:gRNA system generates a double-strand break within 18-26 nucleotides 5' of the PAM site on the target strand and within 10-18 nucleotides 3' of the PAM site on the non-target strand. Nuclease activity can be assayed by various methods, including those described in the Examples. In some embodiments, the CasX variant has a k that is at least 2-fold, or at least 3-fold, or at least 4-fold, or at least 5-fold, or at least 6-fold, or at least 7-fold, or at least 8-fold, or at least 9-fold, or at least 10-fold greater than the reference CasX. 切断 It has a constant.
[0177] In some embodiments, the CasX variant protein has improved RNP formation characteristics with a gRNA, resulting in a higher percentage of cleavage-competent RNPs compared to the RNPs of a reference CasX protein and gRNA of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, as described in the Examples. Cleavage competent means that the RNPs formed have the ability to cleave a target nucleic acid. In some embodiments, the RNPs of the CasX variant and gRNA exhibit at least two-fold, or at least three-fold, or at least four-fold, or at least five-fold, or at least ten-fold faster cleavage rates compared to the RNPs of a reference CasX protein of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 and a gRNA of Table 2. In the foregoing embodiments, the improved competency rate can be demonstrated in in vitro assays such as those described in the Examples.
[0178] In some embodiments, the CasX variant protein has increased target strand loading for double-strand cleavage compared to a reference CasX. Variants with increased target strand loading activity can be generated, for example, through amino acid changes in the TLS domain. Without wishing to be bound by theory, amino acid changes in the TLS domain can result in a CasX variant protein with improved catalytic activity. Alternatively, or additionally, amino acid changes surrounding the binding channel of the RNA:DNA duplex can also improve the catalytic activity of a CasX variant protein. In some embodiments, the CasX variant protein has increased incidental cleavage activity compared to a reference CasX protein. As used herein, "incidental cleavage activity" refers to the additional non-targeted cleavage of nucleic acids following recognition and cleavage of a target nucleic acid sequence. In some embodiments, the CasX variant protein has decreased incidental cleavage activity compared to a reference CasX protein.
[0179] In some embodiments, including applications in which cleavage of a target nucleic acid sequence is not the desired outcome, improving the catalytic activity of a CasX variant protein includes altering, reducing, or eliminating the catalytic activity of the CasX variant protein. In some embodiments, a ribonucleoprotein complex comprising a dCasX variant protein binds to a target nucleic acid sequence and does not cleave the target nucleic acid.
[0180] In some embodiments, a CasX ribonucleoprotein complex containing a CasX variant protein binds to target DNA but generates single-stranded nicks in the target DNA. In some embodiments, particularly those in which the CasX protein is a nickase, the CasX variant protein has reduced target strand loading for single-strand nicking. Variants with reduced target strand loading can be generated, for example, through amino acid changes in the TSL domain.
[0181] Exemplary methods for characterizing the catalytic activity of a CasX protein can include, but are not limited to, in vitro cleavage assays, including those in the Examples below. In some embodiments, electrophoresis of DNA products on an agarose gel can examine the kinetics of strand scission.
[0182] j.CasX fusion protein In some embodiments, the present disclosure provides a CasX protein comprising a heterologous protein fused to CasX. In some cases, the CasX is a reference CasX protein. In other cases, the CasX is a CasX variant of any of the embodiments described herein.
[0183] In some embodiments, the CasX variant protein comprises any one of SEQ ID NOS: 59, 72-99, 101-148, and 26908-27154 of the sequences in Table 4 fused to one or more proteins or domains thereof with different desired activities, resulting in a fusion protein. In some embodiments, the CasX variant protein comprises any one of SEQ ID NOS: 36-99, 101-148, and 26908-27154 fused to one or more proteins or domains thereof. In some embodiments, the CasX variant protein comprises any one of SEQ ID NOS: 132-148, 26908-2715 fused to one or more proteins or domains thereof. For example, in some embodiments, the CasX variant protein is fused to a protein (or domain thereof) that inhibits transcription, modifies a target nucleic acid sequence, or modifies a polypeptide associated with a nucleic acid (e.g., a histone modification).
[0184] In some embodiments, a heterologous polypeptide (or heterologous amino acid, such as a cysteine residue or an unnatural amino acid) can be inserted at one or more positions within a CasX protein to generate a CasX fusion protein. In other embodiments, a cysteine residue can be inserted at one or more positions within a CasX protein, followed by conjugation of a heterologous polypeptide, as described below. In some alternative embodiments, a heterologous polypeptide or heterologous amino acid can be added to the N-terminus or C-terminus of a CasX variant protein. In other embodiments, a heterologous polypeptide or heterologous amino acid can be inserted internally within the sequence of a CasX protein.
[0185] In some embodiments, the CasX variant fusion protein retains RNA-guided, sequence-specific target nucleic acid binding and cleavage activity. In some embodiments, the CasX variant fusion protein retains 50% or more of the activity (e.g., cleavage and / or binding activity) of a corresponding CasX variant protein without the heterologous protein insertion. In some embodiments, the CasX variant fusion protein retains at least about 60%, or at least about 70% or more, or at least about 80%, or at least about 90%, or at least about 92%, or at least about 95%, or at least about 98%, or at least about 100% of the activity (e.g., cleavage and / or binding activity) of a corresponding CasX protein without the heterologous protein insertion.
[0186] In some cases, the CasX variant fusion protein retains (has) target nucleic acid binding activity compared to the activity of the CasX protein without the inserted heterologous amino acid or polypeptide. In some cases, the CasX variant fusion protein retains at least about 60%, or at least about 70% or more, at least about 80%, or at least about 90%, or at least about 92%, or at least about 95%, or at least about 98%, or at least about 100% of the binding activity of the corresponding CasX protein without the inserted heterologous protein.
[0187] In some cases, the CasX variant fusion protein retains (has) target nucleic acid binding and / or cleavage activity compared to the activity of the parent CasX protein without the inserted heterologous amino acid or polypeptide. For example, in some cases, the CasX variant fusion protein retains (has) 50% or more of the binding and / or cleavage activity of the corresponding parent CasX protein (the CasX protein without the insertion). For example, in some cases, the CasX variant fusion protein retains (has) 60% or more (70% or more, 80% or more, 90% or more, 92% or more, 95% or more, 98% or more, or 100%) of the binding and / or cleavage activity of the corresponding parent CasX protein (the CasX protein without the insertion). Methods for measuring the cleavage and / or binding activity of CasX proteins and / or CasX fusion proteins are known to those of skill in the art, and any convenient method can be used.
[0188] A variety of heterologous polypeptides are suitable for inclusion in the reference CasX or CasX variant fusion proteins of the present disclosure. In some cases, the fusion partner can modulate (e.g., inhibit transcription, increase transcription) transcription of the target DNA. For example, in some cases, the fusion partner is a protein (or a domain derived from a protein) that represses transcription (e.g., a protein that functions via a transcriptional repressor, recruitment of a transcriptional repressor protein, modification of the target DNA such as methylation, recruitment of a DNA modifier, modulation of histones associated with the target DNA, recruitment of histone modifiers such as those that modify histone acetylation and / or methylation, etc.).
[0189] In some cases, the fusion partner is a protein (or a domain from a protein) that increases transcription (e.g., a protein that acts via a transcriptional activator, recruitment of a transcriptional activator protein, modification of target DNA such as demethylation, recruitment of a DNA modifier, regulation of histones associated with target DNA, recruitment of histone modifiers such as those that modify histone acetylation and / or methylation, etc.). In some cases, the fusion partner has an enzymatic activity that modifies a target nucleic acid sequence, such as nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity, or glycosylase activity. In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 36-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 59, 72-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 132-148 or 26908-27154, and a polypeptide having methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylating activity, deadenylating activity, sumoylating activity, desumoylating activity, ribosylation activity, deribosylation activity, myristoylating activity, or demyristoylating activity.
[0190] In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 36-99, 101-148, and 26908-27154, or any one of SEQ ID NOs: 59, 72-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 132-148 or 26908-27154, and a fusion partner having an enzymatic activity that modifies a polypeptide (e.g., a histone) associated with a target nucleic acid (e.g., a methyltransferase activity, a demethylase activity, an acetyltransferase activity, a deacetylase activity, a kinase activity, a phosphatase activity, a ubiquitin ligase activity, a deubiquitinating activity, an adenylating activity, a deadenylating activity, a sumoylating activity, a desumoylating activity, a ribosylation activity, a deribosylation activity, a myristoylating activity, or a demyristoylating activity). Examples of proteins (or fragments thereof) that can be used as fusion partners to increase transcription include transcription activators (e.g., VP16, VP64, VP48, VP160, p65 subdomains (e.g., from NFkB), and the activation domain of EDLL and / or TAL activation domains (e.g., active in plants); histone lysine methyltransferases (e.g., SET1A, SET1B, MLL1-5, ASH1, SYMD2, NSD1, etc.); histone lysine demethylases (e.g., JHDM2a / b, UTX, JMJD3, etc.); histone acetyltransferases (e.g., GCN5, PCAF, CBP, p300, TAF1, TIP60 / PLIP, MOZ / MYST3, MORF / MYST4, SRC1, ACTR, P160, CLOCK, etc.); and DNA demethylases (e.g., Ten-Eleven Translocation (TET) dioxygenase 1 (TET1CD), TET1, DME, DML1, DML2, ROS1, etc.
[0191] Examples of proteins (or fragments thereof) that can be used as fusion partners to reduce transcription include, but are not limited to, transcriptional repressors (e.g., Kruppel-associated box (KRAB or SKD)); KOX1 repression domain; Mad mSIN3-interacting domain (SID); ERF repressor domain (ERF repressor domain, ERD), SRDX repression domain (e.g., for repression in plants), etc.; histone lysine methyltransferases (e.g., Pr-SET7 / 8, SUV4-20H1, RIZ1, etc.); histone lysine demethylases (e.g., JMJD2A / JHDM3A, JMJD2B, JMJD2C / GASC1, JMJD2D, JARID1A / RBP2, JARID1B / PLU-1, JARID1C / SMCX, JARID1D / SMCY, etc.); histone lysine deacetylases (e.g., HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC7, HDAC9, SIRT1, SIRT2, HDAC11, etc.); DNA methylases (e.g., HhaI DNA m5c-methyltransferase (M.HhaI), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3 (plants), ZMET2, CMT1, CMT2 (plants), etc.); and peripheral mobilization elements (e.g., Lamin A, Lamin B, etc.).
[0192] In some cases, the fusion partner for the CasX variant has an enzymatic activity that modifies a target nucleic acid sequence (e.g., ssRNA, dsRNA, ssDNA, dsDNA). Examples of enzymatic activities that can be provided by the fusion partner include nuclease activity (e.g., that provided by a restriction enzyme (e.g., FokI nuclease)), methyltransferase activity (e.g., that provided by a methyltransferase (e.g., HhaI DNA m5c-methyltransferase (M.Hhal), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3 (plants), ZMET2, CMT1, CMT2 (plants), etc.), demethylase activity (e.g., a demethylase (e.g., Ten-Eleven Translocation (TET) dioxygenase 1 (TET1)), etc.), and the like. CD), TET1, DME, DML1, DML2, ROS1, etc.), DNA repair activity, DNA damage activity, deamination activity (e.g., provided by a deaminase (e.g., a cytosine deaminase enzyme, e.g., an APOBEC protein such as rat APOBEC1)), dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity (e.g., provided by an integrase and / or resolvase (e.g., a Gin invertase (e.g., a high activity mutant of Gin invertase GinH106Y)), human immunodeficiency virus type 1 integrase (IN), Tn3 resolvase, etc.), transposase activity, recombinase activity (e.g., provided by a recombinase (e.g., the catalytic domain of Gin recombinase)), polymerase activity, ligase activity, helicase activity, photolyase activity, and glycosylase activity.
[0193] In some cases, the CasX variant proteins of the present disclosure are fused to a polypeptide selected from a domain for increasing transcription (e.g., a VP16 domain, a VP64 domain), a domain for decreasing transcription (e.g., a KRAB domain (e.g., from the Kox1 protein)), a core catalytic domain of a histone acetyltransferase (e.g., histone acetyltransferase p300), a protein / domain that provides a detectable signal (e.g., a fluorescent protein such as GFP), a nuclease domain (e.g., a FokI nuclease), or a base editor (e.g., a cytidine deaminase such as APOBEC1).
[0194] In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 36-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 59, 72-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 132-148 or 26908-27154, and a fusion partner (e.g., a histone, an RNA-binding protein, a DNA-binding protein, etc.) having enzymatic activity that modifies a protein associated with a target nucleic acid (e.g., ssRNA, dsRNA, ssDNA, dsDNA).Examples of enzymatic activities (which modify proteins associated with the target nucleic acid) that can be provided by the fusion partner include histone methyltransferase activity (e.g., histone methyltransferases (HMTs) (e.g., suppressor of variegation 3-9 homolog 1 (SUV39H1, also known as KMT1A), euchromatin histone lysine methyltransferase 2 (G9A, also known as KMT1C and EHMT2), SUV39H2, ESET / SETDB, and the like). 1, such as those provided by SET1A, SET1B, MLL1-5, ASH1, SYMD2, NSD1, DOT1L, Pr-SET7 / 8, SUV4-20H1, EZH2, and RIZ1); demethylase activity (e.g., provided by histone demethylases (e.g., lysine demethylase 1A (KDM1A, also known as LSD1), JHDM2a / b, JMJD2A / JHDM3A, JMJD2B, JMJD2C / GASC1, JMJD2D, JARID1A / RBP2, JARID1B / PLU-1, JARID1C / SMCX, JARID1D / SMCY, UTX, and JMJD3); acetyltransferase activity (e.g., provided by histone acetyltransferases (e.g., the catalytic core / fragment of human acetyltransferase p300, GCN)); 5, PCAF, CBP, TAF1, TIP60 / PLIP, MOZ / MYST3, MORF / MYST4, HB01 / MYST2, HMOF / MYST1, SRC1, ACTR, P160, CLOCK, etc.), deacetylase activity (e.g., provided by histone deacetylases (e.g., HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC7, HDAC9, SIRT1, SIRT2, HDAC11, etc.)), kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylating activity, deadenylating activity, sumoylating activity, desumoylating activity, ribosylation activity, deribosylation activity, myristoylating activity, and demyristoylating activity.
[0195] Further examples of suitable fusion partners for CasX variants include (i) a dihydrofolate reductase (DHFR) destabilization domain (e.g., to generate chemically controllable RNA-guided polypeptides of interest or conditionally active RNA-guided polypeptides), and (ii) a chloroplast transit peptide. In some embodiments, the CasX variant is selected from the group consisting of any one of SEQ ID NOs: 36-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 59, 72-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 132-148 or 26908-27154, or a sequence in Table 4 and a chloroplast transit peptide (MASMISSSAVTTVSRASRGQSAAMAPFGGLKSMTGFPVRKVNTDITSITSNGGR VKCMQVWPPIGKKKFETLSYLPPLTRDSRA (SEQ ID NO: 154); MASMISSSAVTTVSRASRGQSAAMAPFGGLKSMTGFPVRKVNTDITSITSNGGRVKS (SEQ ID NO: 155); MASSMLSSATMVASPAQATMVAPFNGLKSSAAFPATRKANNDITSITSNGGRVNCMQV WPPIEKKKFETLSYLPDLTDSGGRVNC (SEQ ID NO: 156); MAQVSRICNGVQNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIG SELRPLKVMSSVSTAC (SEQ ID NO: 157); MAQVSRICNGVWNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIG SELRPLKVMSSVSTAC (SEQ ID NO: 158); MAQINNMAQGIQTLNPNSNFHKPQVPKSSSFLVFGSKKLKNSANSMLVLKKDSIFMQLF CSFRISASVATAC (SEQ ID NO: 159); MAALVTSQLATSGTVLSVTDRFRRPGFQGLRPRNPADAALGMRTVGASAAPKQSRKPH RFDRRCLSMVV (SEQ ID NO: 160);MAALTTSQLATSATGFGIADRSAPSSLLRHGFQGLKPRSPAGGDATSLSVTTSARATPKQ QRSVQRGSRRFPSVVVC (SEQ ID NO: 161); MASSVLSSAAVATRSNVAQANMVAPFTGLKSAASFPVSRKQNLDITSIASNGGRVQC (SEQ ID NO: 162); MESLAATSVFAPSRVAVPAARALVRAGTVVPTRRTSSTSGTSGVKCSAAVTPQASPVIS RSAAAA (SEQ ID NO: 163); and MGAAATSMQSLKFSNRLVPPSRRLSPVPNNVTCNNLPKSAAPVRTVKCCASSWNSTINGAAATTNGASAASS (SEQ ID NO: 164).
[0196] In some cases, a CasX variant protein of the present disclosure may comprise an endosomal escape peptide. In some cases, the endosomal escape polypeptide comprises the amino acid sequence GLFXALLXLLXSLWXLLLXA (SEQ ID NO: 165), where each X is independently selected from lysine, histidine, and arginine. In some cases, the endosomal escape polypeptide comprises the amino acid sequence GLFHALLHLLHSLWHLLLHA (SEQ ID NO: 166) or HHHHHHHHH (SEQ ID NO: 167).
[0197] When targeting an ssRNA target nucleic acid sequence, non-limiting examples of fusion partners for use with the CasX variant protein include (but are not limited to) splicing factors (e.g., RS domains); protein translation components (e.g., translation initiation, elongation, and / or termination factors; e.g., eIF4G); RNA methylases; RNA editing enzymes (e.g., RNA deaminases (e.g., adenosine deaminase acting on RNA (ADAR)), including A-to-I and / or C-to-U editing enzymes); helicases; RNA binding proteins, etc. It is understood that the heterologous polypeptide can comprise an entire protein, or in some cases, can comprise a fragment of a protein (e.g., a functional domain).
[0198] In some embodiments, the CasX variant comprises any one of SEQ ID NOs: 36-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 59, 72-99, 101-148, or 26908-27154, or any one of SEQ ID NOs: 132-148 or 26908-27154, and a fusion partner of any domain capable of interacting with ssRNA (for purposes of this disclosure, this includes, for example, double-stranded RNA duplexes, e.g., hairpins, stem-loops, etc., including intramolecular and / or intermolecular secondary structures). Effector domains, whether transient or irreversible, direct or indirect, include, but are not limited to, endonucleases (e.g., RNase III, CRR22 DYW domain, Dicer, and PINs (PilT) from proteins such as SMG5 and SMG6). N-terminal (N-terminal) domains); proteins and protein domains involved in stimulation of RNA cleavage (e.g., CPSF, CstF, CFIm, and CFIIm); exonucleases (e.g., XRN-1 or exonuclease T); deadenylases (e.g., HNT3); proteins and protein domains involved in nonsense-mediated RNA decay (e.g., UPF1, UPF2, UPF3, UPF3b, RNPSI, Y14, DEK, REF2, and SRm160); proteins and protein domains involved in RNA stabilization (e.g., PABP); proteins and protein domains involved in translational repression domains (e.g., Ago2 and Ago4); proteins and protein domains involved in stimulating translation (e.g., Staufen); proteins and protein domains involved in regulating translation (e.g., capable of regulating translation) (e.g., translation factors (e.g., initiation factors, elongation factors, termination factors, etc., e.g., eIF4G)); proteins and protein domains involved in polyadenylation of RNA (e.g., PAP1, GLD-2, and Star-PAP); proteins and protein domains involved in polyuridinylation of RNA (e.g., CID1 and terminal uridylate transferase);Proteins and protein domains involved in RNA localization (e.g., from IMP1, ZBP1, She2p, She3p, and Bicaudal-D); proteins and protein domains involved in nuclear retention of RNA (e.g., Rrp6); proteins and protein domains involved in nuclear export of RNA (e.g., TAP, NXF1, THO, TREX, REF, and Aly); proteins and protein domains involved in repression of RNA splicing (e.g., PTB, Sam68, and hnRNP A1); proteins and protein domains involved in stimulation of RNA splicing (e.g., serine / arginine-rich (SR) domains); proteins and protein domains involved in reducing transcription efficiency (e.g., FUS (TLS)); proteins and protein domains involved in stimulation of transcription (e.g., CDK7 and HIV Tat). Alternatively, the effector domain can be selected from the group comprising: endonucleases; proteins and protein domains capable of stimulating RNA cleavage; exonucleases; deadenylases; proteins and protein domains with nonsense-mediated RNA degradation activity; proteins and protein domains capable of stabilizing RNA; proteins and protein domains capable of repressing translation; proteins and protein domains capable of stimulating translation; proteins and protein domains capable of regulating translation (e.g., translation factors (e.g., initiation factors, elongation factors, release factors, etc., e.g., eIF4G)); proteins and protein domains capable of polyadenylation of RNA; proteins and protein domains capable of polyuridinylation of RNA; proteins and protein domains with RNA localization activity; proteins and protein domains capable of nuclear retention of RNA; proteins and protein domains with RNA export activity; proteins and protein domains capable of repressing RNA splicing; proteins and protein domains capable of stimulating RNA splicing; proteins and protein domains capable of reducing transcription efficiency;and proteins and protein domains capable of stimulating transcription. Another suitable heterologous polypeptide is a PUF RNA-binding domain, which is described in more detail in WO 2012 / 068627, which is incorporated herein by reference in its entirety.
[0199] Several RNA splicing factors that can be used (in whole or in fragments) as fusion partners with CasX variants have a modular organization, with distinct sequence-specific RNA-binding and splicing effector domains. For example, members of the serine / arginine-rich (SR) protein family contain an N-terminal RNA recognition motif (RRM) that binds to exonic splicing enhancers (ESEs) in pre-mRNA and a C-terminal RS domain that promotes exon inclusion. As another example, the hnRNP protein hnRNP A1 binds to exonic splicing silencers (ESSs) via its RRM domain and inhibits exon inclusion via its C-terminal glycine-rich domain. Some splicing factors can regulate the selective use of splice sites (ss) by binding to regulatory sequences between the two alternative sites. For example, ASF / SF2 can recognize ESEs and promote the use of intron-proximal sites, whereas hnRNPAl can bind to ESSs and shift splicing toward the use of intron-distal sites. One application of such factors is to create ESFs that regulate the alternative splicing of endogenous genes (especially disease-related genes). For example, Bcl-x pre-mRNA produces two splicing isoforms with two alternative 5' splice sites that encode proteins of opposite functions. The long splicing isoform, Bcl-xL, is a potent apoptosis inhibitor expressed in long-lived postmitotic cells and is upregulated in many cancer cells, protecting them from apoptotic signals. The short isoform, Bcl-xS, is a pro-apoptotic isoform and is expressed at high levels in cells with high metabolic rates (e.g., developing lymphocytes).The ratio of the two Bcl-x splicing isoforms is regulated by multiple cc elements located either in the core exon region or in the exon extension region (i.e., between the two alternative 5' splice sites). For further examples, see WO 2010 / 075303, which is incorporated herein by reference in its entirety.
[0200] Additional suitable fusion partners for use with CasX variants include, but are not limited to, proteins (or fragments thereof) that are boundary elements (e.g., CTCF), proteins and fragments thereof that provide peripheral recruitment (e.g., lamin A, lamin B, etc.), and protein docking elements (e.g., FKBP / FRB, Pill / Abyl, etc.).
[0201] In some cases, a heterologous polypeptide (fusion partner) for use with a CasX variant provides for subcellular localization. That is, the heterologous polypeptide comprises a subcellular localization sequence (e.g., a nuclear localization signal (NLS) for targeting to the nucleus, a sequence for retaining the fusion protein outside the nucleus (e.g., a nuclear export sequence (NES)), a sequence for retaining the fusion protein in the cytoplasm, a mitochondrial localization signal for targeting to mitochondria, a chloroplast localization signal for targeting to chloroplasts, an ER retention signal, etc.). In some embodiments, the subject RNA guide polypeptide or conditionally active RNA guide polypeptide and / or the subject CasX fusion protein does not comprise an NLS, so that the protein is not targeted to the nucleus (this can be advantageous, for example, when the target nucleic acid sequence is an RNA present in the cytosol). In some embodiments, the fusion partner can provide a tag to facilitate tracking and / or purification (i.e., the heterologous polypeptide is a detectable label) (e.g., a fluorescent protein, e.g., green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), cyan fluorescent protein (CFP), mCherry, tdTomato, etc.; a histidine tag, e.g., a 6xHis tag; a hemagglutinin (HA) tag; a FLAG tag; a Myc tag, etc.).
[0202]
[0203] Generally, the NLS (or NLSs) is strong enough to drive the accumulation of the expressed CasX variant fusion protein in the nucleus of a eukaryotic cell. Detection of nuclear accumulation can be performed by any suitable technique. For example, a detectable marker can be fused to the CasX variant fusion protein so that its subcellular location can be visualized. Cell nuclei can also be isolated from cells, and their contents can then be analyzed by any suitable process for detecting proteins (e.g., immunohistochemistry, Western blot, or enzyme activity assay). Nuclear accumulation can also be determined indirectly.
[0204] In some cases, the CasX variant fusion protein contains a "protein transduction domain" or PTD (also known as a CPP cell-penetrating peptide), which refers to a protein, polynucleotide, carbohydrate, or organic or inorganic compound that facilitates crossing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane. A PTD bound to another molecule (which can range from small polar molecules to large macromolecules and / or nanoparticles) facilitates the molecule's crossing of a membrane, e.g., translocation from the extracellular space to the intracellular space, or from the cytosol into an organelle. In some embodiments, the PTD is covalently attached to the amino terminus of the CasX variant fusion protein. In some embodiments, the PTD is covalently attached to the carboxyl terminus of the CasX variant fusion protein. In some cases, the PTD is inserted internally into the sequence of the CasX variant fusion protein at a suitable insertion site. In some cases, the CasX variant fusion protein contains (is conjugated to, or fused to) one or more PTDs (e.g., two or more, three or more, four or more PTDs). In some cases, the PTD comprises one or more nuclear localization signals (NLS).Examples of PTDs include, but are not limited to, the peptide transduction domain of HIV TAT, including YGRKKRRQRRR (SEQ ID NO: 205), RKKRRQRR (SEQ ID NO: 206); YARAAARQARA (SEQ ID NO: 207); THRLPRRRRRR (SEQ ID NO: 208); and GGRRARRRRRR (SEQ ID NO: 209); a polyarginine sequence (SEQ ID NO: 26793) containing a sufficient number of arginine residues to direct cell entry (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50 arginine residues); a VP22 domain (Zender et al. (2002) Cancer Gene Ther. 9(6):489-96); the Drosophila antennapedia protein transduction domain (Noguchi et al. (2003) Diabetes 52(7):1732-1737); a truncated human calcitonin peptide (Trehin et al. (2003) Diabetes 52(7):1732-1737); al. (2004) Pharm. Research 21:1248-1256); polylysine (Wender et al. (2000) Proc. Natl. Acad. Sci. USA 97:13003-13008); RRQRRTSKLMKR (SEQ ID NO: 210); transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 211); KALAWEAKLAKALAKALAKHLAKALAKALKCEA (SEQ ID NO: 212); and RQIKIWFQNRRMKWKK (SEQ ID NO: 213). In some embodiments, the PTD is an activatable CPP (ACPP) (Aguilera et al. (2009) Integr Biol (Camb) June;1(5-6):371-381). ACPPs contain a polycationic CPP (e.g., Arg9 or "R9") linked to a matching polyanion (e.g., Glu9 or "E9") via a cleavage-competent linker, which reduces the net charge to near zero, thereby inhibiting adhesion and uptake into cells. Upon cleavage of the linker, the polyanion is released, locally unmasking the polyarginine and its inherent adhesive properties, thus "activating" the ACPP and allowing it to cross membranes.
[0205] In some embodiments, a CasX variant fusion protein for use in the system can comprise a CasX protein linked to a heterologous amino acid or polypeptide (heterologous amino acid sequence) inserted therein via a linker polypeptide (e.g., one or more linker polypeptides). In some embodiments, the CasX variant fusion protein can be linked at the C-terminus and / or N-terminus to a heterologous polypeptide (fusion partner) via a linker polypeptide (e.g., one or more linker polypeptides). The linker polypeptide can have any of a variety of amino acid sequences. Proteins can be linked by a spacer peptide, which is generally flexible in nature, although other chemical bonds are not excluded. Suitable linkers include polypeptides between 4 and 40 amino acids in length, or between 4 and 25 amino acids in length. These linkers are generally generated by coupling proteins using oligonucleotides encoding synthetic linkers. Peptide linkers with some degree of flexibility can be used. The connecting peptide can have virtually any amino acid sequence, with the understanding that preferred linkers will generally have sequences that result in flexible peptides. The use of small amino acids such as glycine and alanine is useful in generating flexible peptides. The generation of such sequences is routine for one of skill in the art. A variety of different linkers are commercially available and may be suitable for use.Exemplary linker polypeptides include RS, (G)n (SEQ ID NO: 27212), (GS)n (SEQ ID NO: 27213), (GSGGS)n (SEQ ID NO: 214), (GGSGGS)n (SEQ ID NO: 215), (GGGS)n (SEQ ID NO: 216), (wherein n is an integer from 1 to 5), GGSG (SEQ ID NO: 217), GGSGG (SEQ ID NO: 218), GSGSG (SEQ ID NO: 219), GSGGG (SEQ ID NO: 220), GGGSG (SEQ ID NO: 221), GSSSG (SEQ ID NO: 222), and the like. 222), GPGP (SEQ ID NO: 223), GGP, PPP, PPAPPA (SEQ ID NO: 224), PPPG (SEQ ID NO: 27214), PPPGPPP (SEQ ID NO: 225), PPP(GGGS)n (SEQ ID NO: 27215), (GGGS)nPPP (SEQ ID NO: 27216), AEAAAKEAAAKEAAAKA (SEQ ID NO: 27217), and TPPKTKRKVEFE (SEQ ID NO: 27218), where n is 1 to 5. Those skilled in the art will recognize that the design of peptides conjugated to any of the above elements can include a fully or partially flexible linker, such that the linker can include one or more moieties that impart a less flexible structure as well as flexible linkers.
[0206] V. Systems and Methods for Modification of the BCL11A Gene The CRISPR proteins, guide nucleic acids, and variants thereof provided herein are useful for a variety of applications, including as therapeutic agents, diagnostic agents, and for research. In some embodiments, a programmable CasX:gRNA system is provided herein for implementing the disclosed methods for gene editing. The programmable nature of the systems provided herein allows for precise targeting to achieve desired modifications in one or more regions of interest in a BCL11A gene target nucleic acid. Various strategies and methods can be used to modify target nucleic acid sequences in cells using the systems provided herein. As used herein, "modification" includes, but is not limited to, cleavage, nicking, editing, deletion, knockout, knockdown, mutagenesis, repair, exon skipping, and the like. Depending on the system components utilized, the editing event can be a cleavage event followed by the introduction of a random insertion or deletion (indel) or other mutation (e.g., a substitution, duplication, or inversion of one or more nucleotides) by utilizing, for example, the imprecise non-homologous DNA end joining (NHEJ) repair pathway, which can generate a frameshift mutation. Alternatively, the editing event may be a cleavage event followed by homology directed repair (HDR), homology-independent targeted integration (HITI), microhomology-mediated end joining (MMEJ), single-strand annealing (SSA), or base excision repair (BER), resulting in modification of the target nucleic acid sequence.
[0207] In some embodiments of this method, the BCL11A gene to be modified comprises a sequence corresponding to a polynucleotide encoding all or part of the sequence of SEQ ID NO: 100, or comprises a polynucleotide sequence spanning all or part of chr2 60450520-60554467 of the human genome on chromosome 2 (GRCh38 / hg38 Ensembl 100). In other embodiments of this method, the target nucleic acid sequence to be modified comprises a region of the BCL11A gene that encodes the BCL11A protein, a BCL11A regulatory element, a non-coding region of the BCL11A gene, or overlapping portions thereof. In certain embodiments of this method, the target nucleic acid sequence to be modified comprises a GATA1-binding motif sequence or its complement.
[0208] In some embodiments, the present disclosure provides a method for modifying a BCL11A target nucleic acid in a cell, the method comprising introducing a class 2, type V CRISPR system into the cell. In some embodiments of the method, the modified cells are autologous to the subject receiving the cells. In other embodiments, the modified cells are allogeneic to the subject receiving the cells. Thus, the systems and methods described herein can be used to engineer various cells in which mutations are present in the β-globin gene and are associated with diseases (e.g., sickle cell disease and hemoglobinopathies, including α- and β-thalassemia). Thus, this approach can be used to modify cells for application in subjects with hemoglobinopathies, such as, but not limited to, sickle cell disease and α- and β-thalassemia.
[0209] In some embodiments, the present disclosure provides a method for modifying a BCL11A target nucleic acid in a cell, the method comprising introducing into the cell: i) a CasX:gRNA system comprising CasX and a gRNA as described in any one of the embodiments described herein; ii) a CasX:gRNA system comprising CasX, a gRNA, and a donor template as described in any one of the embodiments described herein; iii) a nucleic acid encoding CasX and a gRNA, and optionally comprising a donor template; iv) a vector comprising the nucleic acid of (iii) above; v) an XDP comprising the CasX:gRNA system as described in any one of the embodiments described herein; or vi) a combination of two or more of (i)-(v), wherein a target nucleic acid sequence in the cell is modified by the CasX protein and, optionally, the donor template. In some embodiments, the vector is an AAV vector. In some embodiments, the disclosure provides a CasX:gRNA system for use in a method of modifying a BCL11A gene in a cell, the method comprising identifying a CasX:gRNA system that is at least 60% identical, at least 70% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, or at least 90% identical to a CasX variant selected from the group consisting of SEQ ID NOs: 36-99, 101-148, and 26908-27154, or a CasX variant selected from the group consisting of SEQ ID NOs: 59, 72-99, 101-148, and 26908-27154, or a CasX variant selected from the group consisting of SEQ ID NOs: 132-148 and 26908-27154, or at least 60% identical, at least 70% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, or at least 90% identical to a CasX variant selected from the group consisting of SEQ ID NOs: 132-148 and 26908-27154. and wherein the gRNA scaffold comprises a sequence selected from the group consisting of SEQ ID NOs: 2101-2285, 26794-26839, and 27219-27265 shown in Table 3, or SEQ ID NOs: 2281-2285,26794 to 26839, and 27219 to 27265, or at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 100% identical, at least 101% identical, at least 102% identical, at least 103% identical, at least 104% identical, at least 105% identical, at least 106% identical, at least 107% identical, at least 108% identical, at least 109% identical, at least 110% identical, at least 111% identical, at least 112% identical, at least 113% identical, at least 114% identical, at least 115% identical, at least 116% identical, at least 117% identical, at least 118% identical, at least 119% identical, at least 120% identical, at least 121% identical, at least 122% identical, at least 123% identical, at least 124% identical, at least 125% identical, at least 126% identical, at least 127% identical, at least 128% identical, at least 129% identical, at least 130% identical, at least 131% identical, at 3% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical, and the gRNA comprises a targeting sequence selected from the group consisting of SEQ ID NOs: 272-2100 or 2286-26789, or a sequence at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, or at least 95% identical thereto, and has 15-20 nucleotides. In certain embodiments, the targeting sequence of the gRNA is complementary to, and therefore capable of hybridizing to, a sequence within, or 5' or 3' to, the GATA1-binding motif sequence. In one embodiment, the targeting sequence of the gRNA is UGGAGCCUGUGAUAAAAGCA (SEQ ID NO: 22), which hybridizes to the BCL11A GATA1 erythroid-specific enhancer binding site sequence, or a sequence having at least 90% or at least 95% sequence identity thereto. In another embodiment, the targeting sequence of the gRNA is UGCUUUUAUCACAGGCUCCA (SEQ ID NO: 23), which hybridizes to a sequence complementary to the reverse complement of the BCL11A GATA1 erythroid-specific enhancer binding site sequence, or a sequence having at least 90% or at least 95% sequence identity thereto. In another specific embodiment, the targeting sequence of the gRNA is complementary to, and thus capable of hybridizing to, a sequence within the promoter of the BCL11A gene. In one embodiment of this method, the CasX and gRNA areThey associate together in a ribonucleoprotein complex (RNP). In some embodiments of the method for modifying a BCL11A target nucleic acid sequence in a cell, the modification comprises introducing a single-strand break in the target nucleic acid sequence. In other embodiments of the method, the modification comprises introducing a double-strand break in the target nucleic acid sequence. In some embodiments of the method, the modification comprises introducing an insertion, deletion, substitution, duplication, or inversion of one or more nucleotides in the target nucleic acid sequence. As described herein, CasX variants that introduce a double-strand break in the target nucleic acid generate a double-strand break within 18-26 nucleotides 5' of the PAM site on the target strand and within 10-18 nucleotides 3' of the PAM site on the non-target strand. Thus, in some embodiments, the modification obtained by the method can result in a random insertion or deletion (indel), or substitution, duplication, or inversion of one or more nucleotides in those regions by a non-homologous DNA end joining (NHEJ) repair mechanism.
[0210] In other embodiments of methods for modifying a BCL11A target nucleic acid sequence in a cell, the method includes contacting the target nucleic acid sequence with a CasX:gRNA system having first and second or multiple gRNAs that target different or overlapping portions of the BCL11A gene (e.g., the targeting sequence of the second gRNA is complementary to a sequence 5' or 3' to the GATAl binding site), wherein the CasX protein introduces multiple cleavages into the target nucleic acid, resulting in permanent indels or mutations in the target nucleic acid or excision of the GATAl binding motif sequence with corresponding alterations in the regulation of expression or function of the BCL11A gene product, as described herein, thereby generating an edited cell. In some of the foregoing cases, the multiple gRNAs target positions 5' and 3' to the GATAl binding motif sequence in the BCL11A gene, such that part or all of the GATAl binding motif sequence is excised from the target gene between the dual cleavage sites targeted by the two gRNAs. It will be understood that the foregoing embodiments of the method may also be achieved through the use of encoding nucleic acids, vectors containing the encoding nucleic acids, or XDPs containing the CasX:gRNA system components.
[0211] In some embodiments, the disclosed methods provide a CasX protein and gRNA pair that generates a site-specific double-strand break (DSB) or single-strand break (SSB) (e.g., when the CasX protein is a nickase that can cleave only one strand of the target nucleic acid) within 18-24 nucleotides 3' of the PAM site, which can then be repaired by either non-homologous end joining (NHEJ), homology-directed repair (HDR), homology-independent targeted integration (HITI), microhomology-mediated end joining (MMEJ), single-strand annealing (SSA), or base excision repair (BER), resulting in a modification of the BCL11A gene that introduces an insertion, deletion, inversion, or duplication of one or more nucleotides compared to the wild-type sequence, accompanied by a corresponding alteration in the regulation or function of the BCL11A gene product, thereby generating an edited cell.
[0212] In some cases, the CasX:gRNA system for use in the method of modifying the BCL11A gene further includes a donor template nucleic acid of any of the embodiments disclosed herein, wherein the donor template can be inserted by the host cell's homology-directed repair (HDR) or homology-independent targeted integration (HITI) repair mechanisms. Thus, in some cases, the methods provided herein include contacting the BCL11A gene with the donor template by introducing the donor template (into a cell in vitro or in vivo), wherein the donor template, a portion of the donor template, a copy of the donor template, or a portion of the copy of the donor template is integrated into the BCL11A gene to replace a portion of the BCL11A gene. The donor template can be a short single- or double-stranded oligonucleotide, or a long single- or double-stranded oligonucleotide. In some embodiments, the donor template comprises at least a portion of the BCL11A gene, wherein the portion of the BCL11A gene is selected from the group consisting of a BCL11A exon, a BCL11A intron, a BCL11A intron-exon junction, a BCL11A regulatory element, or a combination thereof. In some embodiments, the disclosure provides donor templates for use in targeting or disrupting a transcriptional activator GATA1 binding site in a BCL11A target sequence, wherein the donor template comprises a sequence that is non-homologous to a region of DNA within or near the GATA1 site in the BCL11A gene, flanked by two regions of homology 5' and 3' to the cleavage site ("homologous arms"), such that repair mechanisms between the target DNA region and the two flanking sequences result in insertion of the donor template at the target region to facilitate insertion by HDR. The donor template may contain one or more single base changes, insertions, deletions, inversions or rearrangements with respect to the genomic sequence, but there must be sufficient homology with the target nucleic acid sequence to support its incorporation into the target nucleic acid, which may result in a frameshift or other mutation such that the BCL11A protein is not expressed (knockout) or is expressed at a lower level (knockdown).The exogenous donor template inserted by HITI can be of any length, e.g., a relatively short sequence of 10-50 nucleotides in length, or a longer sequence of about 50-1000 nucleotides in length. The lack of homology can be, for example, 20-50% or less sequence identity and / or a lack of specific hybridization at low stringency. In other cases, the lack of homology can further include 5, 6, 7, 8, or 9 bp or less identity. In some embodiments, the donor template polynucleotide comprises at least about 10, at least about 50, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000, at least about 10,000, or at least about 15,000 nucleotides. In other embodiments, the donor template comprises at least about 10 to about 15,000 nucleotides, or at least about 100 to about 10,000 nucleotides, or at least about 400 to about 8,000 nucleotides, or at least about 600 to about 5,000 nucleotides, or at least about 1,000 to about 2,000 nucleotides. The donor template sequence may contain specific sequence differences compared to the genomic sequence, such as restriction sites, nucleotide polymorphisms, or selectable markers (e.g., drug resistance genes, fluorescent proteins, enzymes, etc.), which can be used to assess successful insertion of the donor nucleic acid at the cleavage site or, in some cases, for other purposes (e.g., to demonstrate expression at the target genomic locus). Alternatively, these sequence differences may include adjacent recombination sequences (e.g., FLP sequences, loxP sequences, etc.) that can be subsequently activated to remove the marker sequence.
[0213] In some embodiments of methods for modifying a BCL11A target nucleic acid in a cell in vitro or ex vivo to induce cleavage or any desired modification to the target nucleic acid, a gRNA and / or CasX protein of the disclosure, and optionally a donor template sequence, whether introduced as a nucleic acid or polypeptide, a complexed RNP, a vector, or an XDP, are provided to the cell for about 30 minutes to about 24 hours, or at least about 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 18 hours, 20 hours, or any other period of time from about 30 minutes to about 24 hours, which can be repeated at a frequency of about every day to about every 4 days, e.g., every 1.5 days, every 2 days, every 3 days, or any other frequency from about every day to about every 4 days. The agent can be provided to the subject cells one or more times, e.g., once, twice, three times, or more than three times, and the cells can be incubated with the agent for a period of time (e.g., 30 minutes to about 24 hours) after each contact event. For in vitro-based methods, after the incubation period with CasX and gRNA (and optionally the donor template), the medium is replaced with fresh medium and the cells are further cultured.
[0214] In some embodiments of the methods for modifying a BCL11A target nucleic acid in a cell, the method further comprises contacting a target nucleic acid sequence in the cell with: a) an additional CRISPR nuclease and gRNA that targets a different or overlapping portion of the BCL11A target nucleic acid compared to the first gRNA; b) a polynucleotide encoding the additional CRISPR nuclease and gRNA of (a); c) a vector comprising the polynucleotide of (b); or d) an XDP comprising the additional CRISPR nuclease and the gRNA of (a), wherein the contacting results in modification of the BCL11A target nucleic acid at a different position in the sequence compared to the first gRNA. Optionally, the additional CRISPR nuclease is a CasX protein having a different sequence from the CasX protein of any of the preceding claims. In other cases, the additional CRISPR nuclease is not a CasX protein and is selected from the group consisting of Cas9, Cas12a, Cas12b, Cas12c, Cas12d (CasY), Cas12j, Cas12k, Cas13a, Cas13b, Cas13c, Cas13d, CasY, Cas14, Cpfl, C2cl, Csn2, Cas Phi, and sequence variants thereof.
[0215] In cases where the modification results in knockdown of the BCL11A gene, expression of the BCL11A protein is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to unmodified cells. In other cases where the modification results in knockout of the BCL11A gene, the target nucleic acid of the cell population is modified so that expression of the BCL11A protein is undetectable. Expression of the BCL11A protein can be measured by flow cytometry, ELISA, cell-based assays, Western blot, qRT-PCR, or other methods known in the art, or as described in the Examples.
[0216] In some embodiments, the present disclosure provides a method for modifying a BCL11A target nucleic acid in a cell population in a subject in vivo. In some embodiments, modification of the target nucleic acid sequence is performed ex vivo in eukaryotic cells, where the eukaryotic cells are selected from the group consisting of hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), CD34+ cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), common myeloid progenitor cells, proerythroblast cells, and erythroblast cells. In the foregoing embodiments, the modified cell population may be utilized in a method of treatment in a subject, where the modified cells are administered to a subject in need thereof, where the subject is selected from the group consisting of a mouse, a rat, a pig, a non-human primate, and a human. In some cases, the ex vivo cells are autologous and isolated from the bone marrow or peripheral blood of the subject. In other cases, the ex vivo cells are allogeneic and isolated from the bone marrow or peripheral blood of a different subject. In the treatment methods, the modified cells can be administered to a subject by a route of administration selected from intraparenchymal, intravenous, intraarterial, intramuscular, subcuticular, intra-articular, intracardiac, intrapericardial, intravitreal, subcapsular, or by subcutaneous injection, and can be implanted into a subject by implantation, local injection, systemic infusion, or a combination thereof. In the foregoing embodiments, the method results in the persistence of the modified cells or their progeny for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years.
[0217] In some embodiments of the method for modifying a target nucleic acid sequence, modifying the BCL11A gene comprises binding a CasX:gRNA complex to the target nucleic acid sequence and introducing it into a cell as an RNP. In some embodiments, the CasX is a catalytically inactive CasX (dCasX) protein that retains the ability to bind to the gRNA and the target nucleic acid sequence. For example, the target nucleic acid sequence includes a BCL11A sequence that includes a sequence complementary to a GATAl-binding motif sequence, and binding of the dCasX:gRNA complex to the target sequence prevents or suppresses transcription of the BCL11A allele. In some embodiments, the dCasX includes mutations at residues D672, E769, and / or D935, corresponding to the CasX protein of SEQ ID NO:1, or D659, E756, and / or D922, corresponding to the CasX protein of SEQ ID NO:2. In some of the foregoing embodiments, the mutations in the variant CasX protein are substitutions of residues with alanine or glycine, and can be utilized in any of the variants described herein.
[0218] Introduction of a recombinant expression vector containing a component of a system embodiment or a nucleic acid encoding the component into a target cell can be performed in vivo, in vitro, or ex vivo. In some embodiments of the method, the vector can be provided directly to the target host cell. Methods for introducing nucleic acids (e.g., a nucleic acid containing a donor polynucleotide sequence, one or more nucleic acids (DNA or RNA) encoding a CasX protein and / or gRNA, or a vector containing the same) into cells are known in the art, and any convenient method can be used to introduce the nucleic acid (e.g., an expression construct) into a cell. Suitable methods include, for example, viral infection, transfection, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, nucleofection, electroporation, direct loading with a cell-permeable CasX protein fused to or mobilizing donor DNA, cell squeezing, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, etc. Nucleic acids can be introduced into cells using well-developed, commercially available transfection techniques, such as the use of the TransMessenger® reagent from Qiagen, the Stemfect™ RNA transfection kit from Stemgent, and the TransIT®-mRNA transfection kit from Mirus Bio LLC, Lonza nucleofection, Maxagen electroporation, etc. Introduction of a recombinant expression vector containing a sequence encoding the disclosed CasX:gRNA system (and optionally a donor sequence) into cells under in vitro conditions can be carried out in any suitable culture medium and under any suitable culture conditions that promote cell survival. For example, cells can be contacted with a vector containing a nucleic acid of interest (e.g., a recombinant expression vector having a donor template sequence and nucleic acids encoding CasX and gRNA) such that the vector is taken up by the cell.The vector used to provide the nucleic acid encoding the gRNA and / or CasX protein to the target host cell can include a suitable promoter for driving expression (i.e., transcriptional activation) of the nucleic acid of interest. In some cases, the encoding nucleic acid of interest is operably linked to a promoter. This can include a ubiquitously acting promoter (e.g., the CMV-β-actin promoter) or an inducible promoter (e.g., a promoter that is active in a specific cell population or that responds to the presence of a drug such as tetracycline or kanamycin). By transcriptional activation, it is intended that transcription be increased by at least about 10-fold, at least about 100-fold, or more usually at least about 1000-fold above basal levels in the target host cell containing the vector. In addition, the vector used to provide the nucleic acid encoding the gRNA and / or CasX protein to the cell can include a nucleic acid sequence encoding a selectable marker in the target cell to identify cells that have incorporated the CasX protein and / or gRNA.
[0219] For viral vector delivery, cells can be contacted with viral particles containing the subject viral expression vector and nucleic acids encoding CasX and gRNA, and optionally a donor template. In some embodiments, the vector is an adeno-associated viral (AAV) vector, where the AAV is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV44.9, AAV-Rh74, or AAVRh10. In other cases, the AAV is selected from AAV1, AAV2, AAV5, AAV6, AAV7, AAV8, and AAV9, which are efficient for muscle transduction (Gruntman AM, et al. Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol. 14(14D):3(2013)). Embodiments of AAV vectors are described in more detail below. In other embodiments, the vector is a lentiviral vector. Retroviruses (e.g., lentiviruses) may be suitable for use in the methods of the present disclosure. Commonly used retroviral vectors are "defective," e.g., unable to produce viral proteins necessary for productive infection. Rather, vector replication requires propagation in a packaging cell line. To generate viral particles containing a nucleic acid of interest, the retroviral nucleic acid containing the nucleic acid is packaged into a viral capsid by the packaging cell line. Different packaging cell lines offer different envelope proteins (ecotropic, amphotropic, or xenotropic) that are incorporated into the capsid, and this envelope protein determines the specificity or tropism of the viral particle for cells (ecotropic for mouse and rat; amphotropic for most mammalian cell types, including human, dog, and mouse; xenotropic for most mammalian cell types except mouse cells). An appropriate packaging cell line can be used to ensure cell targeting by the packaged viral particles.Methods for introducing a subject vector expression vector into a packaging cell line and harvesting viral particles produced by the packaging line are well known in the art, including U.S. Patent No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989). Nucleic acids can also be introduced by direct microinjection (e.g., injection of RNA).
[0220] In other embodiments of the method for modifying the BCL11A gene, the method utilizes a CasX delivery particle (XDP) for targeted delivery of RNP to cells of a subject. XDPs are particles that closely resemble viruses but do not contain viral genetic material and are therefore non-infectious. In some embodiments, the XDP contains CasX and gRNA complexed as an RNP, and optionally a donor template containing all or a portion of the BCL11A gene for knocking down or knocking out the BCL11A gene or a portion of the gene by insertion via HDR or HITI mechanisms. Embodiments of XDPs are described in more detail below.
[0221] VI. Polynucleotides and Vectors In another aspect, the present disclosure relates to polynucleotides encoding class 2, type V nucleases and gRNAs useful in editing the BCL11A gene. In some embodiments, the present disclosure provides polynucleotides encoding CasX proteins and gRNAs of the CasX:gRNA systems of the embodiments described herein. In additional embodiments, the present disclosure provides donor template polynucleotides encoding part or all of the BCL11A gene. In some cases, the donor template comprises a mutation or heterologous sequence to knock down or knock out the BCL11A gene upon insertion into a target nucleic acid. In still further embodiments, the present disclosure provides vectors comprising polynucleotides encoding the CasX proteins and CasX gRNAs described herein, as well as donor templates of the embodiments.
[0222] In some embodiments, the present disclosure provides polynucleotide sequences encoding any of the CasX variants of the embodiments described herein, including CasX protein variants of SEQ ID NOs: 59, 72-99, 101-148, and 26908-27154 set forth in Table 4, or sequences having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the sequences of SEQ ID NOs: 59, 72-99, 101-148, and 26908-27154 in Table 4. In some embodiments, the present disclosure provides polynucleotide sequences encoding any of the CasX variants of the embodiments described herein, including CasX protein variants of SEQ ID NOs: 36-99, 101-148, and 26908-27154 set forth in Table 4, or sequences having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the sequences of SEQ ID NOs: 36-99, 101-148, and 26908-27154 in Table 4. In some embodiments, the present disclosure provides isolated polynucleotide sequences encoding the gRNA sequence of any of the embodiments described herein, comprising a targeting sequence of SEQ ID NO: 272-2100 or 2286-26789, along with the sequence of SEQ ID NO: 4-16, 2238-2285, 26794-26839, or 27219-27265 in Tables 2 and 3. In some embodiments, the present disclosure provides isolated polynucleotide sequences encoding the gRNA sequence of any of the embodiments described herein, comprising a targeting sequence of SEQ ID NO: 272-2100 or 2286-26789, along with the sequence of SEQ ID NO: 2101-2285, 26794-26839, and 27219-27265.In some embodiments, the disclosure provides an isolated polynucleotide sequence encoding the gRNA sequence of any of the embodiments described herein, comprising the sequences of SEQ ID NOs: 2281-2285, 26794-26839, and 27219-27265, as well as a targeting sequence of SEQ ID NOs: 272-2100 or 2286-26789. In some embodiments, the sequence encoding the CasX protein is codon-optimized for expression in eukaryotic cells.
[0223] In some embodiments, the present disclosure provides polynucleotides encoding gRNA scaffold sequences of SEQ ID NOs: 4-16, 2238-2285, 26794-26839, or 27219-27265, or gRNA scaffold sequences set forth in Table 2 or Table 3, or sequences having at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto. In other embodiments, the present disclosure provides targeting sequence polynucleotides of Table 1, or sequences having at least about 65%, at least about 75%, at least about 85%, or at least about 95% identity thereto. In some embodiments, the targeting sequence polynucleotide is then ligated to the 3' end of the gRNA scaffold sequence (either as an sgRNA or dgRNA). In other embodiments, the present disclosure provides gRNAs comprising targeting sequence polynucleotides having one or more single nucleotide polymorphisms (SNPs) compared to the sequences of SEQ ID NOs: 272-2100 or 2286-26789.
[0224] In other embodiments, the present disclosure provides isolated polynucleotide sequences encoding gRNAs comprising a targeting sequence that is complementary to, and thus capable of hybridizing to, the BCL11A gene. In some embodiments, the polynucleotide sequences encode gRNAs comprising a targeting sequence that hybridizes to a BCL11A exon. In other embodiments, the polynucleotide sequences encode gRNAs comprising a targeting sequence that hybridizes to a BCL11A intron. In other embodiments, the polynucleotide sequences encode gRNAs comprising a targeting sequence that hybridizes to a BCL11A intron-exon junction. In other embodiments, the polynucleotide sequences encode gRNAs comprising a targeting sequence that hybridizes to an intergenic region of the BCL11A gene. In other embodiments, the polynucleotide sequences encode gRNAs comprising a targeting sequence that hybridizes to a BCL11A regulatory element. In some cases, the BCL11A regulatory element is a BCL11A promoter or enhancer. In some cases, the BCL11A regulatory element is located 5' to the BCL11A transcription start site, 3' to the BCL11A transcription start site, or in a BCL11A intron. In other embodiments, the polynucleotide sequence encodes a gRNA comprising a targeting sequence that hybridizes to a sequence located 5' to the GATAl binding motif sequence. In other embodiments, the polynucleotide sequence encodes a gRNA comprising a targeting sequence that hybridizes to a sequence that overlaps with the GATAl binding motif sequence. In certain of the foregoing embodiments, the polynucleotide sequence encodes a gRNA comprising a targeting sequence having SEQ ID NO: 22. In some cases, the BCL11A regulatory element is in an intron of the BCL11A gene. In other cases, the BCL11A regulatory element comprises the 5' UTR of the BCL11A gene. In still other cases, the BCL11A regulatory element comprises the 3' UTR of the BCL11A gene.
[0225] In other embodiments, the disclosure provides a donor template nucleic acid, wherein the donor template comprises a nucleotide sequence having homology to a BCL11A target nucleic acid sequence. In some embodiments, the BCL11A donor template is intended for gene editing in conjunction with a CasX:gRNA system and comprises at least a portion of the BCL11A gene. In other embodiments, the BCL11A donor sequence comprises a sequence encoding at least a portion of a BCL11A exon. In other embodiments, the BCL11A donor template has a sequence encoding at least a portion of a BCL11A intron. In other embodiments, the BCL11A donor template has a sequence encoding at least a portion of a BCL11A intron-exon junction. In other embodiments, the BCL11A donor template has a sequence encoding at least a portion of an intergenic region of the BCL11A gene. In other embodiments, the BCL11A donor template has a sequence encoding at least a portion of a BCL11A regulatory element. In some cases, the BCL11A donor template is a wild-type sequence encoding at least a portion of SEQ ID NO: 100. In other cases, the BCL11A donor template sequence contains one or more mutations compared to the wild-type BCL11A gene. In certain embodiments, the donor template has a sequence that encodes part or all of the GATA1 binding motif sequence but has at least 1-5 mutations compared to the wild-type sequence. In the foregoing embodiments, the donor template is at least 10 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, at least 900 nucleotides, at least 1,000 nucleotides, at least 2,000 nucleotides, at least 3,000 nucleotides, at least 4,000 nucleotides, at least 5,000 nucleotides, at least 6,000 nucleotides, at least 7,000 nucleotides, at least 8,000 nucleotides, at least 9,000 nucleotides, at least 10,000 nucleotides, at least 12,000 nucleotides, or at least 15,000 nucleotides.In some embodiments, the donor template comprises at least about 10 to about 15,000 nucleotides. In some embodiments, the donor template is a single-stranded DNA template. In other embodiments, the donor template is a single-stranded RNA template. In other embodiments, the donor template is a double-stranded DNA template. In some embodiments, the donor template can be provided as naked nucleic acid in a system for editing the BCL11A gene and does not need to be incorporated into a vector. In other embodiments, the donor template can be incorporated into a vector (e.g., a viral vector) to facilitate its delivery to a cell.
[0226] In another aspect, the present disclosure relates to methods for producing polynucleotide sequences encoding any of the CasX variants or gRNAs (including homologous variants thereof) of the embodiments described herein, as well as methods for expressing proteins or RNAs transcribed by the polynucleotide sequences. Generally, the methods involve producing a polynucleotide sequence encoding any of the CasX variants or gRNAs of the embodiments described herein and incorporating the coding gene into an expression vector suitable for a host cell. Standard recombinant techniques in molecular biology can be used to make the polynucleotides and expression vectors of the present disclosure. For the production of the encoded reference CasX, CasX variant, or gRNA of any of the embodiments described herein, the method involves transforming a suitable host cell with the expression vector containing the coding polynucleotide and culturing the host cell under conditions that cause or allow the resulting reference CasX, CasX variant, or gRNA of any of the embodiments described herein to be expressed or transcribed in the transformed host cell, thereby producing the CasX variant or gRNA, which is recovered by the methods described herein or by standard purification methods known in the art or as described in the Examples.
[0227] In accordance with the present disclosure, nucleic acid sequences encoding any of the CasX variants or gRNAs (or their complements) of the embodiments described herein are used to generate recombinant DNA molecules that direct expression in suitable host cells. Several cloning strategies are suitable for practicing the present disclosure, many of which are used to generate constructs containing genes encoding compositions of the present disclosure or their complements. In some embodiments, a cloning strategy is used to generate genes encoding constructs containing nucleotides encoding the CasX variants or gRNAs that are used to transform host cells for expression of the compositions.
[0228] In some approaches, a construct is first prepared containing a DNA sequence encoding a CasX variant or gRNA. Exemplary methods for preparing such constructs are described in the Examples. The construct is then used to generate an expression vector suitable for transforming a host cell (e.g., in the case of CasX or gRNA, a prokaryotic or eukaryotic host cell for expression and recovery of the protein construct). If desired, the host cell is E. coli. In other embodiments, the host cell is a eukaryotic cell. Eukaryotic host cells can be selected from Baby Hamster Kidney (BHK) cells, human embryonic kidney 293 (HEK293), human embryonic kidney 293T (HEK293T), NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells, hybridoma cells, NIH3T3 cells, CV-1 (simian) origin (COS) cells carrying SV40 genetic material, HeLa, Chinese hamster ovary (CHO), or yeast cells, or other eukaryotic cells known in the art suitable for producing recombinant products. Exemplary methods for generating expression vectors, transforming host cells, and expressing and recovering CasX variants or gRNAs are described in the Examples.
[0229] Genes encoding CasX variants or gRNA constructs can be generated in one or more steps, either entirely synthetically or by synthesis in combination with enzymatic processes such as restriction enzyme-mediated cloning, PCR, and overlap extension, including methods described in more detail in the Examples. The methods disclosed herein can be used, for example, to ligate polynucleotide sequences encoding the various component (e.g., CasX and gRNA) genes of a desired sequence. Genes encoding polypeptide compositions are assembled from oligonucleotides using standard techniques of gene synthesis.
[0230] In some embodiments, the nucleotide sequence encoding the CasX protein is codon-optimized for the intended host cell. This type of optimization can involve altering the coding nucleotide sequence to mimic the codon preferences of the intended host organism or cell while still encoding the same CasX protein. Thus, codons can be changed, but the encoded protein or gRNA remains unchanged. For example, if the intended target cell of the CasX protein is a human cell, a human-codon-optimized CasX-encoding nucleotide sequence can be used. As another non-limiting example, if the intended host cell is a mouse cell, a mouse-codon-optimized CasX-encoding nucleotide sequence can be generated. Gene design can be performed using algorithms that optimize codon usage and amino acid composition appropriate for the host cell utilized in the production of the reference CasX or CasX variant. In one method of the present disclosure, a library of polynucleotides encoding the components of the construct is generated and then constructed as described above. The resulting genes are then assembled as described herein, the resulting genes are used to transform host cells, and the CasX variant or gRNA composition is produced and recovered for evaluation of its properties.
[0231] The present disclosure provides for the use of plasmid expression vectors that contain replication and control sequences compatible with and recognized by a host cell and operably linked to a gene encoding a polypeptide for controlled expression of the polypeptide or transcription of RNA. Such vector sequences are well known for a variety of bacteria, yeast, and viruses. Useful expression vectors that can be used include, for example, segments of chromosomal, non-chromosomal, and synthetic DNA sequences. An "expression vector" refers to a DNA construct containing a DNA sequence operably linked to suitable control sequences capable of effecting expression of the DNA encoding a polypeptide in a suitable host. The prerequisite is that the vector be replicable and viable in the selected host cell. Low-copy or high-copy vectors can be used as desired. The control sequences of the vector include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding a suitable mRNA ribosomal binding site, and sequences to control termination of transcription and translation. In some embodiments, a nucleotide sequence encoding a gRNA is operably linked to a control element (e.g., a transcriptional control element such as a promoter). In some embodiments, the nucleotide sequence encoding the CasX protein is operably linked to a control element (e.g., a transcriptional control element such as a promoter). In other cases, the nucleotides encoding CasX and the gRNA are concatenated and operably linked to a single control element. The promoter may be any DNA sequence that exhibits transcriptional activity in the selected host cell and may be derived from a gene encoding a protein either homologous or heterologous to the host cell. Exemplary control elements include transcriptional promoters, transcriptional enhancer elements, transcription termination signals, internal ribosome entry sites (IRES) or P2A peptides that allow translation of multiple genes from a single transcript, polyadenylation sequences that facilitate downstream transcription termination, sequences for optimizing translation initiation, and translation termination sequences. In some cases, the promoter is a constitutively active promoter. In some cases, the promoter is a regulatable promoter.In some cases, the promoter is an inducible promoter. In some cases, the promoter is a tissue-specific promoter. In some cases, the promoter is a cell-type-specific promoter. In some cases, the transcriptional control element (e.g., promoter) is functional in a targeted cell type or targeted cell population. For example, in some cases, the transcriptional control element may be functional in eukaryotic cells (e.g., packaging cells for viruses or XDP vectors, hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), CD34+ cells, mesenchymal stem cells (MSCs), embryonic stem cells (ESs), induced pluripotent stem cells (iPSCs), common myeloid progenitor cells, proerythroid cells, and erythroid cells).
[0232] Non-limiting examples of pol II promoters include EF-1α, EF-1α core promoter, Jens Tornoe (JeT), promoter from cytomegalovirus (CMV), CMV immediate early (CMVIE), CMV enhancer, herpes simplex virus (HSV) thymidine kinase, early and late simian virus 40 (SV40), SV40 enhancer, long terminal repeats (LTR) from retroviruses, mouse metallothionein-I, adenovirus major late promoter (Ad MLP), CMV full-length promoter, minimal CMV promoter, chicken
[0233] [ka] (CBA), CBA hybrid (CBh), chicken with cytomegalovirus enhancer
[0234] [ka] (CB7), chicken β-actin promoter and rabbit β-globin splice acceptor site fusion (CAG), Rous sarcoma virus (RSV) promoter, HIV-Ltr promoter, hPGK promoter, HSV TK promoter, 7SK promoter, Mini-TK promoter, human synapsin I (SYN) promoter conferring neuron-specific expression, β-actin promoter, super core promoter 1 (SCP1), Mecp2 promoter for selective expression in neurons, minimal IL-2 promoter, Rous sarcoma virus enhancer / promoter (single), spleen focus-forming virus long terminal repeat (LTR) promoter, TBG promoter, promoter derived from human thyroxine-binding globulin gene (liver-specific), PGK promoter, human ubiquitin C promoter C, UBC), UCOE promoter (promoter of HNRPA2B1-CBX3), synthetic CAG promoter, histone H2 promoter, histone H3 promoter, U1a1 small nuclear RNA promoter (226 nt), U1a1 small nuclear RNA promoter (226 nt), U1b2 small nuclear RNA promoter (246 nt), GUSB promoter, CBh promoter, rhodopsin (Rho) promoter, silencing-prone spleen focus forming virus (SFFV) promoter, human H1 promoter (H1), POL1 promoter, TTR minimal enhancer / promoter, b-kinesin promoter, mouse mammary tumor virus long terminal repeat (LTR) promoter, human eukaryotic initiation factor 4A (EIF4A1) promoter, ROSA26 promoter, glyceraldehyde 3-phosphate dehydrogenase (GUSB) promoter, CBh promoter, rhodopsin (Rho) promoter, silencing-prone spleen focus forming virus (SFFV) promoter, human H1 promoter (H1), POL1 promoter, TTR minimal enhancer / promoter, b-kinesin promoter, mouse mammary tumor virus long terminal repeat (LTR) promoter, human eukaryotic initiation factor 4A (EIF4A1) promoter, ROSA26 promoter, glyceraldehyde 3-phosphate dehydrogenase (GUSB) promoter, dehydrogenase, GAPDH) promoters, tRNA promoters, and truncated versions and sequence variants of the foregoing.In certain embodiments, the pol II promoter is EF-1α, and the promoter enhances transfection efficiency, transcription or expression of the CRISPR nuclease transgene, the percentage of expression-positive clones, and the copy number of the episomal vector in long-term culture.
[0235] Non-limiting examples of Pol III promoters include, but are not limited to, U6, mini-U6, U6 truncated promoter, 7SK and H1 variants, BiH1 (bidirectional H1 promoter), BiU6, Bi7SK, BiH1 (bidirectional U6, 7SK, and H1 promoter), gorilla U6, rhesus U6, human 7SK, human H1 promoter, and sequence variants thereof. In the foregoing embodiments, the Pol III promoter enhances transcription of the gRNA.
[0236] Selection of an appropriate vector and promoter, as it relates to expression control (e.g., for modifying the BCL11A gene), is well within the level of ordinary skill in the art. Expression vectors may also contain a ribosome binding site for translation initiation and a transcription terminator. Expression vectors may also contain appropriate sequences for amplifying expression. Expression vectors may also contain nucleotide sequences encoding protein tags (e.g., 6xHis tags, hemagglutinin tags, fluorescent proteins, etc.) that can be fused to the CasX protein, thereby obtaining chimeric CasX proteins that can be used for purification or detection.
[0237] The recombinant expression vectors of the present disclosure can also include elements that promote strong expression of the CasX proteins and gRNAs of the present disclosure. For example, the recombinant expression vectors can include one or more polyadenylation signals (poly(A)), intron sequences, or post-transcriptional regulatory elements (e.g., woodchuck hepatitis post-transcriptional regulatory element (WPRE)). Exemplary poly(A) sequences include the hGH poly(A) signal (short), the HSV TK poly(A) signal, a synthetic polyadenylation signal, the SV40 poly(A) signal, the β-globin poly(A) signal, and the like. Those skilled in the art will be able to select appropriate elements for inclusion in the recombinant expression vectors described herein.
[0238] In some embodiments, provided herein are one or more recombinant expression vectors comprising one or more of the following: (i) a nucleotide sequence of a donor template nucleic acid, wherein the donor template comprises a nucleotide sequence having homology to a sequence of a target BCL11A locus of a target nucleic acid (e.g., a target genome), (ii) a nucleotide sequence encoding a gRNA (e.g., configured as a single or dual guide RNA) that hybridizes to a target sequence of the BCL11A locus of the target genome operably linked to a promoter that is operable in a target cell, such as a eukaryotic cell, and (iii) a nucleotide sequence encoding a CasX protein operably linked to a promoter that is operable in a target cell, such as a eukaryotic cell. In some embodiments, the donor template, gRNA, and CasX protein-encoding sequences are in different recombinant expression vectors; in other embodiments, one or more polynucleotide sequences (of the donor template, CasX, and gRNA) are in the same recombinant expression vector. In other cases, CasX and gRNA are delivered to the target cell as RNPs (e.g., by electroporation or chemical means) and the donor template is delivered by a vector.
[0239] Polynucleotide sequences can be inserted into vectors by a variety of procedures. Generally, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components uses standard ligation techniques known to those skilled in the art. Such techniques are well known in the art and are described extensively in the scientific and patent literature. A variety of vectors are publicly available. Vectors can be in the form of, for example, a plasmid, cosmid, viral particle, or phage, which can be conveniently subjected to recombinant DNA procedures, and the choice of vector often depends on the host cell into which the vector is to be introduced. Thus, a vector can be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication (e.g., a plasmid). Alternatively, a vector can be one that, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated. Upon introduction into a suitable host cell, expression of proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response can be determined using any nucleic acid or protein assay known in the art. For example, the presence of transcribed mRNA of a reference CasX or CasX variant can be detected and / or quantified by conventional hybridization assays (e.g., Northern blot analysis), amplification procedures (e.g., RT-PCR), SAGE (U.S. Pat. No. 5,695,937), and array-based technologies (see, e.g., U.S. Pat. Nos. 5,405,783, 5,412,087, and 5,445,934) using probes complementary to any region of the polynucleotide.
[0240] Polynucleotides and recombinant expression vectors can be delivered to target host cells by a variety of methods, including, but not limited to, viral infection, transfection, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, microinjection, liposome-mediated transfection, particle gun technology, nucleofection, direct loading with a cell-permeable CasX protein fused to or mobilizing donor DNA, cell squeezing, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, as well as using commercially available TransMessenger® reagents from Qiagen, Stemfect™ RNA transfection kits from Stemgent, and TransIT®-mRNA transfection kits from Mirus Bio LLC, Lonza nucleofection, Maxagen electroporation, and the like.
[0241] Recombinant expression vector sequences can be packaged into viruses or virus-like particles (also referred to herein as "particles" or "virions") for subsequent infection and transformation of cells ex vivo, in vitro, or in vivo. Such particles or virions typically contain proteins that encapsidate or package the vector genome. Suitable expression vectors can include viral expression vectors based on vaccinia virus; poliovirus; adenovirus; retroviral vectors (e.g., murine leukemia virus), spleen necrosis virus, and vectors derived from retroviruses (e.g., Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus), and the like. In some embodiments, a recombinant expression vector of the present disclosure is a recombinant adeno-associated virus (AAV) vector. In some embodiments, a recombinant expression vector of the present disclosure is a recombinant lentiviral vector. In some embodiments, a recombinant expression vector of the present disclosure is a recombinant retroviral vector.
[0242] In some embodiments, the recombinant expression vector of the present disclosure is a recombinant adeno-associated virus (AAV) vector. In some embodiments, the recombinant expression vector of the present disclosure is a recombinant lentivirus vector. In some embodiments, the recombinant expression vector of the present disclosure is a recombinant retrovirus vector.
[0243] AAV is a small (20 nm), non-pathogenic virus that is useful for treating human diseases in situations where viral vectors are used for delivery to cells, such as eukaryotic cells, either in vivo or ex vivo for cells prepared for administration to a subject. Constructs (e.g., constructs encoding any of the CasX proteins and / or CasX gRNAs of the embodiments described herein) are generated and flanked by AAV inverted terminal repeat (ITR) sequences, which allow packaging of the AAV vector into an AAV viral particle.
[0244] An "AAV" vector may refer to a naturally occurring wild-type virus itself or a derivative thereof. The term encompasses all subtypes, serotypes, and pseudotypes, as well as both naturally occurring and recombinant forms, unless otherwise required. As used herein, the term "serotype" refers to an AAV that is identified and distinguished from other AAVs based on the reactivity of the capsid protein with a specific antiserum. For example, there are many known serotypes of primate AAV. In some embodiments, the AAV vector is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV44.9, AAV-Rh74 (AAV derived from rhesus monkeys), and AAVRh10, and modified capsids of these serotypes. For example, serotype AAV-2 is used to refer to an AAV containing a capsid protein encoded by the AAV-2 cap gene and a genome containing 5' and 3' ITR sequences from the same AAV-2 serotype. Pseudotyped AAV refers to an AAV containing a capsid protein from one serotype and a viral genome containing 5'-3' ITRs from a second serotype. Pseudotyped rAAV is expected to have the cell surface binding characteristics of the capsid serotype and genetic characteristics consistent with the ITR serotype. Pseudotyped recombinant AAV (rAAV) is produced using standard techniques described in the art. As used herein, for example, rAAV1 can be used to refer to an AAV having both capsid protein and 5'-3' ITRs from the same serotype, or it can refer to an AAV having capsid protein from serotype 1 and 5'-3' ITRs from a different AAV serotype (e.g., AAV serotype 2). For each example exemplified herein, the description of vector design and production describes the serotype of the capsid and 5'-3' ITR sequences.
[0245] "AAV virus" or "AAV viral particle" refers to a viral particle composed of at least one AAV capsid protein (preferably all of the capsid proteins of wild-type AAV) and an encapsidated polynucleotide. When the particle further comprises a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome that is delivered to a mammalian cell), it is typically referred to as an "rAAV." An exemplary heterologous polynucleotide is a polynucleotide comprising a CasX protein and / or sgRNA of any of the embodiments described herein, and optionally a donor template.
[0246] "Adeno-associated virus inverted terminal repeat" or "AAV ITR" refers to the art-recognized regions found at each end of the AAV genome, which together function in cis as an origin of DNA replication and a viral packaging signal. The AAV ITRs, together with the AAV rep coding region, provide for efficient excision and rescue from, and integration of, nucleotide sequences inserted between the two flanking ITRs into, the mammalian cell genome. The nucleotide sequences of the AAV ITR regions are known. See, e.g., Kotin, RM (1994) Human Gene Therapy 5:793-801; Berns, KI "Parvoviridae and Their Replication" in Fundamental Virology, 2 ndEdition, (BN Fields and DMKnipe, eds.). As used herein, AAV ITRs need not have the wild-type nucleotide sequence shown, but may be modified, for example, by the insertion, deletion, or substitution of nucleotides. Additionally, AAV ITRs can be derived from any of several AAV serotypes (including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-Rh74, and AAVRh10), as well as modified capsids of these serotypes. Furthermore, the 5' and 3' ITRs flanking a selected nucleotide sequence in an AAV vector need not necessarily be identical or derived from the same AAV serotype or isolate, so long as they function as intended (i.e., allow excision and rescue of the sequence of interest from the host cell genome or vector, and allow integration of the heterologous sequence into the genome of a recipient cell if the AAV Rep gene product is present in the cell). The use of AAV serotypes for the integration of heterologous sequences into host cells is known in the art (see, e.g., WO 2018 / 195555 (A1) and U.S. Patent Application Publication No. Incorporated 2018 / 0258424 (A1), which are incorporated herein by reference).
[0247] The term "AAV rep coding region" refers to the region of the AAV genome that encodes the replication proteins Rep78, Rep68, Rep52, and Rep40. These Rep expression products have been shown to have multiple functions, including recognition, binding, and nicking of the AAV DNA replication origin, DNA helicase activity, and regulation of transcription from AAV (or other heterologous) promoters. Collectively, the Rep expression products are required for replicating the AAV genome. The term "AAV cap coding region" refers to the region of the AAV genome that encodes the capsid proteins VP1, VP2, and VP3, or their functional homologs. Collectively, these Cap expression products provide the packaging functions required for packaging the viral genome.
[0248] In some embodiments, the AAV capsid utilized to deliver the coding sequence for CasX and gRNA, and optionally DMPK donor template nucleotides, to a host cell can be derived from any of several AAV serotypes, including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV44.9, AAV-Rh74 (AAV derived from rhesus monkeys), and AAVRh10, with the AAV ITRs being derived from AAV serotype 2. In certain embodiments, AAV1, AAV7, AAV6, AAV8, or AAV9 is utilized for delivery of CasX, gRNA, and optionally donor template nucleotides to a host muscle cell.
[0249] To produce rAAV viral particles, the AAV expression vector is introduced into a suitable host cell using known techniques (e.g., transfection). Packaging cells are typically used to form viral particles. Such cells include HEK293 cells (and other cells known in the art) that package adenovirus. Many transfection techniques are generally known in the art. See, for example, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York. Particularly suitable transfection methods include calcium phosphate coprecipitation, direct microinjection into cultured cells, electroporation, liposome-mediated gene transfer, lipid-mediated transduction, and nucleic acid delivery using high-velocity biolistics.
[0250] An advantage of the rAAV constructs of the present disclosure is that the smaller size of the CRISPR type V nuclease (e.g., CasX in the present embodiment) allows for all necessary editing and ancillary expression components to be included in the transgene, such that a single rAAV particle can deliver and transduce a target cell in a form that results in expression of the CRISPR nuclease and gRNA that can effectively modify the target nucleic acid in the target cell. A representative schematic of such a construct is shown in Figure 13. This is in stark contrast to other CRISPR systems, such as Cas9, which typically use a two-particle system to deliver the necessary editing components to the target cell. Thus, in some embodiments of the rAAV system, the present disclosure provides i) a first plasmid comprising the ITRs, a sequence encoding a CasX variant, a sequence encoding one or more gRNAs, a first promoter operably linked to CasX and a second promoter operably linked to the gRNA, and optionally one or more enhancer elements; ii) a second plasmid comprising rep and cap genes; and iii) a third plasmid comprising helper genes, such that upon transfection of a suitable packaging cell, the cell can produce an rAAV capable of single-particle delivery to a target cell of a sequence capable of expressing a CasX nuclease and a gRNA capable of editing a target nucleic acid in the target cell.In some embodiments of the rAAV system, the sequences encoding the CRISPR proteins and the sequences encoding at least the first gRNA are less than about 3100, less than about 3090, less than about 3080, less than about 3070, less than about 3060, less than about 3050, or less than about 3040 nucleotides in length, such that the sequences encoding the first promoter and the second promoter, and optionally one or more enhancer elements, combined can have a length of at least about 1300, at least about 1350, at least about 1360, at least about 1370, at least about 1380, at least about 1390, at least about 1400, at least about 1500, at least about 1600 nucleotides, at least 1650, at least about 1700, at least about 1750, at least about 1800, at least about 1850, or at least about 1900 nucleotides. In some embodiments of the rAAV system, the sequences encoding the first promoter and at least one accessory element, combined, have a length of at least about 1300, at least about 1350, at least about 1360, at least about 1370, at least about 1380, at least about 1390, at least about 1400, at least about 1500, at least about 1600 nucleotides, at least 1650, at least about 1700, at least about 1750, at least about 1800, at least about 1850, or at least about 1900 or more nucleotides. In some embodiments of the rAAV system, the sequences encoding the first and second promoters and at least one accessory element, combined, have a length of at least about 1300, at least about 1350, at least about 1360, at least about 1370, at least about 1380, at least about 1390, at least about 1400, at least about 1500, at least about 1600 nucleotides, at least 1650, at least about 1700, at least about 1750, at least about 1800, at least about 1850, or at least about 1900 or more nucleotides.
[0251] In some embodiments, host cells transfected with the above-described AAV expression vectors are enabled to provide AAV helper functions for replicating and encapsidating nucleotide sequences flanking the AAV ITRs to produce rAAV viral particles. AAV helper functions are generally AAV-derived coding sequences that are expressed to provide AAV gene products that can then function in trans for productive AAV replication. AAV helper functions are used herein to complement necessary AAV functions missing from an AAV expression vector. Thus, AAV helper functions include one or both of the major AAV ORFs (open reading frames) encoding the rep and cap coding regions, or functional homologs thereof. Accessory functions can be introduced into host cells using methods known to those skilled in the art and then expressed in the host cells. Typically, accessory functions are provided by infection of the host cells with an unrelated helper virus. In some embodiments, accessory functions are provided using an accessory function vector. Depending on the host / vector system utilized, any of a number of suitable transcriptional and translational control elements may be used in the expression vector, including constitutive and inducible promoters, transcriptional enhancer elements, transcriptional terminators, etc. In some embodiments, the present disclosure provides host cells comprising the AAV vectors of the embodiments disclosed herein.
[0252] In other embodiments, suitable vectors may comprise virus-like particles (VLPs). Virus-like particles (VLPs) are particles that closely resemble viruses but do not contain viral genetic material and are therefore non-infectious. In some embodiments, VLPs comprise a polynucleotide encoding a transgene of interest (e.g., any of the CasX proteins and / or gRNAs of the embodiments) packaged with one or more viral structural proteins, and optionally a donor template polynucleotide as described herein. In other embodiments, the present disclosure provides in vitro-produced XDPs comprising a CasX:gRNA RNP complex and, optionally, a donor template. Combinations of structural proteins from different viruses can be used to generate XDPs. These include components from viral families including Parvoviridae (e.g., adeno-associated virus), Retroviridae (e.g., alpharetrovirus, betaretrovirus, gammaretrovirus, deltaretrovirus, epsilonretrovirus, or lentivirus), Flaviviridae (e.g., Hepatitis C virus), Paramyxoviridae (e.g., Nipah), and bacteriophage (e.g., Qβ, AP205). In some embodiments, the present disclosure provides XDP systems engineered using components from retroviruses (including lentiviruses (such as HIV) and alpharetroviruses, betaretroviruses, gammaretroviruses, deltaretroviruses, and epsilonretroviruses), where individual plasmids containing polynucleotides encoding the various components are introduced into packaging cells, which then produce the XDP.In some embodiments, the present disclosure provides XDPs comprising one or more components of the gag polyprotein selected from: i) a protease; ii) a protease cleavage site; iii) one or more components of the gag polyprotein selected from: matrix protein (MA), nucleocapsid protein (NC), capsid protein (CA), p1 peptide, p6 peptide, P2A peptide, P2B peptide, P10 peptide, p12 peptide, PP21 / 24 peptide, P12 / P3 / P8 peptide, and P20 peptide; v) CasX; vi) gRNA; and vi) a targeting glycoprotein or antibody fragment, wherein the resulting XDP particle encapsidates a CasX:gRNA RNP. The polynucleotides encoding Gag, CasX, and gRNA may further comprise paired components designed to assist in transport of the components from the host cell nucleus to the budding XDP. Non-limiting examples of such transport components include MS2 hairpins, PP7 hairpins, Qβ hairpins, and U1 hairpin II and U1A signal recognition particles, which have binding affinity for MS2 coat protein, PP7 coat protein, and Qβ coat protein, respectively. In other embodiments, the gRNA can comprise a Rev response element (RRE) or a portion thereof with binding affinity for Rev, which can be linked to the Gag polyprotein. In other embodiments, the gRNA can comprise one or more RREs and one or more MS2 hairpin sequences. In other embodiments, the gRNA can comprise a Rev response element (RRE) or a portion thereof with binding affinity for Rev, which can be linked to the Gag polyprotein. The RRE can be selected from the group consisting of stem IIB of the Rev response element (RRE), stems II-V of the RRE, stem II of the RRE, the Rev-binding element (RBE) of stem IIB, and a full-length RRE.In the foregoing embodiment, the components include UGGGCGCAGCGUCAAUGACGCUGACGGUACA (Stem IIB; SEQ ID NO: 27266), GCACUAUGGGCGCAGCGUCAAUGACGCUGACGGUACAGGCCAGACAAUUAUUGUCUGGUAUAGUGC (Stem II; SEQ ID NO: 27267), GCUGACGGUACAGGC (RBE, SEQ ID NO: 27268), CAGGAAGCACUAUGGGCGCAGCGUCAAUGACGCUGACGGUACAGGCCAGACAAUUAUUGUCUGGUAUAGUGCAGCAGCAGAACAAUUUGCUGAGGGCUAUUGAGGCGCAACAGCAUCUGUUGCAACUCACAGUC The gRNA may comprise one or more RREs and one or more MS2 hairpin sequences. In certain embodiments, the gRNA comprises an MS2 hairpin variant optimized to increase binding affinity for the MS2 coat protein, thereby enhancing incorporation of the gRNA and associated CasX into the budding XDP. gRNA variants containing MS2 hairpin variants include gRNA variants 275 to 315 and 317 to 320 (SEQ ID NOs: 2722 to 27264).
[0253] The targeting glycoprotein or antibody fragment on the surface provides tropism for the XDP to the target cell, and upon administration and entry into the target cell, the RNP molecule is free to transport into the nucleus of the cell. The envelope glycoprotein can be derived from any of the following enveloped viruses known in the art to confer tropism to XDPs: Argentine hemorrhagic fever virus, Australian bat virus, Autographa californica nuclear polyhedrosis virus, avian leukosis virus, baboon endogenous virus, Bolivian hemorrhagic fever virus, Borna disease virus, Breda virus, Bunyamwera virus, Chandipura virus, Chikungunya virus, Crimean-Congo hemorrhagic fever virus, Dengue virus, Duvenhague virus, Eastern equine encephalitis virus, Ebola hemorrhagic fever virus, Ebola-Zaire virus, enteric adenovirus, ephemerovirus, Epstein-Barr virus, and the like. viru (EBV), European bat virus 1, European bat virus 2, Fug synthetic gP fusions, gibbon ape leukemia virus, hantavirus, Hendra virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, hepatitis G virus (GB virus C), herpes simplex virus type 1, herpes simplex virus type 2, human cytomegalovirus (HHV5), human foamy virus, human herpesvirus (HHV), human herpesvirus type 7, human herpesvirus type 6, human herpesvirus type 8, human immunodeficiency virus 1 (HIV-1), human metapneumovirus, human T-lymphotropic virus 1, influenza A virus, influenza B virus, influenza C virus, Japanese encephalitis virus, Kaposi's sarcoma-associated herpesvirus sarcoma-associated herpesvirus (HHV8), Kyasanur Forest disease virus, La Crosse virus, Lagos bat virus, Lassa fever virus, lymphocytic choriomeningitis virusvirus (LCMV), Machupo virus, Marburg hemorrhagic fever virus, measles virus, Middle East respiratory syndrome-associated coronavirus, Mokola virus, Moloney murine leukemia virus, monkeypox, mouse mammary tumor virus, mumps virus, murine gammaherpesvirus, Newcastle disease virus, Nipah virus, Norwalk virus, Omsk hemorrhagic fever virus, papillomavirus, parvovirus, pseudorabies virus, Quaranfil virus, rabies virus, RD114 feline endogenous retrovirus, respiratory syncytial virus (RSV), Rift Valley fever virus, Ross River virus, r-rotavirus, Rous sarcoma virus, rubella virus, Sabia-associated hemorrhagic fever virus, SARS-associated coronavirus (SARS-CoV), Sendai virus, Tacaribe virus, Thogoto virus, tick-borne encephalitis virus, varicella-zoster virus (varicella zoster virus) virus (HHV3), varicella-zoster virus (HHV3), variola major virus, variola minor virus, Venezuelan equine encephalitis virus, Venezuelan hemorrhagic fever virus, vesicular stomatitis virus (VSV), VSV-G, vesiculovirus, West Nile virus, Western equine encephalitis virus, and Zika virus.
[0254] In other embodiments, the present disclosure provides the aforementioned XDPs, further comprising one or more components of the pol polyprotein (e.g., a protease) and, optionally, a second CasX or donor template. The present disclosure contemplates multiple configurations of the arrangement of the encoded components, including several copies of the encoded components. The foregoing provides advantages over other vectors in the art in that viral transduction of dividing and non-dividing cells is efficient, and XDPs deliver potent, short-lived RNPs that evade the subject's immune surveillance mechanisms that would otherwise detect the foreign protein. Non-limiting exemplary XDP systems are described in International Application PCT / US20 / 63488 and International Publication WO2021 / 113772 (A1) (incorporated herein by reference). In some embodiments, the present disclosure provides host cells comprising a polynucleotide or vector encoding any of the aforementioned XDP embodiments.
[0255] Upon generating and recovering an XDP comprising a CasX:gRNA RNP of any of the embodiments described herein, the XDP may be used in methods for editing target cells of a subject by administration of such an XDP, as described in more detail below.
[0256] VII.Cells In another aspect, provided herein is a cell population comprising a BCL11A gene modified ex vivo by any embodiment of the system or method described herein. In some embodiments, such genetically modified cells can be administered to a subject for purposes such as gene therapy. For example, in methods for treating hemoglobinopathy-associated diseases such as sickle cell disease or beta-thalassemia, administration results in increased expression of γ-globin and increased fetal hemoglobin (HbF) in the subject. In other embodiments, the present disclosure provides compositions of modified cells for use as a pharmaceutical in treating hemoglobinopathy-associated diseases.
[0257] Cells of the present disclosure suitable for ex vivo modification of the BCL11A gene with a class 2, type V Cas nuclease and one or more guides targeting a BCL11A target nucleic acid can be hematopoietic progenitor cells (HPCs), hematopoietic stem cells (HSCs), CD34+ cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), common myeloid progenitor cells, proerythroblastic cells, or erythroblastic cells. In some embodiments, the cell population to be modified is an animal cell, e.g., derived from a rodent, rat, mouse, rabbit, dog, or non-human primate cell (e.g., cynomolgus monkey cell). In some embodiments, the cell is a human cell. In some cases, the modified cell is autologous to the subject to whom the cell is administered. In other cases, the cell is allogeneic to the subject to whom the cell is administered. In some cases, the ex vivo cell is isolated from the subject's bone marrow or peripheral blood.
[0258] In some embodiments, the present disclosure provides methods and cell populations modified thereby, by introducing into each cell population: i) a CasX:gRNA system comprising CasX and gRNA of any one of the embodiments described herein; ii) a CasX:gRNA system comprising CasX, gRNA, and a donor template of any one of the embodiments described herein; iii) a nucleic acid encoding CasX and gRNA, optionally comprising a donor template; iv) a vector comprising the nucleic acid of (iii) above, which may be an AAV of any of the embodiments described herein; v) an XDP comprising the CasX:gRNA system of any one of the embodiments described herein; or vi) a combination of two or more of (i)-(v), wherein the BCL11A target nucleic acid sequence of the cells targeted by the gRNA is modified by the CasX protein and, optionally, the donor template. In some embodiments, the method further comprises administering a second gRNA or a nucleic acid encoding the second gRNA, wherein the second gRNA has a targeting sequence complementary to a different or overlapping portion of the target nucleic acid sequence compared to the first gRNA. In some cases, CasX and gRNA are delivered to the cell population as RNPs (embodiments of which are described herein above) and, optionally, as a donor template. In some embodiments, the present disclosure provides cell populations modified by the aforementioned methods, in which the cells have been modified so that at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the modified cells do not express detectable levels of BCL11A protein. In other embodiments, the present disclosure provides cell populations in which the cells have been modified such that expression of BCL11A protein is reduced by at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% compared to unmodified cells. In yet other embodiments, the present disclosure provides cell populations in which expression of BCL11A protein is undetectable in the modified cell population.The effect of the modifications may be assessed by Western blot, flow cytometry, ELISA, cell-based assays, qRT-PCR, electrochemiluminescence assays, and sense transcripts may be analyzed by RNA fluorescence in situ hybridization (FISH) assays, or other methods known in the art or described in the Examples.
[0259] In some embodiments, the present disclosure provides methods for modifying a BCL11A target nucleic acid in a cell population by in vitro or ex vivo methods. The methods provide that cells can be obtained from a subject using any number of techniques known to those skilled in the art (e.g., by obtaining a bone marrow biopsy or a peripheral blood sample). The desired cells can be separated from the remainder of the sample, washed to remove fluid and debris, and optionally placed in an appropriate buffer or medium for subsequent processing steps. The methods can include one or more of the following steps: i) introducing into the cells CasX:gRNA system components for editing the target nucleic acid; ii) introducing into the cells a nucleic acid or vector encoding the CasX:gRNA system components; iii) growing the cells in a suitable medium under conditions suitable for their growth; and iv) cryopreserving the cells for subsequent administration to a subject. Thus, the CasX:gRNA systems and methods described herein can be used to modify various cells associated with hemoglobinopathies to produce cell populations with reduced or eliminated BCL11A protein expression and increased HbF. Thus, this approach can be used in therapeutic methods for subjects with hemoglobinopathies, such as sickle cell anemia or beta-thalassemia, among others. In some cases, cells are contacted with CasX and a gRNA, where the gRNA is a guide RNA (gRNA). In other cases, cells are contacted with CasX and a gRNA, where the gRNA is a chimera comprising DNA and RNA. As described herein, in any combination (combination of scaffold and targeting sequences, which may be configured as sgRNA or dgRNA) embodiments, each of the gRNA molecules can be provided as an RNP with a CasX of the embodiments described herein for incorporation into the cell to be modified. In one embodiment, a target nucleic acid of a cell is modified by contacting the cell with CasX protein, a guide nucleic acid (gRNA) comprising a targeting sequence complementary to a BCL11A target nucleic acid, and a donor template, where the donor template is inserted into or replaces a portion of the target nucleic acid sequence of the cell, such that BCL11A protein is not expressed or is expressed at a reduced level.In other cases, CasX and gRNA in a vector are delivered to a cell population (embodiments of which are described herein above), and the target nucleic acid is modified so that the BCL11A protein is not expressed or is expressed at reduced levels.
[0260] In some embodiments, the cell population is contacted with a CasX variant comprising a sequence of Table 4, or a sequence at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical thereto, and the gRNA scaffold is or a sequence at least 81% identical, at least 82% identical, at least 83% identical, at least 84% identical, at least 85% identical, at least 86% identical, at least 86% identical, at least 87% identical, at least 88% identical, at least 89% identical, at least 89% identical, at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, or at least 99.5% identical, and wherein the gRNA comprises a targeting sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789 in Table 1, or a sequence at least 65% identical, at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, or at least 95% identical thereto, and has 15-20 amino acids. In other cases, CasX and one or more gRNAs are introduced into a cell population as encoding polynucleotides using a vector, embodiments of which are described herein.Additional methods for modifying cells using CasX:gRNA system components include viral infection, transfection, conjugation, protoplast fusion, particle gun technology, calcium phosphate precipitation, direct microinjection, etc. The choice of method generally depends on the cell type to be transformed and the environment in which the transformation is performed (e.g., in vitro, ex vivo, or in vivo). A general discussion of these methods can be found in Ausubel, et al., Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995.
[0261] Upon hybridization of CasX and the gRNA with the target nucleic acid, CasX introduces one or more single- or double-stranded breaks in the BCL11A gene, resulting in a modification of the target nucleic acid, such as a permanent indel (deletion or insertion) or other mutation (e.g., substitution, duplication, or inversion) in the target nucleic acid, which, in conjunction with the host cell's repair machinery, results in a corresponding reduction or elimination of functional BCL11A protein expression, thereby generating an engineered cell population. As described herein, CasX variants that introduce double-stranded breaks in the target nucleic acid generate double-stranded breaks within 18-26 nucleotides 5' of the PAM site on the target strand and within 10-18 nucleotides 3' of the PAM site on the non-target strand. Thus, in some embodiments, modifications obtained by this method can result in random insertions or deletions (indels) of one or more nucleotides in those regions, or substitutions, duplications, or inversions, via non-homologous DNA end joining (NHEJ) repair mechanisms.
[0262] In some embodiments of the method for modifying a cell population, the first gRNA comprises a targeting sequence that is complementary to a sequence proximal to or within any one of the exons of the BCL11A gene. In one embodiment, the first gRNA comprises a targeting sequence that is complementary to a sequence proximal to, within, or adjacent to any one of the regulatory elements of the BCL11A gene. In certain embodiments, the first gRNA comprises a targeting sequence that is complementary to a sequence within or adjacent to the 5' side of the GATA1 binding motif sequence of the BCL11A gene. In certain embodiments, the targeting sequence is SEQ ID NO: 22. In accordance with the foregoing, disruption of the target nucleic acid sequence results in modification of the BCL11A gene such that expression of functional BCL11A protein is reduced or eliminated in the modified cell population.
[0263] In some embodiments of the method, the target nucleic acid of the cell population is modified using multiple (e.g., two, three, four, or more) gRNAs that target different or overlapping portions of the BCL11A gene, and the CasX protein introduces multiple cuts in the target nucleic acid sequence, resulting in permanent indels (deletions or insertions) or other mutations (e.g., substitutions, duplications, or inversions of one or more nucleotides), thereby reducing or eliminating expression of functional BCL11A protein in the modified cell population.
[0264] In other embodiments, the present disclosure provides a modified cell population by contacting cells with a CasX protein of any of the embodiments described herein, one or more gRNAs comprising a targeting sequence, and a donor template, where the donor template is inserted into the cleavage site introduced by the nuclease to replace all or part of the target nucleic acid sequence of the BCL11A gene to be modified. In one of the foregoing embodiments, the donor template comprises at least a portion of a BCL11A exon, and one or more mutations and cellular modifications result in genetic modification, thereby reducing or eliminating expression of functional BCL11A protein in the modified cell population. In another of the foregoing embodiments, the donor template comprises a sequence within or 5'-adjacent to the GATAl binding motif sequence, but with one or more mutations compared to the wild-type sequence, and the cellular modifications result in reduced or eliminated expression of functional BCL11A protein in the modified cell population. In such cases, it is understood that the replacement by the donor template is larger in the 5' and 3' directions than the location of the cleavage site introduced by the nuclease at the particular portion of the target nucleic acid to be replaced, and further includes homology arms 5' and 3' to the cleavage site introduced by the nuclease to facilitate its insertion. In some cases, the donor template is a single-stranded DNA template or a single-stranded RNA template. In other cases, the donor template is a double-stranded DNA template. Insertion of the donor template at the target region can be mediated by homology-directed repair (HDR, as described above) or homology-independent targeted integration (HITI). The exogenous sequence inserted by HITI can be of any length, for example, a relatively short sequence of 10 to 50 nucleotides in length, or a longer sequence of about 50 to 1000 nucleotides in length. The donor template sequence may contain certain sequence differences compared to the genomic sequence, such as restriction sites, nucleotide polymorphisms, barcodes, selectable markers (e.g., drug resistance genes, fluorescent proteins, enzymes, etc.), which may be used to assess successful insertion of the donor nucleic acid at the cleavage site, or, in some cases, for other purposes (e.g., to indicate expression at the target genomic locus).Alternatively, these sequence differences may include flanking recombination sequences (eg, FLP sequences, loxP sequences, etc.) that can be subsequently activated to remove the marker sequence.
[0265] In some embodiments of the methods of modifying a cell population, the method further comprises contacting a target nucleic acid sequence of a BCL11A gene of the cell population with: i) an additional CRISPR nuclease and gRNA that targets a different or overlapping portion of the BCL11A target nucleic acid compared to the first gRNA; ii) a polynucleotide encoding the additional CRISPR nuclease and gRNA of (i); iii) a vector comprising the polynucleotide of (ii); or iv) an XDP comprising the additional CRISPR nuclease and gRNA of (i), wherein the contacting results in modification of the BCL11A gene at a different position in the sequence compared to the sequence targeted by the first gRNA. In one such embodiment, the additional CRISPR nuclease is a CasX protein having a different sequence from the CasX protein of the previous embodiment. In another embodiment of the foregoing, the additional CRISPR nuclease is not a CasX protein and is selected from the group consisting of Cas9, Cas12a, Cas12b, Cas12c, Cas12d (CasY), Cas12j, Cask, Cas13a, Cas13b, Cas13c, Cas13d, Cas14, Cpfl, C2cl, Csn2, and sequence variants thereof.
[0266] In other embodiments, the present disclosure provides a method for modifying a BCL11A target nucleic acid in a cell population of a subject in vivo. In one embodiment of the in vivo modification method, the method comprises administering to the subject a vector of the embodiments described herein at a therapeutically effective dose. In some embodiments, the vector is administered in a therapeutically effective dose of at least about 1 x 10 5 Vector genome (vg / kg), at least approximately 1 × 10 6 vg / kg, at least about 1 × 10 7 vg / kg, at least about 1 × 10 8 vg / kg, at least about 1 × 10 9 vg / kg, at least about 1 × 10 10vg / kg, at least about 1 × 10 11 vg / kg, at least about 1 × 10 12 vg / kg, at least about 1 × 10 13 vg / kg, at least about 1 × 10 14 vg / kg, at least about 1 × 10 15 vg / kg, or at least about 1 × 10 16 In other embodiments, the vector is administered to a subject at a dose of at least about 1 x 10 vg / kg. 5 vg / kg ~ at least about 1 × 10 16 vg / kg, or at least about 1 × 10 6 vg / kg ~ approx. 1×10 15 vg / kg, or at least about 1 × 10 7 vg / kg ~ approx. 1×10 14 vg / kg, or at least about 1 × 10 8 vg / kg ~ approx. 1×10 14 The XDP is administered to the subject at a dose of 1×10 vg / kg. In another embodiment of the in vivo modification method, the method comprises administering to the subject a therapeutically effective dose of XDP, wherein the XDP comprises CasX and gRNA complexed in an RNP, and optionally a donor template (described in more detail above), and the XDP has tropism for target cells and can deliver the RNP for editing the BCL11A gene as described herein. Embodiments of XDP utilized in the aforementioned editing methods are described herein. In one embodiment, the XDP is at least about 1×10 5 particles / kg, at least about 1 × 10 6 particles / kg, at least about 1 × 10 7 At least about 1 x 10 particles / kg 8 particles / kg, at least about 1 × 10 9 particles / kg, at least about 1 × 10 10 particles / kg, at least about 1 × 10 11 particles / kg, at least about 1 × 10 12 particles / kg, at least about 1 × 10 13 particles / kg, at least about 1 × 10 14 particles / kg, at least about 1 × 10 15 particles / kg, at least about 1 × 1016 particles / kg, or at least about 1 x 10 6 Particles / kg ~ approx. 1×10 15 particles / kg, or at least about 1 x 10 7 Particles / kg ~ approx. 1×10 14 In the foregoing embodiments of this paragraph, the vector or XDP is administered to the subject by a route of administration selected from intraparenchymal, intravenous, intraarterial, intraperitoneal, intravesical, subcutaneous, intramuscular, intraabdominally, or a combination thereof, and the method of administration is injection, transfusion, or transplantation.
[0267] VIII. Treatment method In another aspect, the disclosure relates to a method of treating a hemoglobinopathy-associated disease, including but not limited to sickle cell disease or beta thalassemia, in a subject in need thereof, wherein suppressing or eliminating expression of the BCL11A protein by modifying the BCL11A gene in target cells of the subject ameliorates the signs, symptoms, or effects of the disease, although the subject may still be afflicted with the underlying disease.
[0268] Several therapeutic strategies have been used to design compositions for use in methods for treating subjects with hemoglobinopathy-related diseases. In some embodiments, the methods comprise administering to a subject with a hemoglobinopathy (e.g., sickle cell anemia or beta-thalassemia) a therapeutically effective dose of a Class 2, Type V CRISPR nuclease and guide RNA disclosed herein. In some embodiments, a method of treatment comprises administering to a subject a therapeutically effective dose of: i) a CasX:gRNA system comprising a first CasX protein and a first gRNA having a targeting sequence complementary to a target nucleic acid; ii) a CasX:gRNA system comprising a first CasX protein, a first gRNA having a targeting sequence complementary to a target nucleic acid, and a donor template; iii) a nucleic acid encoding the CasX:gRNA system of (i) or (ii); iv) a vector comprising the nucleic acid of (iii), which may be an AAV of any of the embodiments described herein; v) an XDP comprising the CasX:gRNA system of (i) or (ii); or vi) a combination of two or more of (i)-(v), wherein: 1) the BCL11A gene in the subject's cells targeted by the first gRNA is modified (e.g., knocked down or knocked out) by the CasX protein and optionally the donor template; and 2) increased production of hemoglobin F (HbF) occurs in the subject. In some embodiments, the method of treatment further comprises administering a second gRNA or a nucleic acid encoding the second gRNA, wherein the second gRNA has a targeting sequence that is complementary to a different or overlapping portion of the target nucleic acid sequence compared to the first gRNA. In some cases, the cells targeted for modification are selected from the group consisting of hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), CD34+ cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), common myeloid progenitor cells, proerythroblastic cells, and erythroblastic cells. In some embodiments, the subject to be treated is selected from the group consisting of a rodent, a mouse, a rat, and a non-human primate. In another embodiment, the subject is a human.
[0269] In some embodiments of the method of treatment, the vector is an AAV vector encoding a CasX:gRNA system, and is at least about 1 x 10 5 Vector genome (vg / kg), at least approximately 1 × 10 6 vg / kg, at least about 1 × 10 7 vg / kg, at least about 1 × 10 8 vg / kg, at least about 1 × 10 9 vg / kg, at least about 1 × 10 10 vg / kg, at least about 1 × 10 11 vg / kg, at least about 1 × 10 12 vg / kg, at least about 1 × 10 13 vg / kg, at least about 1 × 10 14 vg / kg, at least about 1 × 10 15 vg / kg, or at least about 1 × 10 16 In other embodiments of this method, the AAV vector is administered to the subject at a dose of at least about 1 x 10 vg / kg. 5 vg / kg ~ approx. 1×10 16 vg / kg, at least about 1 × 10 6 vg / kg ~ approx. 1×10 15 vg / kg, or at least about 1 × 10 7 vg / kg ~ approx. 1×10 14 In another embodiment, the method of treatment comprises administering to a subject a therapeutically effective dose of an XDP comprising a CasX:gRNA system. In one embodiment, the XDP is administered to a subject at a dose of at least about 1 x 10 5 particles / kg, at least about 1 × 10 6 particles / kg, at least about 1 × 10 7 particles / kg, at least about 1 × 10 8 particles / kg, at least about 1 × 10 9 particles / kg, at least about 1 × 10 10 particles / kg, at least about 1 × 10 11 particles / kg, at least about 1 × 10 12 particles / kg, at least about 1 × 10 13 particles / kg, at least about 1 × 10 14 particles / kg, at least about 1 × 10 15particles / kg, at least about 1 × 10 16 In another embodiment, the XDP is administered to a subject at a dose of at least about 1 x 10 particles / kg. 5 Particles / kg ~ approx. 1×10 16 particles / kg, or at least about 1 x 10 6 Particles / kg ~ approx. 1×10 15 particles / kg, or at least about 1 x 10 7 Particles / kg ~ approx. 1×10 14 The subject is administered a dose of 1000 particles / kg. In the preceding embodiments of this paragraph, the vector or XDP is administered to the subject by a route of administration selected from intraparenchymal, intravenous, intraarterial, intraperitoneal, intravesical, subcutaneous, intramuscular, intraabdominal, or a combination thereof, and the administration method is injection, transfusion, or transplantation. The administration can be once, twice, or multiple times using a weekly, biweekly, monthly, quarterly, or six-monthly regimen schedule.
[0270] In some embodiments, the method of treatment comprises administering to a subject a vector comprising a polynucleotide encoding CasX and multiple gRNAs targeting different or overlapping regions of the BCL11A gene, wherein the administration results in contacting a target nucleic acid sequence of interest with an expression product of the vector in a cell of the subject, and the BCL11A gene is modified in the cell of the subject. In other embodiments of the method of treatment, the method comprises administering to a subject a vector encoding a CasX protein and a gRNA, and further comprising a donor template, wherein the administration results in modification of the target nucleic acid sequence in the cell of the subject by cleavage by the CasX protein and insertion of the donor template into the target nucleic acid. In other embodiments, the method includes administering to a subject a first vector comprising a polynucleotide encoding CasX and multiple gRNAs targeting different or overlapping sequences of the BCL11A gene, and a second vector comprising a donor template polynucleotide encoding at least a portion or all of the BCL11A gene, wherein administration of the vectors results in contacting the target nucleic acid sequence in the subject's cells with expression products of the CasX and gRNA vectors and the donor template, and the BCL11A gene is modified in the subject's cells as described herein. In some embodiments of the method, the vector administered to the subject is an AAV vector described herein. In the foregoing, the AAV vector is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-Rh74, or AAVRh10. In some embodiments of the method, the vector administered to the subject is an XDP described herein comprising an RNP of the CasX:gRNA system.
[0271] In some embodiments of the method, the modifying comprises introducing a single-strand break in the BCL11A gene of the cell population. In other cases, the modifying comprises introducing a double-strand break in the BCL11A gene of the cell population. In some embodiments, the modifying introduces one or more mutations in the BCL11A target nucleic acid, such as an insertion, deletion, substitution, duplication, or inversion of one or more nucleotides in the BCL11A gene, such that expression of BCL11A protein in the subject's cells is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to unmodified cells. In some cases, the BCL11A gene of the subject's cells is modified such that at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the modified cells do not express detectable levels of BCL11A protein. In other cases of the methods of treatment, the modifying results in an increase in the production of HbF in the subject's circulating blood of at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%, compared to the level of HbF in the subject before treatment. In other embodiments, the method results in a ratio of HbF to hemoglobin S (HbS) in the subject's circulating blood of at least 0.01:1.0, at least 0.025:1.0, at least 0.05:1.0, at least 0.075:1.0, at least 0.1:1.0, at least 0.2:1.0, at least 0.3:1.0, at least 0.4:1.0, at least 0.5:1:0, at least 0.75:1.0, at least 1.0:1.0, at least 1.25:1.0, at least 1.5:1.0, or at least 1.75:1.0. In other embodiments, the method results in an HbF level of at least about 5%, or at least about 10%, or at least about 20%, or at least about 30% of the total circulating hemoglobin in the subject. In the foregoing embodiments, the subject is selected from the group consisting of a mouse, a rat, a pig, a non-human primate, and a human.Methods for obtaining samples (e.g., body fluids or tissues) from treated subjects for analysis to determine the effectiveness of treatment, and methods for preparing samples to enable analysis, are well known to those skilled in the art. Methods for analyzing RNA and protein levels have been discussed above and are well known to those skilled in the art. The effectiveness of treatment can also be assessed by measuring biomarkers related to the expression of target genes in the aforementioned body fluids, tissues, or organs collected from animals contacted with one or more compounds of the present invention, using routine clinical methods known in the art. Biomarkers for hemoglobinopathy diseases include, but are not limited to, the percentage of sickle red blood cells in circulating blood, BCL11A levels, BCL11A RNA, hemoglobin S levels, hemoglobin-gamma levels, and hemoglobin F levels.
[0272] In some cases, the method of treating a hemoglobinopathy in a subject further comprises administering a therapeutically effective dose of an additional CRISPR nuclease or a polynucleotide encoding the additional CRISPR nuclease. In one embodiment, the additional CRISPR nuclease is a CasX protein having a sequence different from that of the first CasX. In another embodiment, the additional CRISPR nuclease is not a CasX protein (i.e., Cas9, Cas12a, Cas12b, Cas12c, Cas12d (CasY), Cas12j, Cas12k, Cas13a, Cas13b, Cas13c, Cas13d, Cas14, Cpfl, C2cl, Csn2) or a sequence variant thereof. In some embodiments, the method of treating a hemoglobinopathy in a subject further comprises administering a chemotherapeutic agent.
[0273] In other embodiments, the present disclosure provides a method of treating a hemoglobinopathy-associated disease in a subject in need thereof by administering to the subject a therapeutically effective amount of a cell population that has been modified in vitro or ex vivo with a CasX:gRNA system composition of the embodiments described herein, comprising: i) a CasX:gRNA system comprising a first CasX protein and a first gRNA having a targeting sequence complementary to a target nucleic acid; ii) a CasX:gRNA system comprising a first CasX protein, a first gRNA having a targeting sequence complementary to a target nucleic acid, and a donor template; iii) a nucleic acid encoding the CasX:gRNA system of (i) or (ii); iv) a vector comprising the nucleic acid of (iii), which may be an AAV of any of the embodiments described herein; v) an XDP comprising the CasX:gRNA system of (i) or (ii); or vi) a combination of two or more of (i)-(v). In one embodiment, a method of treatment includes: i) isolating induced pluripotent stem cells (iPSCs) or hematopoietic stem cells (HSCs) from a subject; ii) modifying a BCL11A target nucleic acid in the iPSCs or HSCs by any of the methods described herein; iii) differentiating the modified iPSCs or HSCs into hematopoietic progenitor cells; and iv) transplanting the hematopoietic progenitor cells into a subject with a hemoglobinopathy, wherein the method results in an increase in the level of hemoglobin F (HbF) in the circulating blood of the subject by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50% compared to the level of HbF in the subject before treatment. In some cases, the cells are autologous to the subject to whom the cells are administered and are isolated from the bone marrow or peripheral blood of the subject. In other cases, the cells are allogeneic to the subject to whom the cells are administered and are isolated from the bone marrow or peripheral blood of a different subject. The modified cells can be implanted into a subject by transplantation, local injection, systemic infusion, or a combination thereof.Methods for modifying cells for administration to a subject are described herein, but briefly, modifying includes contacting the cells with: i) a CasX:gRNA system comprising a first CasX protein and a first gRNA having a targeting sequence complementary to a target nucleic acid; ii) a CasX:gRNA system comprising a first CasX protein, a first gRNA having a targeting sequence complementary to a target nucleic acid, and a donor template; iii) a nucleic acid encoding the CasX:gRNA system of (i) or (ii); iv) a vector comprising the nucleic acid of (iii), which may be an AAV of any of the embodiments described herein; v) an XDP comprising the CasX:gRNA system of (i) or (ii); or vi) a combination of two or more of (i)-(v), wherein expression of BCL11A protein is reduced or the cells do not express detectable levels of BCL11A protein. In some embodiments, the method further comprises administering a second gRNA or a nucleic acid encoding the second gRNA, wherein the second gRNA has a targeting sequence complementary to a different or overlapping portion of the target nucleic acid sequence compared to the first gRNA. In some cases, CasX and gRNA as an RNP (embodiments of which are described herein above), and optionally a donor template, are delivered to a cell population, and the target nucleic acid is modified so that BCL11A protein is not expressed or is expressed at reduced levels. In other cases, CasX and gRNA in a vector (embodiments of which are described herein above) are delivered to a cell population, and the target nucleic acid is modified so that BCL11A protein is not expressed or is expressed at reduced levels. In some embodiments, the cell population modified by administration of the composition is a eukaryotic cell selected from the group consisting of rodent cells, mouse cells, rat cells, and non-human primate cells. In some embodiments, the eukaryotic cell is a human cell. In some embodiments, the eukaryotic cell is selected from the group consisting of hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), CD34+ cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), common myeloid progenitor cells, proerythroblast cells, and erythroblast cells.In some embodiments of the methods, the cells or progeny thereof administered to a subject persist in the subject for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 3 years, 4 years, or 5 years after administration to the subject. In some embodiments, the treatment methods of the disclosure result in an increase in the level of hemoglobin F (HbF) in the circulating blood of at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%, compared to the level of HbF in the subject before treatment. In other embodiments, the method results in a ratio of HbF to hemoglobin S (HbS) in the subject of at least 0.01:1.0, at least 0.025:1.0, at least 0.05:1.0, at least 0.075:1.0, at least 0.1:1.0, at least 0.2:1.0, at least 0.3:1.0, at least 0.4:1.0, at least 0.5:1:0, at least 0.75:1.0, at least 1.0:1.0, at least 1.25:1.0, at least 1.5:1.0, or at least 1.75:1.0. In other embodiments, the method results in an HbF level of at least about 5%, or at least about 10%, or at least about 20%, or at least about 30% of the total circulating hemoglobin in the subject.
[0274] In other embodiments, the disclosure provides a method of increasing fetal hemoglobin (HbF) in a subject with a hemoglobinopathy by genome editing, comprising: i) administering to a subject an effective dose of a vector or XDP of an embodiment described herein, wherein the vector or XDP delivers a CasX:gRNA system to a cell of the subject; ii) a BCL11A target nucleic acid in the cell of the subject is edited by CasX targeted by a first gRNA; and iii) the editing comprises introducing an insertion, deletion, substitution, duplication, or inversion of one or more nucleotides in the target nucleic acid sequence such that expression of BCL11A protein is reduced or eliminated, wherein the method results in an increase in the level of hemoglobin F (HbF) in the circulating blood of the subject by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, or at least about 50%, compared to the level of HbF in the subject before treatment. In the foregoing, the cell is selected from the group consisting of hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), CD34+ cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), common myeloid progenitor cells, proerythroblastic cells, and erythroblastic cells. In one embodiment of this method, the target nucleic acid of the cell is edited such that expression of BCL11A protein is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to the target nucleic acid of the unedited cell. In some cases, the subject is selected from the group consisting of a mouse, a rat, a pig, and a non-human primate. In other cases, the subject is a human.
[0275] In some embodiments of the method of treating a hemoglobinopathy in a subject, the method results in an improvement in at least one clinically relevant parameter selected from the group consisting of incidence of end-organ disease, albuminuria, hypertension, state of weakness, hypotonicity, diastolic dysfunction, functional exercise capacity, acute coronary syndrome, pain events, pain severity, anemia, hemolysis, tissue hypoxia, organ dysfunction, abnormal hematocrit, pediatric mortality, incidence of stroke, hemoglobin level compared to baseline, HbF level, reduction in incidence of pulmonary embolism, incidence of vaso-occlusive crisis, concentration of hemoglobin S in red blood cells, hospitalization rate, liver iron concentration, required transfusion, and quality of life score. In other embodiments of the method of treating a hemoglobinopathy in a subject, the method results in an improvement in at least two clinically relevant parameters selected from the group consisting of incidence of end-organ disease, albuminuria, hypertension, state of weakness, hypotonicity, diastolic dysfunction, functional exercise capacity, acute coronary syndrome, pain events, pain severity, anemia, hemolysis, tissue hypoxia, organ dysfunction, abnormal hematocrit, pediatric mortality, incidence of stroke, hemoglobin level compared to baseline, HbF level, reduction in incidence of pulmonary embolism, incidence of vaso-occlusive crisis, concentration of hemoglobin S in red blood cells, hospitalization rate, liver iron concentration, required transfusion, and quality of life score.
[0276] In some embodiments, the method of treatment comprises administering to a subject a liposome or lipid nanoparticle comprising a CasX protein and a gRNA, hi some embodiments, the liposome or lipid nanoparticle further comprises a donor template of any of the embodiments described herein.
[0277] In some embodiments, the present disclosure provides a method of treating a subject with a hemoglobinopathy-associated disease, the method comprising administering to the subject a therapeutically effective dose of a CasX:gRNA composition, vector, or XDP comprising an RNP of the CasX:gRNA composition of any of the embodiments disclosed herein, according to a treatment regimen comprising one or more consecutive doses. In some embodiments of the treatment regimen, the therapeutically effective dose of the composition or vector is administered as a single dose. In other embodiments of the treatment regimen, the therapeutically effective dose is administered to the subject as two or more doses over a period of at least two weeks, or at least one month, or at least two months, or at least three months, or at least four months, or at least five months, or at least six months. In some embodiments of the treatment regimen, the effective dose is administered by a route selected from the group consisting of implantation, local injection, systemic infusion, or a combination thereof.
[0278] In some embodiments, the method of treatment further comprises administering a chemotherapeutic agent, wherein the agent is effective to ameliorate signs or symptoms associated with a hemoglobinopathy-associated disorder, including, but not limited to, hydroxyurea, L-glutamine oral powder, voxelotor, and pain relievers.
[0279] In some embodiments, the present disclosure provides a CasX:gRNA composition, a nucleic acid encoding the CasX:gRNA composition, a vector comprising the nucleic acid, or an XDP comprising an RNP of the CasX:gRNA for use as a medicament for the treatment of a hemoglobinopathy, including sickle cell disease or β-thalassemia.
[0280] XIV. Kits and Compositions In other embodiments, provided herein are kits comprising a CasX protein, one or more gRNAs of any of the presently disclosed embodiments comprising a targeting sequence specific for the BCL11A gene, and a suitable container (e.g., a tube, vial, or plate). In some embodiments, the kit further comprises a buffer, a nuclease inhibitor, a protease inhibitor, a liposome, a therapeutic agent, a label, a label visualization reagent, or any combination of the foregoing. In some embodiments, the kit further comprises a pharmaceutically acceptable carrier, diluent, or excipient. In some embodiments, the kit comprises a control composition suitable for the genetic modification application and instructions for use. In some embodiments, the kit comprises a vector, the vector comprising a sequence encoding a CasX protein of the present disclosure, a gRNA of the present disclosure, optionally a donor template, or a combination thereof.
[0281] In another embodiment of the kit of the present disclosure, the kit includes a composition for treating a hemoglobinopathy in a subject by modifying a BCL11A target nucleic acid in an isolated cell of the subject, wherein modifying comprises contacting the target nucleic acid sequence of the cell with i) a CasX:gRNA system of an embodiment disclosed herein, ii) a nucleic acid encoding a component of the CasX:gRNA system, iii) a vector comprising the nucleic acid, iv) an XDP comprising a CasX protein and a guide nucleic acid (gRNA), or v) any combination of (i)-(iv), wherein i) the contacting results in modification of the BCL11A target nucleic acid sequence by the CasX protein, ii) reduced expression of the BCL11A protein, and iii) increased production of hemoglobin F (HbF) upon maturation of the cell. In some cases, the cell is an induced pluripotent stem cell (iPSC). In other cases, the cell is a hematopoietic stem cell (HSC). In one embodiment, use of the composition results in a reduction in expression of BCL11A protein by mature cells that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to the unmodified target nucleic acid, hi another embodiment, expression of BCL11A protein by mature cells is undetectable.
[0282] In some embodiments, the kit comprises a plurality of cells edited using the CasX:gRNA system described herein.
[0283] This specification describes numerous example configurations, methods, parameters, etc. However, it should be recognized that such descriptions are not intended as limitations on the scope of the disclosure, but are instead pro...
Claims
1. A system comprising a CasX variant protein and a guide ribonucleic acid (gRNA) variant, wherein the gRNA variant comprises a targeting sequence complementary to a target nucleic acid sequence comprising a polypyrimidine tract binding protein 1 (BCL11A) gene.
2. The gRNA is a) the BCL11A intron; b) BCL11A exons, c) the BCL11A intron-exon junction; d) a BCL11A regulatory element, and e) intergenic regions; The system of claim 1 , further comprising a targeting sequence complementary to a target nucleic acid sequence selected from the group consisting of:
3. The system of claim 1 , wherein the BCL11A gene comprises a wild-type sequence.
4. 2. The system of claim 1, wherein the gRNA variant is a single molecule gRNA (sgRNA).
5. 2. The system of claim 1, wherein the targeting sequence of the gRNA variant comprises a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-26789, or a sequence having at least about 65%, at least about 75%, at least about 85%, or at least about 95% identity thereto.
6. The system of claim 5, wherein the targeting sequence has a single nucleotide removed from the 3' end of the sequence, or has two, three, four or five nucleotides removed from the 3' end of the sequence.
7. 2. The system of claim 1, wherein the targeting sequence of the gRNA variant is complementary to a sequence of a BCL11A exon, wherein the BCL11A exon is selected from the group consisting of a BCL11A exon 1 sequence, a BCL11A exon 2 sequence, a BCL11A exon 3 sequence, a BCL11A exon 4 sequence, a BCL11A exon 5 sequence, a BCL11A exon 6 sequence, a BCL11A exon 7 sequence, a BCL11A exon 8 sequence, and a BCL11A exon 9 sequence.
8. 2. The system of claim 1, wherein the targeting sequence of the gRNA variant is complementary to a sequence of a BCL11A regulatory element, and the regulatory element is selected from the group consisting of a promoter and enhancer regulatory element of the BCL11A gene.
9. 9. The system of claim 8, wherein the targeting sequence of the gRNA variant is complementary to a sequence of an enhancer regulatory element selected from the group consisting of the GATA1 erythroid-specific enhancer binding site (GATA1) of the BCL11A gene and a sequence 5' to the GATA1 binding site of the BCL11A gene.
10. 10. The system of claim 9, wherein the targeting sequence of the gRNA variant comprises a sequence having at least 90%, at least 95%, or at least 100% sequence identity to a sequence selected from the group consisting of UGGAGCCUGUGAUAAAAGCA (SEQ ID NO: 22), UGCUUUUAUCACAGGCUCCA (SEQ ID NO: 23), CAGGCUCCAGGAAGGGUUUG (SEQ ID NO: 2949), GAGGCCAAACCCUUCCUGGA (SEQ ID NO: 2948), AGUGCAAGCUAACAGUUGCU (SEQ ID NO: 15747), and AUACAACUUUGAAGCUAGUC (SEQ ID NO: 15748).
11. The system of claim 1, wherein the gRNA variant has a scaffold comprising a sequence selected from the group consisting of SEQ ID NOs: 2238-2285, 26794-26839, and 27219-27265, or a sequence having at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.
12. 2. The system of claim 1, wherein the targeting sequence is linked to the 3' end of the scaffold of the gRNA variant.
13. The system of claim 1, wherein the CasX variant protein comprises a sequence selected from the group consisting of SEQ ID NOs: 59, 72-99, 101-148, and 26908-27154, or a sequence having at least about 70%, at least about 80%, at least about 90%, or at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% sequence identity thereto.
14. The system of claim 1, wherein the CasX variant protein comprises an array of SEQ ID NO: 126, or an array having at least about 95% identity thereto.
15. the CasX variant protein further comprises one or more nuclear localization signals (NLS); The one or more NLSs are a) at or near the C-terminus of the CasX variant protein b) at or near the N-terminus of the CasX variant protein; or c) at or near the N-terminus and at or near the C-terminus of the CasX variant protein Located, The system of claim 1 .
16. The CasX variant protein can form a ribonucleoprotein complex (RNP) with a gRNA variant, and the CasX variant protein and the gRNA variant RNP exhibit at least one or more improved characteristics compared to a reference CasX protein of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and a gRNA RNP comprising a sequence of any one of SEQ ID NOs: 4-16, wherein the one or more improved characteristics include improved folding of the CasX variant protein, improved binding affinity to a gRNA, improved binding affinity to a target DNA, a wider range of one or more protospacer adjacent motifs (PAMs) including ATC, CTC, GTC, or TTC in editing the target DNA.
2. The system of claim 1, wherein the improved ability to utilize the sequence is selected from one or more of the group consisting of improved ability to unwind the target DNA, increased editing activity, improved editing efficiency, improved editing specificity, increased nuclease activity, improved rate of cleavage of the target nucleic acid sequence, increased target strand loading for double stranded cleavage, decreased target strand loading for single stranded nicking, decreased off-target cleavage, improved binding of non-target DNA strands, improved protein stability, improved protein solubility, improved formation of ribonucleoprotein complexes (RNPs), a higher percentage of cleavage competent RNPs, improved stability of protein:gRNA complexes (RNPs), improved solubility of protein:gRNA complexes, improved protein yield, improved protein expression, and improved fusion characteristics.
17. 17. The system of claim 16, wherein when any one of the PAM sequences TTC, ATC, GTC, or CTC is located one nucleotide 5' to the non-target strand of a protospacer having identity to the targeting sequence of the gRNA in a cellular assay system, the RNP comprising the CasX variant protein and the gRNA variant exhibits higher editing efficiency and / or binding of a target nucleic acid sequence compared to the editing efficiency and / or binding of an RNP comprising a reference CasX protein and a reference gRNA in a comparative assay system.
18. The PAM sequence is TTC, and the targeting sequence of the gRNA variant comprises a sequence selected from the group consisting of SEQ ID NOs: 17904-26789; The PAM sequence is ATC, and the targeting sequence of the gRNA variant comprises a sequence selected from the group consisting of SEQ ID NOs: 272-2100 and 2286-5625; The PAM sequence is CTC and the targeting sequence of the gRNA variant comprises a sequence selected from the group consisting of SEQ ID NOs: 5626-13616; or The PAM sequence is GTC, and the targeting sequence of the gRNA variant comprises a sequence selected from the group consisting of SEQ ID NOs: 13617-17903; 20. The system of claim 17.
19. 18. The system of claim 17, wherein the increased binding affinity to the one or more PAM sequences is at least 1.5-fold greater than the binding affinity to the PAM sequence of any one of the reference CasX proteins of SEQ ID NOs: 1-3, and / or the RNPs have at least 5%, at least 10%, at least 15%, or at least 20% greater percentage of cleavage-competent RNPs compared to the RNPs of the reference CasX protein and the gRNAs of SEQ ID NOs: 4-16.
20. One or more nucleic acids comprising a sequence encoding a CasX variant protein of the system of any one of claims 1 to 19 and a gRNA variant comprising a targeting sequence complementary to a target nucleic acid sequence comprising the polypyrimidine tract binding protein 1 (BCL11A) gene.
21. A nucleic acid comprising a sequence encoding a gRNA variant according to any one of claims 1 to 19.
22. A vector comprising a gRNA variant according to any one of claims 1 to 12, a CasX variant protein according to any one of claims 13 to 19, or one or more nucleic acids encoding a CasX variant protein or encoding or comprising an RNA variant.
23. 23. The vector of claim 22, wherein the vector is selected from the group consisting of a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes simplex viral (HSV) vector, a virus-like particle (VLP), a plasmid, a minicircle, a nanoplasmid, a DNA vector, an RNA vector, a lipid nanoparticle, and a liposome.
24. 23. The vector of claim 22, wherein the vector is an AAV vector, and the AAV vector is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV-Rh74, and AAVRh10.
25. 20. A method of modifying a BCL11A target nucleic acid sequence in a cell population, the method comprising introducing into the cell population one or more nucleic acids comprising or encoding a system according to any one of claims 1 to 19 or a CasX variant protein and a gRNA variant of the system, wherein a target nucleic acid sequence of the BCL11A gene of the cell targeted by the gRNA variant is modified by the CasX variant protein, and said modifying comprises introducing an insertion, deletion, substitution, duplication, or inversion of one or more nucleotides in the BCL11A gene of the cell population.
26. 26. The method of claim 25, wherein the GATA1 binding site sequence of the target nucleic acid is modified.
27. The method of claim 27, wherein: a) expression of the BCL11A protein is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to a cell in which the BCL11A gene is not modified; or b) such that at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% of the modified cells do not express detectable levels of BCL11A protein; 26. The method of claim 25, wherein the BCL11A gene of the cell population is modified.
28. 26. The method of claim 25, wherein the cells are selected from the group consisting of hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), CD34+ cells, mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), common myeloid progenitor cells, proerythroblast cells, and erythroblast cells.
29. 26. The method of claim 25, wherein said modification of the target nucleic acid sequence of the BCL11A gene of said cell population occurs in vitro or ex vivo.
30. 20. One or more nucleic acids encoding a system according to any one of claims 1 to 19 or a CasX variant protein of said system or comprising or encoding a gRNA variant, for use in the treatment of hemoglobinopathies.
31. 20. One or more nucleic acids encoding a system according to any one of claims 1 to 19 or a CasX variant protein of said system, or comprising or encoding a gRNA variant, for use in the manufacture of a medicament for the treatment of a hemoglobinopathy.
